Compositions and methods for controlling cellular responses
Fusion polypeptides with histidines and BRD4 IDR sequences in expression vectors enable precise modulation of inflammatory and immune responses, addressing the need for controlling cellular reactions and treating diseases like sepsis and inflammatory bowel disease, and reducing tumor growth.
Patent Information
- Application Number
- PCT/US2026/026754
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-05
- Filing Date
- 2026-05-05
- Publication Date
- 2026-11-12
AI Technical Summary
Existing technologies lack precise means to modulate inflammatory responses based on the severity of inflammation, necessitating new methods to control cellular responses such as inflammation and immune responses.
The use of fusion polypeptides containing histidines fused to heterologous polypeptides, including mutations and deletions in intrinsically disordered regions (IDRs) of polypeptides, along with expression vectors encoding BRD4 IDR sequences, to confer pH-sensitivity and modulate transcription and immune responses.
These methods effectively increase or decrease transcription and immune responses under low pH conditions, providing therapeutic benefits for diseases like sepsis and inflammatory bowel disease, and reduce tumor growth by modulating cellular activities.
Smart Images

Figure IMGF000040_0001 
Figure IMGF000041_0001 
Figure IMGF000041_0002
Abstract
Description
[0001] Attorney Docket No. 167705-038401PCT
[0002] COMPOSITIONS AND METHODS FOR CONTROLLING CELLULAR RESPONSES
[0003] CROSS REFERENCE TO RELATED APPLICATIONS
[0004] The present application claims priority to and the benefit of U. S. App. No. 63 / 800,312, filed May 5, 2025, the entirety of which is hereby incorporated by reference.
[0005] STATEMENT OF RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH
[0006] This invention was made with government support under Grant No. GM151000 awarded by the National Institutes of Health. The government has certain rights in the invention.
[0007] BACKGROUND OF THE INVENTION
[0008] Inflammation is crucial for maintaining homeostasis and defending the integrity of tissues and organs. Excessive inflammatory responses can result in significant tissue damage. The magnitude, duration and specific impact of inflammatory response must be calibrated to the presence of inflammatory triggers and the extent of pathological outcome. Research has uncovered complex regulatory mechanisms of inflammatory responses, including negative regulators of innate sensing receptors (e.g., decoy receptors, suppressors and degradation mechanisms), anti-inflammatory mediators (11-10, TGFb, glucocorticoids) and factors serving as negative feedback of the inflammatory pathways (e.g., A20, SOCS proteins, ATF3). However, these regulators of inflammation are often constitutively expressed or induced according to the level and persistence of inflammatory stimuli. The precise means by which the inflammatory response is modulated based on the severity of inflammation remains largely elusive. Therefore, new means for modulating inflammatory responses are urgently needed.
[0009] SUMMARY OF THE INVENTION
[0010] As described below, the present disclosure features compositions and methods for modulating cellular responses (e.g., inflammation, an immune response).
[0011] In one aspect, the disclosure features a fusion polypeptide containing a series of histidines fused to a heterologous polypeptide.
[0012] In another aspect, the disclosure features a polypeptide containing a mutation in a histidine residue of an intrinsically disordered region (IDR) of the polypeptide.
[0013] In another aspect, the disclosure features a polypeptide containing a deletion mutation of one or more amino acid residues of an IDR of the polypeptide, where the deletion mutation is in a domain associated with transcription.Attorney Docket No. 167705-038401PCT
[0014] In another aspect, the disclosure features an expression vector containing a polynucleotide encoding a BRD4 IDR sequence.
[0015] In another aspect, the disclosure features a polynucleotide encoding the fusion polypeptide of any aspect, or the polypeptide of any aspect.
[0016] In another aspect, the disclosure features an expression vector containing the polynucleotide of a previous aspect. In one embodiment, the expression vector further contains an inducible promoter driving expression of the polynucleotide. In one embodiment the promoter is a TetOn promoter.
[0017] In another aspect, the disclosure features a cell containing the fusion polypeptide of any previous aspect, the polypeptide of any previous aspect, the polynucleotide of a previous aspect, or the expression vector of any aspect. In one embodiment, the cell is a human cell (e.g., an immune cell, such as a macrophage, T cell, or B cell).
[0018] In another aspect, the disclosure features a method of conferring pH-sensitivity on a heterologous protein, the method involving fusing the heterologous protein to a polypeptide sequence containing at least about 6-12 (e.g., 6, 7, 8, 9, 10, 11, 12) histidine amino acid residues, thereby conferring pH-sensitivity on the heterologous protein, where the heterologous protein contains an intrinsically disordered region (IDR). In one embodiment, the polypeptide sequence contains at least about 9-12 (e.g., 9, 10, 11, 12) histidine amino acid residues.
[0019] In another aspect, the disclosure features a method of conferring pH-sensitivity on a heterologous protein, the method involving fusing the heterologous protein to a polypeptide sequence containing at least about 4-8 (e.g., 4, 5, 6, 7, 8) histidine amino acid residues, thereby conferring pH-sensitivity on the heterologous protein, where the heterologous protein contains an intrinsically disordered region (IDR), where the IDR contains a polypeptide sequence containing at least about 15-20 (e.g., 15, 16, 17, 18, 19, 20) proline and / or glutamine amino acid residues. In one embodiment, the IDR is fused to the polypeptide sequence.
[0020] In another aspect, the disclosure features a method of conferring pH-sensitivity on a heterologous protein, the method involving fusing the heterologous protein to a polypeptide sequence containing at least about 4-8 histidine amino acid residues and 15-20 proline and / or glutamine amino acid residues, thereby conferring pH-sensitivity on the heterologous protein, where the heterologous protein contains an intrinsically disordered region (IDR).
[0021] Un another aspect, the disclosure features a method of conferring pH-sensitivity on a cell, the method involving transducing the cell with a polynucleotide encoding a heterologous protein fused to a polypeptide sequence containing at least about 6 histidine to about 12 histidine (e.g., 6, 7, 8, 9, 10, 11, 12) amino acid residues, thereby conferring pH-sensitivity on the cell. In one embodiment, the cell is in vitro or in vivo. In one embodiment, the cell is a human cell.Attorney Docket No. 167705-038401PCT
[0022] In another aspect, the disclosure features a method of modulating transcription and / or expression of a polynucleotide of Tables 1-4, the method involving contacting a cell with a polypeptide of any previous aspect, a polynucleotide of a previous aspect, or the expression vector of any previous aspect, thereby modulating transcription and / or expression of a polynucleotide of Tables 1-4 as compared to a reference.
[0023] In another aspect, the disclosure features a method of increasing transcription and / or expression of a polynucleotide of Tables 1-4 under low pH conditions, the method involving contacting a cell with a polypeptide containing a BRD4 IDR polypeptide sequence, a polynucleotide encoding a polypeptide containing a BRD4 IDR polypeptide sequence, or an expression vector containing a polynucleotide encoding a polypeptide containing a BRD4 IDR polypeptide sequence. In one embodiment, the BRD4 IDR sequence is a wild-type IDR sequence.
[0024] In another aspect, the disclosure features a method of increasing transcription and / or expression of a polynucleotide of Tables 1-4 under low pH conditions, the method involving contacting a cell with a polypeptide of any previous aspect, a polynucleotide of a previous aspect, or the expression vector of any previous aspect, thereby increasing transcription and / or expression of a polynucleotide of Tables 1-4 under low pH conditions as compared to a reference.
[0025] In another aspect, the disclosure features a method of decreasing transcription and / or expression of a polynucleotide of Tables 1-4, the method involving contacting a cell with a polypeptide of any previous aspect, a polynucleotide of a previous aspect, or the expression vector of any previous aspect, thereby decreasing transcription and / or expression of a polynucleotide of Tables 1-4 as compared to a reference.
[0026] In another aspect, the disclosure features a method of modulating immune response, the method involving contacting an immune cell with a polypeptide containing a BRD4 IDR polypeptide sequence, a polynucleotide encoding a polypeptide containing a BRD4 IDR polypeptide sequence, or an expression vector containing a polynucleotide encoding a polypeptide containing a BRD4 IDR polypeptide sequence.
[0027] In another aspect, the disclosure features a method of modulating immune response, the method involving contacting an immune cell with a polypeptide of any previous aspect, a polynucleotide of a previous aspect, or the expression vector of any previous aspect.
[0028] In another aspect, the disclosure features a method of modulating an immune response in a subject in need thereof, the method involving administering to the subject a polypeptide containing a BRD4 IDR polypeptide sequence, a polynucleotide encoding a polypeptideAttorney Docket No. 167705-038401PCT
[0029] containing a BRD4 IDR polypeptide sequence, or an expression vector containing a polynucleotide encoding a polypeptide containing a BRD4 IDR polypeptide sequence.
[0030] In another aspect, the disclosure features a method of modulating an immune response in a subject in need thereof, the method involving administering to the subject a polypeptide of any previous aspect, a polynucleotide of a previous aspect, or the expression vector of a previous aspect.
[0031] In another aspect, the disclosure features a method of treating a disease associated with an excessive or inadequate immune response in a subject in need thereof, the method involving administering to the subject a polypeptide containing a BRD4 IDR polypeptide sequence, a polynucleotide encoding a polypeptide containing a BRD4 IDR polypeptide sequence, or an expression vector containing a polynucleotide encoding a polypeptide containing a BRD4 IDR polypeptide sequence.
[0032] In another aspect, the disclosure features a method of treating a disease associated with an excessive or inadequate immune response in a subject in need thereof, the method involving administering to the subject a polypeptide of any previous aspect, a polynucleotide of a previous aspect, or the expression vector of any previous aspect. In one embodiment, the disease is sepsis or inflammatory bowel disease (IBD). In one embodiment, the subject has hypoxia.
[0033] In another aspect, the disclosure features a method of reducing the proliferation or survival of a neoplastic cell, the method involving contacting the neoplastic cell with a cell of any previous aspect.
[0034] In another aspect, the disclosure features a method of reducing the proliferation or survival of a neoplastic cell, the method involving contacting the neoplastic cell with an immune cell containing: a polypeptide of any previous aspect, a polynucleotide encoding a polypeptide of any previous aspect, or an expression vector containing a polynucleotide encoding a polypeptide of any previous aspect.
[0035] In another aspect, the disclosure features a method of reducing the growth or survival of a tumor in a subject, the method involving administering to the subject a cell of any previous aspect.
[0036] In another aspect, the disclosure features a method of reducing the growth or survival of a tumor in a subject, the method involving to the subject an immune cell containing: a polypeptide of any previous aspect, a polynucleotide encoding a polypeptide of any previous aspect, or an expression vector containing a polynucleotide encoding a polypeptide of any previous aspect.
[0037] In another aspect, the disclosure features a method of treating a subject having a neoplasia, the method involving administering to the subject a cell of any previous aspect.Attorney Docket No. 167705-038401PCT
[0038] In another aspect, the disclosure features a method of treating a subject having a neoplasia, the method involving administering to the subject an immune cell containing: a polypeptide of any previous aspect, a polynucleotide encoding a polypeptide of any previous aspect, or an expression vector containing a polynucleotide encoding a polypeptide of any previous aspect.
[0039] In various embodiments of any of the above aspects or of any aspect of the disclosure delineated herein, the heterologous polypeptide contains an intrinsically disordered region (IDR). In various embodiments of any of the above aspects or of any aspect of the disclosure delineated herein, the heterologous polypeptide is a condensate forming polypeptide. In various embodiments, an ability of the fusion polypeptide to form condensates is disrupted at acidic pH. In various embodiments of any of the above aspects or of any aspect of the disclosure delineated herein, the ability of the fusion polypeptide to form condensates is disrupted below pH 6.5. In various embodiments of any of the above aspects the series of histidines contains at least about 6 histidines, contains between about 6-12, and / or contains at least 9-12 histidines. In various embodiments of any of the above aspects, the IDR is proximal to the series of histidines. In various embodiments of any of the above aspects, the series of histidines is inserted within the IDR. In various embodiments of any of the above aspects, the fusion polypeptide further contains a series of proline and / or glutamine residues. In various embodiments of any of the above aspects, the series of proline and / or glutamine residues contains at least 15-20 proline and / or glutamine residues. In various embodiments of any of the above aspects, the number of proline and / or glutamine residues is about the same. In various embodiments of any of the above aspects, the number of proline residues is within 1-5 residues of the number of glutamine residues. In various embodiments of any of the above aspects, the series of histidines contains at least 4-8 histidines. In various embodiments of any of the above aspects, the mutation is a histidine to alanine mutation. In various embodiments of any of the above aspects, the mutation is a histidine to arginine mutation. In various embodiments of any of the above aspects, the IDR contains a series of histidines, and where the mutation is in a histidine of the series of histidines. In various embodiments of any of the above aspects, the series of histidines contains at least 4-12 histidines. In various embodiments of any of the above aspects, the IDR contains a plurality of series of histidines. In various embodiments of any of the above aspects, a mutation is in the 1st, 2nd, or 3rdseries of histidines in the plurality of series of histidines. In various embodiments of any of the above aspects, the polypeptide is BRD4, or a fragment thereof. In various embodiments of any of the above aspects, the polypeptide is an IDR of BRD4. In various embodiments of any of the above aspects, the polypeptide has at least 85%, 90%, 95%, 99%, or 100% sequence identity to a sequence of Table 6. In various embodiments of any of the aboveAttorney Docket No. 167705-038401PCT
[0040] aspects, the domain associated with transcription is a domain associated with recruitment of a polymerase. In various embodiments of any of the above aspects, the polymerase is an RNA polymerase. In various embodiments of any of the above aspects, the domain associated with transcription is a domain associated with recruitment of a transcription factor. In various embodiments of any of the above aspects, the transcription factor is a positive transcription elongation factor (pTEFb). In various embodiments of any of the above aspects, the deletion mutation is a deletion of the domain associated with transcription. In various embodiments of any of the above aspects, the deletion mutation is a truncation of the domain associated with transcription. In various embodiments of any of the above aspects, the domain associated with transcription is a C-terminal domain of the IDR. In various embodiments of any of the above aspects, the polypeptide is BRD4, or a fragment thereof. In various embodiments of any of the above aspects, the polypeptide is an IDR of BRD4. In various embodiments of any of the above aspects, the polypeptide has at least 85%, 90%, 95%, 99%, or 100% sequence identity to a sequence of Table 6. In various embodiments of any of the above aspects, the intracellular or extracellular pH is less than about 7.4, less than about 7.0, about 6.5, of less than about 6.5. In various embodiments of any of the above aspects, the low pH conditions comprise hypoxic conditions. In various embodiments of any of the above aspects, the intracellular or extracellular pH is at least 7.5, between about 7.0 and 7.5, or greater than about 6.5. In various embodiments of any of the above aspects, the immune cell is a macrophage, a T cell, or a B cell.
[0041] Other features and advantages of the invention will be apparent from the detailed description, and from the claims.
[0042] Definitions
[0043] Unless defined otherwise, all technical and scientific terms used herein have the meaning commonly understood by a person skilled in the art to which this invention belongs. The following references provide one of skill with a general definition of many of the terms used in this invention: Singleton et al., Dictionary of Microbiology and Molecular Biology (2nd ed. 1994); The Cambridge Dictionary of Science and Technology (Walker ed., 1988); The Glossary of Genetics, 5th Ed., R. Rieger et al. (eds.), Springer Verlag (1991); and Hale & Marham, The Harper Collins Dictionary of Biology (1991). As used herein, the following terms have the meanings ascribed to them below, unless specified otherwise.
[0044] By "agent" is meant any small molecule chemical compound, nucleic acid molecule, polypeptide, or fragments thereof, or cell. In some embodiments, the agent is a heterologous protein fused to a peptide comprising a series of histidines (e.g., 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20). In some embodiments, the series of histidines comprises between 6-Attorney Docket No. 167705-038401PCT
[0045] 12 histidine residues. In some embodiments, the agent is a cell comprising a fusion protein comprising a heterologous protein fused to a series of histidines (e.g., between 6-12 histidine residues). In some embodiments, fusion of the peptide alters the pH-sensitivity of the heterologous protein and / or the ability of the heterologous protein to form condensates as efficiently at pH 6.5 or below as compared to a reference (e.g., condensate formation at pH 7.4) In some embodiments, the agent is a cell expressing a heterologous protein fused to a series of histidine residues (e.g., 6-12 contiguous histidine residues).
[0046] By “alteration” is meant a change in the structure, expression levels or activity of a polynucleotide or polypeptide as detected by standard art known methods such as those described herein. The alteration can be an increase or a decrease. As used herein, an alteration includes a 10% change in expression levels, a 25% change, a 40% change, and a 50% or greater change in expression levels.
[0047] By “ameliorate” is meant decrease, suppress, attenuate, diminish, arrest, or stabilize the development or progression of a disease or disease process.
[0048] By “BRD4 Intrinsically Disordered Region” is meant a fragment of BRD4 that comprises an amino acid sequence having at least 85%, 90%, 95%, 99%, or greater sequence identity to: AGSSKMKGFSSSESESTSESSSSDSEDSETEMAPKSKKKGHTGRDOKKHHHHHHPOMQP APAPVPOOPPPPPOOPPPPPPPOOOOOOPPPPPPPPSMPOOTAPAMKSSPPPFITAQVPVLE POLPGSVFDPIGHFTOPILHLPOPELPPHLPQPPEHSTPPHLNOHAVVSPPALHNALPOOPS RPSNRAAALPPKPTRPPAVSPALAOPPLLPOPPMAOPPOVLLEDEEPPAPPLTSMOMQLY LOOLOKVOPPTPLLPSVKVOSOPPPPLPPPPHPSVOOOOLOPOPPPPPPPOPQPPPOOOHO PPPRPVHLPSMPFSAHIOOPPPPPGOOPTHPPPGOOPPPPOPAKPOOVIQHHPSPRHHKSD PYSAGHLREAPSPLMIHSPOMPOFOSLTHOSPPOONVOPKKOVKGRAEPQPPGPVMGOG OGCPPASPAAVPMLSOELRPPSVVOPQPLVVVKEEKIHSPIIRSEPFSTSLRPEPPKHPENI KAPVHLPORPEMKPVDIGRPVIRPPEOSAPPPGAPDKDKOKOEPKTPVAPKKDLKIKNM GSWASLVOKHPTTPSSTAKSSSDSFEHFRRAAREKEEREKALKAOAEHAEKEKERLRQE RMRSREDEDALEOARRAHEEARRROEOOOOOOOOROEOOOOOOOAAAVAAASAPQA QSSOPOSMLDOORELARKREQERRRREAMAATIDMNFOSDLLSIFEENLF. In some embodiments, a wild-type form of BRD4 IDR has pH-sensing activity and an BRD4 IDR variant lacks or has reduced pH-sensing activity. In some embodiments, BRD4 IDRs of the present disclosure facilitate the formation of molecular condensates. In some embodiments, a wild-type form of BRD4 IDR facilitates the formation of condensates at neutral or basic pH (e.g., pH 7.0 or greater) and fails to facilitate the formation of condensates at acidic pH (e.g., less than pH 7.0), and an BRD4 IDR variant forms condensates at acidic, neutral, and basic pH.Attorney Docket No. 167705-038401PCT
[0049] By “BRD4 Polypeptide” is meant a protein or functional fragment thereof having at least 85% identity to one of the following amino acid sequences. In some embodiments, the BRD4 Polypeptide or functional fragment thereof has pH-sensing activity. In embodiments, the BRD4 polypeptide includes functional variants or mutants thereof (e.g., variants or mutants that are pH insensitive). In one embodiment, the BRD4 protein has at least about 85%, 90%, 95% identity to one of the following proteins:
[0050]
[0051] Attorney Docket No. 167705-038401PCT
[0052]
[0053] Attorney Docket No. 167705-038401PCT
[0054] In the first box above the IDR sequence of the BRD4 polypeptide is in underline. In the second box, the histidine residues of the BRD4 IDR sequence are bolded. In the third box, the underlined and bolded residues are histidine residues of the BRD4 IDR sequence that have been mutated to alanine residues.
[0055] In another embodiment, the BRD4 polypeptide has at least about 85%, 90%, 95%, or greater identity to the following amino acid sequence or a fragment thereof
[0056] > XP_054176378. 1 bromodomain -containing protein 4 isoform X4 [Homo sapiens] MSAESGPGTRLRNLPVMGDGLETSQMSTTQAQAQPQPANAASTNPPPPETSNPNKPKRQTNQLQYLLRVV LKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYN KPGDDIVLMAEALEKLFLQKINELPTEETEIMIVQAKGRGRGRKETGTAKPGVSTVPNTTQASTPPQTQT PQPNPPPVQATPHPFPAVTPDLIVQTPVMTVVPPQPLQTPPPVPPQPQPPPAPAPQPVQSHPPI IAATPQ PVKTKKGVKRKADTTTPTTIDPIHEPPSLPPEPKTTKLGQRRESSRPVKPPKKDVPDSQQHPAPEKSSKV SEQLKCCSGILKEMFAKKHAAYAWPFYKPVDVEALGLHDYCDIIKHPMDMSTIKSKLEAREYRDAQEFGA DVRLMFSNCYKYNPPDHEVVAMARKLQDVFEMRFAKMPDEPEEPVVAVSSPAVPPPTKVVAPPSSSDSSS DSSSDSDSSTDDSEEERAQRLAELQEQLKAVHEQLAALSQPQQNKPKKKEKDKKEKKKEKHKRKEEVEEN KKSKAKEPPPKKTKKNNSSNSNVSKKEPAPMKSKPPPTYESEEEDKCKPMSYEEKRQLSLDINKLPGEKL GRVVHIIQSREPSLKNSNPDEIEIDFETLKPSTLRELERYVTSCLRKKRKPQAEKVDVIAGSSKMKGFSS SESESSSESSSSDSEDSETGPA
[0057] In one embodiment, the fragment comprises a BRD4-IDR domain or a C-terminal BRD4-IDR. In an embodiment, the BRD4 polypeptide is a variant BRD4 polypeptide comprising an alteration that reduces or eliminates pH-sensitivity. In an embodiment the fragment comprises a N-terminal BRD4-IDR, a BRD4-IDR C-terminal truncation, or a BRD4-IDR lacking a C-terminal domain (e.g., a C-terminal domain associated with transcription). In an embodiment, the C-terminal domain specifically binds to and / or is associated with the recruitment of a polymerase (e.g., an RNA polymerase such as PolII and / or pTEFb).
[0058] By “Brd4 polynucleotide” is meant a polynucleotide sequence encoding a BRD4 polypeptide or fragment thereof. Exemplary BRD4 polynucleotides are provided in Table I.
[0059] In this disclosure, "comprises," "comprising," "containing", and "having" and the like can have the meaning ascribed to them in U. S. Patent law and can mean " includes," "including," and the like; "consisting essentially of' or "consists essentially" likewise has the meaning ascribed in U. S. Patent law and the term is open-ended, allowing for the presence of more than that which is recited so long as basic or novel characteristics of that which is recited is not changed by the presence of more than that which is recited, but excludes prior art embodiments. Any embodiments specified as “comprising” a particular component s) or element(s) are also contemplated as “consisting of’ or “consisting essentially of’ the particular component(s) or element(s) in some embodiments.Attorney Docket No. 167705-038401PCT
[0060] The term “conservative amino acid substitution” or “conservative mutation” refers to the replacement of one amino acid by another amino acid with a common property. A functional way to define common properties between individual amino acids is to analyze the normalized frequencies of amino acid changes between corresponding proteins of homologous organisms (Schulz, G. E. and Schirmer, R. H., Principles of Protein Structure, Springer-Verlag, New York (1979)). According to such analyses, groups of amino acids can be defined where amino acids within a group exchange preferentially with each other, and therefore resemble each other most in their impact on the overall protein structure (Schulz, G. E. and Schirmer, R. H., supra). Nonlimiting examples of conservative mutations include amino acid substitutions of amino acids, for example, lysine for arginine and vice versa such that a positive charge can be maintained; glutamic acid for aspartic acid and vice versa such that a negative charge can be maintained; serine for threonine such that a free -OH can be maintained; and glutamine for asparagine such that a free -NH2 can be maintained.
[0061] Amino acids generally can be grouped into classes according to the following common side-chain properties:
[0062] (1) hydrophobic: Norleucine, Met, Ala, Vai, Leu, He;
[0063] (2) neutral hydrophilic: Cys, Ser, Thr, Asn, Gin;
[0064] (3) acidic: Asp, Glu;
[0065] (4) basic: His, Lys, Arg;
[0066] (5) residues that influence chain orientation: Gly, Pro;
[0067] (6) aromatic: Trp, Tyr, Phe. “Detect” refers to identifying the presence, absence or amount of the analyte to be detected. By “disease” is meant any condition or disorder that damages or interferes with the normal function of a cell, tissue, or organ. The disease can be caused by an infection (e.g., a viral, eukaryotic, or bacterial infection). In embodiments, the disease is associated with an excessive inflammatory and / or immune response. In embodiments, the disease is sepsis or inflammatory bowel disease (IBD). In some embodiments, the disease is associated with a decrease in the pH of an inter- or intra- cellular environment (e.g., an acidic environment). In some embodiments, the disease is associated with acidification of the intracellular environment. In some embodiments, the intracellular environment associated with the disease is at a pH of under 7, between about pH 6.5 and about pH 7, or below pH 6.5. In some embodiments, the intracellular environment is a tumor microenvironment (TME) and / or the disease is a neoplasia.
[0068] By "effective amount" is meant the amount of an agent required to ameliorate, reduce, or prevent the symptoms of a disease relative to an untreated patient. The effective amount of active compound(s) used to practice the present invention for therapeutic treatment of a diseaseAttorney Docket No. 167705-038401PCT
[0069] varies depending upon the manner of administration, the age, body weight, and general health of the subject. Ultimately, the attending physician or veterinarian will decide the appropriate amount and dosage regimen. Such amount is referred to as an "effective" amount. In some embodiments, the effective amount is the amount required to modulate an immune response in the subject.
[0070] By “heterologous” is meant that the polynucleotide or polypeptide is not naturally present in the cell, tissue, or organism. In an embodiment, a cell is engineered to include a heterologous polynucleotide or polypeptide.
[0071] By “Intrinsically Disordered Region (IDR)” is meant a region of a polypeptide that does not adopt a stable 3D structure (e.g., under physiological conditions). Such regions may be known to favor weak and multivalent interactions and / or to adopt multiple conformations. Such regions may remain unfolded under physiological conditions, but may nonetheless be functional in such disordered state. In some embodiments, IDRs of the present disclosure are associated with proteins that form condensates. In some embodiments, IDRs of the present disclosure may be modified, for example, through fusion to a heterologous sequence (e.g., a polyhistidine sequence). In some embodiments, modified IDRs of the present disclosure may confer pH sensitivity on the protein to which the IDR is associated.
[0072] By “fragment” is meant a portion of a polypeptide or nucleic acid molecule. In embodiments, portion contains, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the entire length of the reference nucleic acid molecule or polypeptide. A fragment may contain 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 nucleotides or amino acids. In an embodiment, a fragment of a BRD4 polypeptide is an IDR domain together with a small number (5, 10, 15, 20, 25) flanking amino acids.
[0073] The term “fusion protein” as used herein refers to a hybrid polypeptide which comprises amino acid sequences from at least two different proteins. In one embodiment, a fusion protein is a protein of interest fused to 6-12 contiguous histidine residues. In one embodiment, the protein of interest comprises an IDR. In some embodiments, fusion of the 6-12 histidine residues alters the pH sensitivity and / or condensate forming properties of the protein of interest.
[0074] The terms “isolated,” “purified,” or “biologically pure” refer to material that is free to varying degrees from components which normally accompany it as found in its native state. “Isolate” denotes a degree of separation from an original source or surroundings. “Purify” denotes a degree of separation that is higher than isolation. A “purified” or “biologically pure” protein is sufficiently free of other materials such that any impurities do not materially affect the biological properties of the protein or cause other adverse consequences. That is, a nucleic acid or peptide of this disclosure is purified if it is substantially free of cellular material, viralAttorney Docket No. 167705-038401PCT
[0075] material, or culture medium when produced by recombinant DNA techniques, or chemical precursors or other chemicals when chemically synthesized. Purity and homogeneity are typically determined using analytical chemistry techniques, for example, polyacrylamide gel electrophoresis or high performance liquid chromatography. The term “purified” can denote that a nucleic acid or protein gives rise to essentially one band in an electrophoretic gel. For a protein that can be subjected to modifications, for example, phosphorylation or glycosylation, different modifications may give rise to different isolated proteins, which can be separately purified.
[0076] By “isolated polynucleotide” is meant a nucleic acid that is free of the genes which, in the naturally occurring genome of the organism from which the nucleic acid molecule of the disclosure is derived, flank the gene. The term therefore includes, for example, a recombinant DNA that is incorporated into a vector; into an autonomously replicating plasmid or virus; or into the genomic DNA of a prokaryote or eukaryote; or that exists as a separate molecule (for example, a cDNA or a genomic or cDNA fragment produced by PCR or restriction endonuclease digestion) independent of other sequences. In addition, the term includes an RNA molecule that is transcribed from a DNA molecule, as well as a recombinant DNA that is part of a hybrid gene encoding additional polypeptide sequence.
[0077] By an “isolated polypeptide” is meant a polypeptide of the disclosure that has been separated from components that naturally accompany it. Typically, the polypeptide is isolated when it is at least 60%, by weight, free from the proteins and naturally occurring organic molecules with which it is naturally associated. In embodiments, the preparation is at least 75%, at least 90%, and or at least 99%, by weight, a polypeptide of the disclosure. An isolated polypeptide of the disclosure may be obtained, for example, by extraction from a natural source, by expression of a recombinant nucleic acid encoding such a polypeptide; or by chemically synthesizing the protein. Purity can be measured by any appropriate method, for example, column chromatography, polyacrylamide gel electrophoresis, or by HPLC analysis.
[0078] By “modulate” is meant increase or decrease. An increase may be by about 1%, 5%, 10%, 25%, 30%, 50%, 75%, 100%, or more, or by 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 25-fold, 50-fold, 75-fold, 100-fold, or more. A decrease may be by about 1%, 5%, 10%, 25%, 30%, 50%, 75%, 100%, or more, or by 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 25-fold, 50-fold, 75-fold, 100-fold, or more.
[0079] By “mutation” is meant an alteration relative to a reference sequence. Such an alteration can be in an amino acid or nucleic acid sequence. In various embodiments, the mutation is an insertion, deletion, inversion, transposition, point mutation, missense mutation, substitution, or other alteration. In an embodiment, a mutation in a genomic polynucleotide is heritable.Attorney Docket No. 167705-038401PCT
[0080] The terms “nucleic acid” and “nucleic acid molecule,” as used herein, refer to a compound comprising a nucleobase and an acidic moiety. In various embodiments, the nucleic acid or nucleic acid molecule comprises a nucleoside, a nucleotide, or a polymer of nucleotides. Typically, polymeric nucleic acids, e.g., nucleic acid molecules comprising three or more nucleotides are linear molecules, in which adjacent nucleotides are linked to each other via a phosphodiester linkage. In some embodiments, “nucleic acid” refers to individual nucleic acid residues (e.g. nucleotides and / or nucleosides). In some embodiments, “nucleic acid” refers to an oligonucleotide chain comprising three or more individual nucleotide residues. As used herein, the terms “oligonucleotide” and “polynucleotide” can be used interchangeably to refer to a polymer of nucleotides (e.g., a string of at least three nucleotides). In some embodiments, “nucleic acid” encompasses RNA as well as single and / or double-stranded DNA. Nucleic acids may be naturally occurring, for example, in the context of a genome, a transcript, an mRNA, tRNA, rRNA, siRNA, snRNA, a plasmid, cosmid, chromosome, chromatid, or other naturally occurring nucleic acid molecule. On the other hand, a nucleic acid molecule may be a non-naturally occurring molecule, e.g., a recombinant DNA or RNA, an artificial chromosome, an engineered genome, or fragment thereof, or a synthetic DNA, RNA, DNA / RNA hybrid, or including non-naturally occurring nucleotides or nucleosides. Furthermore, the terms “nucleic acid,” “DNA,” “RNA,” and / or similar terms include nucleic acid analogs, e.g., analogs having other than a phosphodiester backbone. Nucleic acids can be purified from natural sources, produced using recombinant expression systems and optionally purified, chemically synthesized, etc. Where appropriate, e.g., in the case of chemically synthesized molecules, nucleic acids can comprise nucleoside analogs such as analogs having chemically modified bases or sugars, and backbone modifications. A nucleic acid sequence is presented in the 5' to 3' direction unless otherwise indicated. In some embodiments, a nucleic acid is or comprises natural nucleosides (e.g. adenosine, thymidine, guanosine, cytidine, uridine, deoxyadenosine, deoxythymidine, deoxy guanosine, and deoxy cytidine); nucleoside analogs (e.g., 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolo-pyrimidine, 3-methyl adenosine, 5-methylcytidine, 2-aminoadenosine, C5-bromouridine, C5-fluorouridine, C5-iodouridine, C5-propynyl-uridine, C5-propynyl-cytidine, C5-methylcytidine, 2-aminoadenosine, 7-deazaadenosine, 7-deazaguanosine, 8-oxoadenosine, 8-oxoguanosine, O(6)-methylguanine, and 2-thiocytidine); chemically modified bases; biologically modified bases (e.g., methylated bases); intercalated bases; modified sugars (2' -e.g., fluororibose, ribose, 2'-deoxyribose, arabinose, and hexose); and / or modified phosphate groups (e.g., phosphorothioates and 5'-A-phosphoramidite linkages). In some embodiments, a nucleoside analog is a compound comprising a purine or pyrimidine in which the heterocyclic ring or sugar moiety has been altered.Attorney Docket No. 167705-038401PCT
[0081] As used herein, “obtaining” as in “obtaining an agent” includes synthesizing, purchasing, or otherwise acquiring the agent.
[0082] By “prevent,” “preventing,” “prevention,” “prophylactic treatment”, and the like is meant reducing the probability of developing an infection, disorder, disease, or condition in a subject, who does not have, but is at risk of or susceptible to developing the infection, disorder, disease, or condition.
[0083] By “reduces” is meant a negative alteration of at least 1%, 5%, 10%, 25%, 50%, 75%, or 100%. In embodiments, the alteration is a reduction in inflammation or in an immune response.
[0084] By “reference” is meant a standard or control condition. In one embodiment, the pH sensitivity and / or condensate forming properties of a protein of interest fused to 6-12 histidines is compared to the pH sensitivity and / or condensate forming properties of the protein of interest in the absence of the fusion. For example, a reference subject in some embodiments is a healthy subject. In some embodiments, a reference subject is a subject having a disease, whom has not been administered a composition of the present disclosure, and / or has not been treated according to the methods of the present disclosure. In some embodiments, the reference is meant a healthy condition. In some embodiments, the reference is a non-acidic intracellular environment, or a cellular, intracellular, or physiological response (e.g., an immune response) in a subject to a non-acidic intracellular environment. In some embodiments, the reference is an intracellular environment above pH 7.0, between about pH 7.0 and pH 7.5, or above pH 7.5, or a cellular, intrcellular, or physiological response (e.g., an immune response) in a subject having an intracellular environment with such pH values. In embodiments, the reference is the level of condensate formation (e.g., levels of BRD4 transcriptional condensate formation) or condensatedependent gene transcription (e.g., levels of transcription of genes associated with pH-dependent condensates) at an intracellular environment above pH 7.0, between about pH 7.0 and pH 7.5, or above pH 7.5. In some embodiments, the reference is an acidic intracellular environment (e.g., a pH under 7.4, under 7.0, about 6.5, or below 6.5) or a cellular, intracellular, or physiological response (e.g., an immune response) in a subject to an acidic intracellular environment. In embodiments, the reference is the level of condensate formation (e.g., levels of BRD4 transcriptional condensate formation) or condensate-dependent gene transcription (e.g., levels of transcription of genes associated with pH-dependent condensates) at an intracellular environment below pH 7.4, below 7.0, about 6.5, or below 6.5.
[0085] A “reference sequence” is a defined sequence used as a basis for sequence comparison. A reference sequence may be a subset of or the entirety of a specified sequence; for example, a segment of a full-length cDNA or gene sequence, or the complete cDNA or gene sequence. For polypeptides, the length of the reference polypeptide sequence will generally be at least about 16Attorney Docket No. 167705-038401PCT
[0086] amino acids, at least about 20 amino acids, at least about 25 amino acids, at least about 35 amino acids, at least about 50 amino acids, or at least about 100 amino acids. For nucleic acids, the length of the reference nucleic acid sequence will generally be at least about 50 nucleotides, at least about 60 nucleotides, at least about 75 nucleotides, at least about 100 nucleotides, or at least about 300 nucleotides, or any integer thereabout or therebetween.
[0087] By “series of histidines” is meant a plurality of contiguous histidine residues. In one embodiment, the series of histidines comprises at least about 6. In another embodiment, the series of histidines comprises between 6-25 (e.g., 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25), or between 6-12 (e.g., 6, 7, 8, 9, 10, 11, 12).
[0088] By "subject" or “patient” is meant a mammal, including, but not limited to, a human or non-human mammal, such as a bovine, equine, canine, ovine, or feline. In some embodiments, the subject is a human. The terms “subject” and “patient” are used interchangeably herein.
[0089] Ranges provided herein are understood to be shorthand for all of the values within the range. For example, a range of 1 to 50 is understood to include any number, combination of numbers, or sub-range from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50.
[0090] As used herein, the terms “treat,” treating,” “treatment,” and the like refer to reducing or ameliorating a disorder and / or symptoms associated therewith. It will be appreciated that, although not precluded, treating a disorder or condition does not require that the disorder, condition or symptoms associated therewith be completely eliminated. In some embodiments, a treatment for an infection can include treating a subject to prevent an infection (e.g., through vaccination or administration of a prophylactic drug). In some embodiments, a treatment for a neoplasia can include treating a subject to prevent a neoplasia.
[0091] Unless specifically stated or obvious from context, as used herein, the term "or" is understood to be inclusive. Unless specifically stated or obvious from context, as used herein, the terms "a", "an", and "the" are understood to be singular or plural.
[0092] Unless specifically stated or obvious from context, as used herein, the term “about” is understood as within a range of normal tolerance in the art, for example within 2 standard deviations of the mean. About can be understood as within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.05%, or 0.01% of the stated value. Unless otherwise clear from context, all numerical values provided herein are modified by the term about.
[0093] The recitation of an embodiment for a variable or aspect herein includes that embodiment as any single embodiment or in combination with any other embodiments or portions thereof.Attorney Docket No. 167705-038401PCT
[0094] Any compositions or methods provided herein can be combined with one or more of any of the other compositions and methods provided herein.
[0095] BRIEF DESCRIPTION OF THE DRAWINGS
[0096] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.
[0097] FIGs. 1A-1 J provide flow diagrams, graphs, and bar charts showing that acidic pH regulates gene-specific inflammatory response in macrophages. (FIG. 1A) A diagram illustrating an inflammatory circuit and feedback of sensing tissue microenvironment. (FIG. IB) Blood pH in mice challenged with 10 mg / kg lipopolysaccharide (LPS) intraperitoneally. One-way ANOVA, Dunnett test for multiple comparisons, Mean + / - STD. (FIG. 1C) Extracellular acidification of BMDMs stimulated with 100 ng / mL LPS in vitro. Mean+ / - STD. (FIG. ID) Fold activation of inflammatory genes in BMDMs with 10 ng / mL LPS for 4 hours. Fold change (FC) was normalized to unstimulated conditions at pH 7.4 or 6.5, respectively. Unpaired t-test, Holm-Sidak’s test. (FIG. IE) Time course analysis of gene activation in BMDMs stimulated with 10 ng / mL LPS at pH 7.4 and 6.5. (FIG. IF) Expression of known pH sensors in macrophages, including BMDMs, monocytes, tissue resident macrophages in peritoneal, liver, lung, small and large intestines (ref: Lavin 2014). (FIGs. 1G-1I) Fold changes of selected genes in WT, Gpr65- / ~ and Gpr68-I- BMDMs (FIG. 1G), Hifla-I- BMDMs (FIG. 1H) ^AHif2a-l-BMDMs (FIG. II). (FIG. 1J) Relative expression of inflammatory genes stimulated with 10 ng / mL LPS for 4 hours, in the presence of aphidicolin (APH) or a-amanitin (AM), normalized to spike-in human mRNA. Unpaired t-test, Holm-Sidak’s test. Error bars in FIGs 1A-1J represent Mean ± standard deviation (STD) from triplicates. *p<0.05, **p<0.01, ***p<0.001.
[0098] FIGs. 2A-2I provide venn diagrams, pictures, graphs, and heat maps showing that deconvolution analysis revealed pH-dependent combinatorial control of inflammatory response.
[0099] (FIG. 2A) Venn diagrams of significantly regulated genes by LPS or acidic pH. Fc > 3 and q < 0.05. (FIG. 2B) Illustration of the linear deconvolution model to identify gene regulatory logics between LPS and acidic pH. (FIG. 2C) Evaluation of linear model fitting using expression variance and R-square for each gene. Blue marks all genes and magenta marks differentially expressed genes (FC > 3, q<0.05) in any pair of conditions. (FIG. 2D) Heatmap of inflammatory genes regulated by either LPS stimulation or acidic pH. Left, log2(fold) of model-inferred regulation by acidic pH alone (pH), LPS stimulation alone (LPS) and the interactions between acidic pH and LPS stimulation (LPSPH). Right, heatmap of p-values of each expression component, determined with a null hypothesis that the regulatory effect is less than 1.5-folds.Attorney Docket No. 167705-038401PCT
[0100] Cluster groups (1-20) were determined based on expression component p-values. (FIG. 2E) Functional enrichment for LPS-induced or LPS-repressed genes that are pH-insensitive, pH-antagonistic or pH- synergistic. (FIG. 2F) Expression components of inflammatory cytokines, cytokine receptors, antigen presentation genes, integrins and regulators of Nf-kb
[0101] signaling. (FIG. 2G) Motif enrichment of LPS-induced genes that are pH-insensitive and pH-antagonistic. (FIG. 2H) Western blot of NF-KB, IRF3 and STAT1 signaling activation in BMDMs after LPS stimulation. (FIG. 21) Immunofluorescence staining of p65 (pink) and IRF3 (pink) in BMDMs after LPS stimulation, 1 hour for p65 and 2 hours for IRF3.
[0102] FIGs. 3A-3F provide graphs, bar charts, and diagrams showing that transcription circuit and epigenetic control underlies environment-sensitive inflammatory response. (FIG. 3A) Expression kinetics of LPS-induced genes for top pH-insensitive (100), pH-antagonistic (100) and pH-synergistic groups (58). (FIG. 3B) Activation of inflammatory genes by LPS with 10 ng / mL for 4 hours, at pH 7.4, 6.5 or with 200 ng / mL cycloheximide (CHX). Fold change is calculated as LPS / untreated in each treatment condition. (FIG. 3C) Average profile of ATACseq and ChlP-seq of H3K27Ac and H3K4me3 of pH-regulated genes. Intersection image shows an enlarged profile around TSS. (FIG. 3D) Fold change of H3K27Ac and H3K4me3 ChlPseq counts within Ikb around TSS for pH-insensitive and pH-antagonistic groups. Welch t-test and Holm-Sidak’s multiple comparisons test, ns p>0.05, * p<0.05, ***p<0.001. (FIG. 3E) Profile of ATACseq, H3K27 acetylation, H3K4 tri-methylation, p65 and IRF3 ChlP-seq at selected LPS induced genes. Orange boxes highlight regions with strong differences between pH 7.4 and pH 6.5. (FIG. 3F) model illustration of the activation of pH-sensitive and pH-insensitive inflammatory response.
[0103] FIGs. 4A-4K provide graphs, a bar chart, a box plot, pictures, and flow diagrams showing that acidic pH regulates BRD4 transcriptional condensates (FIG. 4A) Bioinformatic analysis of peptide sequences to identify putative pH sensors in mouse. The 2D-plot shows Acharge by shifting pH from 7.4 to 6.5 and PQ enrichment scores. Orange scale, gene expression in BMDMs. (FIG. 4B) Measurement of pHi in BMDMs. Unpaired Student t-test. (FIG. 4C) Measurement of nuclear pH in iBMDMs using nuclear localized mCherry-SEpHuorin. Unpaired Student t-test. (FIGs. 4D-4E) Immunofluorescent imaging (FIG. 4D) and quantification (FIG.
[0104] 4E) of BRD4 condensates in BMDMs with confocal microscopy. Cells were cultured at pH 7.4 or 6.5 for 4 hours, or treated with 10% 1,6-Hexanediol for 2 min. One way ANOVA test. (FIG.
[0105] 4F) STED imaging of BRD4 condensates in BMDMs at pH 7.4 or 6.5 for 4 hours. (FIGs. 4G-4H) Density plots (FIG. 4G) and histograms (FIG. 4H) of the condensate diameter and intensity in STED experiments. Pixel size corresponds to 15 nm. (FIG. 41) FRAP analysis of mCherry-BRD4 in 293T cells, 3.18 frames / s, means ± SEM (n=15). (FIG. 4J) ImmunofluorescentAttorney Docket No. 167705-038401PCT
[0106] imaging and quantification of BRD4 condensates in isolated BMDM nuclei. Unpaired Student’s t test. (FIG. 4K) An example of live-cell time lapse imaging of mCherry-BRD4 in 293 T cells. In FIGs. 4A-4K, N is the number of analyzed cells. **** p<0.0001.
[0107] FIGs. 5A-5I provide flow diagrams, graphs, pictures, and illustrations showing that BRD4 is a pH sensor and regulates pH-dependent inflammatory response. (FIGs. 5A-5B) Immunofluorescent imaging (FIG. 5A) and quantification (FIG. 5B) of BRD4 condensates in BMDMs. Brown-Forsythe and Welch ANOVA tests. (FIG. 5C) FC of the 200 most repressed genes by acidic pH. FC median is labeled on violin plots. Kruskal-Wallis test. (FIG. 5D) Fold difference of LPS-induced expression at the indicated conditions relative to pH 7.4, stimulated with 10 ng / mL LPS for 4 hours in BMDMs. pH 6.5, 0.5 pM JQ1, 2 pM iBET, 50 nM MS6454 hours conditioning prior to LPS, 1% 1,6-HD treated at 2 hours post LPS. (FIG. 5E) Relative composition of amino acids in IDRBRD4 (675 - 1125) comparing to all annotated IDRs in the mouse proteome. (FIG. 5F) Conservation of HPQ patterns in IDRBRD4. Two identified HPQ regions are displayed in the panels. The sequence alignment of IDRBRD4 was marked with H, P, Q distribution as well as the overall sequence conservation. (FIG. 5G) Live-cell imaging of mCherry-BRD4WT or mCherry-BRD4HA in 293 T cells. (FIGs. 5H-5I) Live cell imaging and quantification of BRD4 variants (FIG. 5H) and IDRFUS variants (FIG. 51) in 293T cells at pH 7.4 or pH 6.5. Unpaired Student’s t test. In FIGs. 5A-5I, N is the number of analyzed cells, ns p>0.05, *p<0.05, **p<0.01, ***p<0.001, **** pO. OOOl.
[0108] FIGs. 6A-6J provide graphs, pictures, a bar chart, and illustrations showing that genespecific regulation is mediated by BRD4-MED1 transcription condensates and BRD9. (FIGs.
[0109] 6A-6B) Immunofluorescent imaging (FIG. 6A) and quantification (FIG. 6B) of BRD4 and MED1 condensates in BMDMs. 10 % 1,6-HD for 2 min, 0.5 pM JQ1, 2 pM iBET and 50 nM MS645 for 4 hours. One way ANOVA. (FIG. 6C) STED imaging of BRD4 and MED1 condensates in BMDMs at pH 7.4 or 6.5 for 4 hours. (FIG. 6D) Fold change of LPS induced gene expression with BRD9 specific inhibitor (iBRD9) or degrader (dBRD9). (FIG. 6E) Effective size ratios of pH-dependent response for dBRD9, iBRD9 and JQ1. (FIG. 6F) Tracks of BRD4 and BRD9 ChlP-seq in BMDMs. Orange boxes highlight regions with significant differences in BRD4 or BRD9 binding. (FIG. 6G) Average profile of BRD4 ChlP-seq at enhancers of pH-regulated gene groups. Enhancers were determined with ATAC-seq and assigned to the nearest gene. (FIG. 6H) Western blot analysis of Co-IP between IDRBRD4 and BRD9. FLAG-mCherry-IDRBRD4 was transfected into 293 T cells to IP BRD9 from total cell lysate, with FLAG-mCherry as control (Ctrl). (FIG. 61) FC of pH-dependent inflammatory genes in iBMDMs, with 100 ng / mL LPS for 6 hours. Mean ±STD. Unpaired t-test, Holm-Attorney Docket No. 167705-038401PCT
[0110] Sidak’s test. (FIG. 6 J) Model diagram of pH-dependent regulation of transcriptional condensates and transcriptional activation.
[0111] In (FIGs. 6A-6J) ns p>0.05, *** p<0.001, **** pO. OOOl.
[0112] FIGs. 7A-7L provide pictures, graphs, and bar charts showing that pHi sensing via BRD4 acts as negative feedback to modulate pH homeostasis and inflammatory response. (FIG.
[0113] 7 A) pHi in BMDMs after LPS stimulation in various indicated conditions, pairwise comparison with Kruskal-Wallis. (FIGs. 7B-7C) Immunofluorescent imaging (FIG. 7B) and quantification (FIG. 7C) of BRD4, MED1 and co-localization. one way ANOVA (F).
[0114] (FIGs. 7D-7E) pHi and BRD4 measurement of thioglycollate-induced peritoneal macrophages in vivo, 24h after i.p. injection with PBS or 3 mg / kg LPS. pH quantification, unpaired Student’s t test (FIG. 7D), Immunofluorescent imaging and quantification of F4 / 80+ macrophages, Mann-Whtiney test (FIG. 7E). (FIG. 7F) pHi of BMDMs treated with 100 ng / mL LPS for 24 h and / or 0.5 uM JQ1 for 8 h, one way ANOVA. (FIG. 7G) Seahorse analysis of glycolytic activity in BMDMs treated with 100 ng / mL LPS and / or 0.5 uM JQ1 for 8 hours, one way ANOVA. (FIG.
[0115] 7H) Glycolytic capacity and rate of BMDMs treated with 100 ng / mL LPS + / - 0.5 uM JQ1 for 8 hours, one way ANOVA. (FIGs. 71, 7L) Immunofluorescent imaging of BRD4 (FIG. 71), HNRNPA1 or SRSF2 (FIG. 7L) phase condensates in murine and human cells. (FIGs. 7J, 7K) BRD4 and MED1 puncta in human macrophages at pH 7.4 and pH 6.5. (FIG. 7 J) Immunofluorescent imaging, (FIG. 7K) Quantification of puncta and co-localization. Mann-Whtiney test.
[0116] p>0.05, *p<0.05, **p<0.01, ***p<0.001, **** pO. OOOL
[0117] FIGs. 8A-8M provide graphs and bar charts. (FIG. 8A) Measurement of extracellular acidification by BMDMs after stimulated with 100 ng / mL LPS in vitro. Mean ± STD. (FIG. 8B) Viability of BMDMs at acidic pH, assayed by flow cytometry using Annexin V and propidium iodide staining. Cells were gated for single cells based on FSC and SSC, and then analyzed as the proportion of Annexin V-and PI- population. (FIG. 8C) Internalization of TLR4 measured by flow cytometry. The median fluorescent intensity of TLR4 staining was subtracted of background (unstained control) and normalized to the surface TLR4 staining before LPS stimulation. Mean ± STD. (FIG. 8D) Fold activation of inflammatory genes in BMDMs stimulated with 10-1000 ng / mL LPS for 4 hours. Unpaired t-test, Holm-Sidak’s test for multiple comparisons. Mean ± STD. (FIG. 8E) Fold activation of inflammatory genes in BMDMs after conditioning at pH 6.5 for 0-12 hours. (FIG. 8F) Fold activation of inflammatory genes stimulated with 10 ng / mL LPS for 4 hours at pH 7.4 or 6.5 in Nlrp3- / - BMDMs. Mean ± STD. Unpaired Student’s t test, Holm-Sidak’s test for multiple comparisons. (FIG. 8G) Expression of 4-1BBL analyzed by flow cytometry. BMDMs were treated with 10 ng / mL LPS at pH 7.4 or 6.5.Attorney Docket No. 167705-038401PCT
[0118] Unpaired t-test, Holm-Sidak’s test for multiple comparisons. Mean ± STD (FIG. 8H) Expression of Endothelin-1 analyzed by western blotting in BMDMs treated with 10 ng / mL LPS at pH 7.4 or 6.5 for 4 hours, with or without 1: 1000 Golgi-plug. (FIG. 81) Western blotting quantification of pSTATl in BMDMs treated with conditioned medium. Conditioned medium was harvest from BMDMs treated with 10 ng / mL LPS for 4 hours at pH 7.4 or 6.5. CM, complete medium as control. (FIG. 8J) RNA-seq expression of pH sensors in BMDMs. (FIGs.
[0119] 8K-8L) Fold activation of inflammatory genes stimulated with 10 ng / mL LPS for 4 hours, in the presence of 100 mM cAMP (FIG. 8K) or 5 mM Camptothecin (FIG. 8L). Mean ± STD.
[0120] Unpaired Student’s t test, Holm-Sidak’s test for multiple comparisons. (FIG. 8M). EdU labeling of cultured BMDMs, at pH 7.4 after withdrawal of CSF1 overnight (-CSF1), or with CSF1 at pH 7.4 and pH 6.5 for 4 hours. EdU labeling was performed with 10 pM EdU for 1 hour., ns p>0.05, * p<0.05, ** p<0.01, *** pO. OOl, **** p<0.0001.
[0121] FIGs. 9A-9I provide a graph, a formula, flow diagrams, a heat map, bar charts, and a picture. (FIG. 9A) Log2 (FC) of LPS-induced genes at both pH 7.4 and pH 6.5. Blue dotted lines indicate 2-fold variations. (FIG. 9B) Linear deconvolution matrix for dissecting the interactions between LPS and pH. (FIG. 9C) The analytic pipeline to identify pH- and LPS-regulated genes. (FIG. 9D) Illustration of pH-sensitive and pH-insensitive classification in the 20 identified clusters shown in FIGs. 2A-2I. (FIG. 9E) Illustration of defining pHIN, pHANTI, and pHSYN groups from 20 identified clusters in FIG. 2D. (FIG. 9F) Gene examples of 20 clusters identified by gene expression components. (FIGs. 9G-9H) Western blotting analysis (FIG. 9G) and quantification (FIG. 9H) of STAT1 phosphorylation in BMDMs treated with 10 ng / mL IFN-b at pH 7.4 or 6.5. Mean±STD. Unpaired Student’s t test. (FIG. 91) Fold activation of inflammatory genes in WT and Ifinarl- / - BMDMs at pH 7.4 or 6.5. Mean±STD. Unpaired Student’s t test, Holm-Sidak’s test for multiple comparisons.
[0122] ns p>0.05, * p<0.05, ** p<0.01.
[0123] FIGs. 10A-10P provide graphs, a box plot, heat maps, and a bar chart. (FIG. 10A) Expression kinetics of pH-insensitive (357), pH-antagonistic (433) and pH- synergistic (58) groups in LPS-induced genes. Mean ± STD. (FIG. 10B) Expression kinetics of pH-insensitive (171) and pH-antagonistic (272) groups in LPS-repressed genes. (FIG. 10C) The LPS-PH interaction component of primary and secondary response genes (classified in Tong et al., 2016).
[0124] (FIG. 10D) Violin plots of the fold activation of pHIN, pHANTI, and pHSYN groups in BMDMs stimulated with 10 ng / mL LPS for 4 hours. pH 6.5, 4 hours prior conditioning; CHX, 200 ng / mL cycloheximide; TSA, 50 mM TSA. The numbers above violin plots indicate the group median. Friedman ANOVA, Dunn’s test for multiple comparisons. (FIG. 10E) Venn diagram of ATAC-seq peaks identified in all 4 conditions. (FIG. 10F) Genomic profiles ofAttorney Docket No. 167705-038401PCT
[0125] ATAC-seq, ChlP-seq of H3K27ac and H3K4me3 at pH 7.4, pH 7.4 LPS 4 hours, pH 6.5, pH 6.5 LPS 4 hours. Left, ATAC-seq peaks with significant increase after LPS at pH 7.4; right, ATAC-seq peaks without significant change at pH 7.4. (FIGs. 10G-10H) Motif enrichment of pH-dependent enhancers (FIG. 10G) and LPS-induced pH-dependent enhancers (FIG. 10H). (FIG.
[0126] 101) Comparison of gene expression, ATAC-seq, ChlP-seq of H3K27ac and H3K4me3 at pH 7.4 for pHIN, pHANTI, and pHSYN groups, for average profile (top) and individual genes (bottom).
[0127] (FIG. 10J) Motif enrichment of enhancers associated with pH-insensitive and pH-antagonistic genes. (FIG. 10K) Fold activation of inflammatory genes stimulated with 10 ng / mL LPS for 4 hours, at pH 7.4, pH 6.5, 50 mM TSA (HDAC inhibitor) or 10 mM C646 (HAT inhibitor). Mean ± STD. (FIG. 10L) The expression of Irf2 in BMDMs treated with 10 ng / mL LPS for 4 hours at pH 7.4 or 6.5. Mean ± STD. (FIG. 10M) IRF2 protein expressed analyzed by western blotting in BMDMs treated with 10 ng / mL LPS at pH 7.4 or 6.5. (FIG. 10N) IRF2 proteins in control and Irf2- / - iBMDMs generated with CRISPR / Cas9. (FIG. 10O) Fold change of Ifinbl expression in control and Irf2- / - iBMDMs. Mean ± STD. (FIG. 10P) pH-dependent activation of Ifnbl in Irf2- / - iBMDMs. Mean ± STD.
[0128] ns p>0.05, ** p<0.01, **** pO. OOOl.
[0129] FIGs. 11A-11K provide graphs, pictures, and bar charts. (FIG. HA) Fold activation of ISGs stimulated with 10 ng / mL recombinant interferon-β at pH 7.4, pH 6.5. Mean ± STD. (FIG.
[0130] 11B) Bioinformatic analysis of Acharge and total charge for peptide sequences shown in FIG. 4A. Each data point is calculated as a window of 20 amino acid residue. (FIG. 11C) Western blot of BRD4 isoforms at pH 7.4 or at pH 6.5 for 4 hours. (FIG. HD) Isoform expression of Brd4 in murine BMDMs at pH 6.5 for the indicated duration. (FIG. HE) Calibration curve for measuring pHi with SNARF-4F. R2=0.999. (FIG. HF) Gene expression of Brd4 in BMDMs at acidic pH. (FIG. 11G) Western blot and quantification of full length BRD4 proteins in BMDMs at pH 6.5. The band intensity of every sample was normalized to 0 hour of each independent experiment, total of two experiments. Mean ± STD. (FIG. 11H) Representative bright field images of BMDMs and isolated BMDM nuclei. (FIG. HI) Immunofluorescent imaging of endogenous BRD4 in 293T cells at pH 7.4 to pH 5.5 for 4 hours. 100 pM 2,3-DNP was added during the last 30 min conditioning. (FIG. 11 J) Quantification of live-cell time lapse imaging of mCherry-BRD4 signals in 293T cells in FIG. 4G. The data represent mean ± SEM from two independent experiments. (FIG. 11K) Live-cell time lapse imaging of 293T cells stably expressing mCherry.
[0131] FIGs. 12A-12L provide bar charts. (FIG. 12A) The recovery of inflammatory gene activation after switching BMDMs from pH 6.5 to pH 7.4 for 4-12 hours. Mean ± STD. (FIG.
[0132] 12B) Deconvolution analysis of Brd4- / - BMDMs stimulated with 10 ng / mL LPS for 4 hours.Attorney Docket No. 167705-038401PCT
[0133] BRD4- dependent and independent genes were analyzed for the LPS-pH interaction expression component. Unpaired Student’s t test. (FIGs. 12C-12E) Comparison of amino acid composition between BRD4-IDR and the mouse proteome (FIG. 12C), BRD4 and the mouse proteome (FIG. 12D), and all annotated IDRs and the mouse proteome (FIG. 12E). (FIG. 12F) Expression of Brd4WT and Brd4HA in 293T cells. The mRNA expression of Brd4WT and Brd4HA was quantified by qRT-PCR and normalized to internal control Gapdh. The relative expression was then normalized against Brd4WT. Mean ± STD. (FIG. 12G) EdU labeling of stable 293 T cell lines expressing different BRD4 variants. Each BRD4 variant cell line was treated with siRNA targeting human Brd4 and scrambled siRNA for 36 hours, prior to EdU labeling. The percentage of Edu labelled cells with siBRD4 was normalized to scrambled siRNA for each cell line. Mean ± STD. (FIG. 12H) Live cell imaging of mCherry-IDRFUS.
[0134] (FIG. 121) mCherry signals analyzed with flow cytometry in mCherry-IDRFUS variants shown in FIG. 51. (FIGs. 12J-12K) Expression of pH-sensitive inflammatory genes activated by LPS at pH 7.4 or pH 6.5 (FIG. 12 J), or by lipid A in the presence of iBRD9 or JQ1 (FIG. 12K). (FIG. 12L) Live cell imaging of IDRFUS variants in 293T cells at pH 7.4, 6.5 or 6.0.
[0135] FIGs. 13A-13J provide graphs, picurtes, and bar charts. (FIG. 13A) Bioinformatic analysis of pH-sensitivity for BET family proteins and MED1. (FIG. 13B) Tracks of H- and PQ-scores for full length BRD2, BRD3, BRD4, BRDT, BRD9 and MED1. (FIG. 13C) immunofluorescence imaging and quantification of BRD4, MED1 and their colocalization in BMDMs stimulated with 10 ng / mL LPS for 0-4 hours. (FIG. 13D) BRD4 ChlP-seq tracks at house-keeping genes Myc, Vwf and Ubc. Underneath lines mark the peaks with significant reduction of BRD4 occupancy comparing pH 6.5 LPS and pH 7.4 LPS. (FIG. 13E) The average profile of ATAC-seq and ChlP-seq signals at enhancers associated with pHinsensitive, pH-antagonistic and pH-synergistic gene groups. (FIG. 13F) Immunofluorescent imaging of colocalization between mCherry- IDRBRD4 or mCherry and endogenous BRD4 in 293T cells. (FIG. 13G) Fold activation of inflammatory genes in iBMDMs after 6 h 100 ng / mL LPS at pH 7.4 or 6.5. Mean ± STD. Unpaired t-test, Holm-Sidak’s test for multiple comparisons. (FIG. 13H) Fold activation of JQ1 dependent and pH-dependent inflammatory genes in BMDMs treated with pH 6.5 or JQ1 for 4 hours. (FIG. 131) Dose-response curve of the activation of inflammatory genes treated with different concentrations of JQ1 in BMDMs. The expression of the analyzed genes was normalized to the condition without JQ1. The data of each gene was fitted with sigmoidal curve to extract IC50. (FIG. 13J) Fitted IC50 of pH-insensitive and pH-sensitive genes as shown (FIG. 131). Unpaired t tests, Mann-Whitney test,
[0136] ns p>0.05, * p>0.05, ** p<0.01, **** pO. OOOl.Attorney Docket No. 167705-038401PCT
[0137] FIGs. 14A-14E provide graphs, a flow diagram, pictures, and a bar chart. (FIG. 14A) pHi of BMDMs at various time points after 100 ng / mL LPS stimulation. ** p<0.01 (FIG. 14B) Flow cytometry gating strategy to isolate peritoneal macrophages, pH calibration, and immunofluorescent imaging of peritoneal macrophage staining 24 hours after 3 mg / kg LPS treatment. (FIG. 14C) Diagram illustrating BRD4 as pH-sensor to control inflammatory response. (FIG. 14D) Seahorse analysis of ECAR on BMDMs treated with JQ1 or acidic pH. (FIG. 14E) The expression of Hkl, Hk2 and Hk3 with 100 ng / mL LPS or 0.5 uM JQ-1 treatment. ** p<0.01
[0138] FIG. 15 provides a schematic and bar charts showing that manipulating the pH microenvironment of the cell can reverse pH-dependent control. Macrophages (iBMDM) were transfected either with a vector encoding Hvl, a voltage-gated outwards proton pump, or with a negative control vector. After transfection, cells were stimulated with LPS, and the pH of the extracellular environment was set to either 7.4 or 6.5. The results showed that by controlling intracellular pH by using Hvl, pH-dependent control / repression (based on the acidification of the extracellular environment) of the expression of transcriptional targets of BRD4 condensates was reversed.
[0139] FIG. 16 provides a bar chart and pictures showing that immune activation leads to a stable change of intracellular pH and BRD4. The bar chart shows that stimulation of macrophages by LPS led to a decrease in intracellular pH. This decrease in intracellular pH was observed to lead to the pH-dependent disruption of BRD4 condensates in macrophages. BRD4 condensates were rescued by raising the extracellular pH to 7.4, and administering the proton ionophore 2-4-Dinitrophenol (2,4-DNP / DNP) to equilibrate extracellular and intracellular pH. These results were mirrored in T cells and B cells, indicating that T cells and B cells also undergo pH-dependent disruption of BRD4 condensates.
[0140] FIG. 17 provides a schematic and a bar chart showing that an acidic extracellular environment reduces antigen presentation by macrophages. Macrophages were placed in culture at pH 7.4, pH 7.4 in the presence of JQ1, a BRD4 inhibitor, or at pH 6.5, and then stimulated with the addition of E. coli expressing ovalbumin (OVA) to induce presentation of OVA antigens to OVA-specific T cells (OT1 T cells). OT1 T cells release interfereon-y (IFNg) in response to antigen presentation, so IFNg levels were recorded as a measurement of antigenpresentation levels. The results indicated that lowering the pH to 6.5 significantly reduced antigen presentation by macrophages as compared to pH 7.4. This effect was associated with the disruption of BRD4 condensates, since JQ1 administration at pH 7.4 had a similar effect on antigen presentation by macrophages.Attorney Docket No. 167705-038401PCT
[0141] DETAILED DESCRIPTION OF THE INVENTION
[0142] The present disclosure features compositions and methods that are useful for modulating the pH sensitivity of polypeptides, of cellular responses, or of intracellular and / or physiological responses (e.g., immune responses). In some embodiments, the immune response is inflammation. In some embodiments, the cellular response is in an immune cell (e.g., a macrophage).
[0143] The invention is based, at least in part, upon the discovery that fusion of a protein of interest to a series of 6-12 or 6-25 histidines (e.g., 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25) alters the pH sensitivity and / or condensate forming characteristics of the protein of interest as outlined in the below provided Examples where pH regulates a switch-like gene-specific inflammatory response in macrophages. Acidic pH was shown to regulate a switch-like gene-specific inflammatory response in macrophages. Acidic pH impacted epigenetic remodeling and transcription circuits to control inflammatory programs independent of well-known pH sensors. BRD4 Transcription condensates were regulated by intracellular pH via pH-sensitive motifs within intrinsically disordered regions. Innate activation decreased intracellular pH and disrupts BRD4 condensates as a negative feedback. Accordingly, provided herein are compositions and methods for modulating the pH sensitivity of polypeptides, cellular responses, and intracellular and / or physiological responses (e.g., immune responses).
[0144] BRD4 was identified as a novel intracellular pH sensor that modulates transcription condensates in a pH-sensitive manner. Without intending to be bound by theory, the Examples provided herein demonstrated that BRD4 senses intracellular pH through its evolutionary conserved histidine-enriched intrinsically disorder region (IDR). Moreover, the inflammatory' activation of macrophages was shown to trigger intracellular acidification and alters transcriptional condensates in vitro and in vivo. Thus, the present disclosure provides a new regulatory mechanism of inflammation, where transcriptional condensates integrate extracellular and intracellular pH via BRD4 to control gene-specific inflammatory response based on microenvironment. Sensing pH deviation by the immune system acts as a feedback mechanism to balance the protective benefits of the immune response against their potentially pathological impact.
[0145] Inflammation
[0146] Inflammation is crucial for maintaining homeostasis and defending the integrity of tissues and organs. Yet, excessive inflammatory responses can result in significant tissue damage. (Meizlish et al., Annu Rev Immunol 39, 1-25.) The magnitude, duration and specific impact ofAttorney Docket No. 167705-038401PCT
[0147] an inflammatory response must be calibrated to both the presence of inflammatory triggers and the extent of pathological outcome. (Medzhitov, Science 374, 1070-1075.)
[0148] The maintenance of a stable pH range is a universal feature of tissue homeostasis.
[0149] Different tissues and organs maintain an interstitial environment within specific pH range, whereas these pH levels are often perturbed during inflammation. (Hajj ar and Zhou, Trends Immunol. 44, 807-825.) For instance, blood pH is tightly regulated between 7.35 and 7.45 through respiration and renal compensation. (Levin and Buck, Annu Rev Physiol 77, 347-362.) In patients with sepsis, severe acidosis indicates a poor prognosis for survival. (Nichol et al., Crit. Care 15, R242; Shapiro et al., Ann. Emerg. Med. 45, 524-528.) In the brain, the cerebrospinal fluid maintains a mildly acidic pH ~7.3; however, ischemic injury can lower this to pH 6.6. (Nedergaard et al., Am. J. Physiol.-Regul., Integr. Comp. Physiol. 260, R581-R588.) The pH of the paracortical zone of lymph nodes is sustained between 6.3 and 7.1, and becomes even more acidic during infection. (Wu et al., Nat Commun 11, 4113.) In addition, the microenvironment of solid tumors frequently exhibits acidic pH due to heightened metabolic activity, hypoxia, and active proton extrusion by malignant cells. (Gallagher et al., Nature 453, 940-943.) These deviations from normal pH levels can indicate an emergent state in affected tissues. Inside cells, pH is similarly tightly controlled in compartmentalized manner: cytosolic pH is -pH 7.2, secretory pathway has a gradient of pH from 7.2 to 5.5 spanning endoplasmic reticulum to the Golgi, and endosomes and lysosomes have a strongly acidic environment, all underscoring the vital role of pH in biology. (Casey et al., Nat. Rev. Mol. Cell Biol. 11, 50-61.) Mammalian cells monitor pH levels both extracellularly and intracellularly. On the cell surface, a broad range of pH values can be detected by a variety of extracellular sensors, including G-protein coupled receptors (GPR4, GPR65, GPR68), acid sensing ion channels (ASIC1, ASIC2, ASIC3, ASIC4) and transient receptor potential cation channel subfamily V member 1 (TRPV1). (Levin and Buck, Annu Rev Physiol 77, 347-362.) These extracellular pH sensors are activated at the pH range of 4 to 8, (Huang et al., Nature 527, 477-483.) (Holzer, Handb. Exp. Pharmacol., 283-332.) regulating various cellular and physiological parameters, from blood pH and lipid metabolism to pain sensations during exercise. (Molliver et al., Mol. Pain 1, 35; Chen et al., Nat Immunol, 1-13; Sun et al., J. Am. Soc. Nephrol. 21, 1745-1755.) In contrast, the mechanisms of intracellular pH sensing and the subsequent regulation of cellular responses are less understood. The Hypoxia-Induced Factors, HIF1 alpha and HIF2 alpha, can be activated by acidic conditions independently of hypoxia. (Mekhail et al., Nat. Cell Biol. 6, 642-647; Corbet et al., Cancer Res. 74, 5507-5519.) In the context of cancers, transcription factors SMAD5 and Sterol Regulatory Element-Binding Protein 2 (SREBP2) have been implicated in cellular responses to intracellular pH. (Kondo et al., Cell Reports 18, 2228-2242;Attorney Docket No. 167705-038401PCT
[0150] Fang et al., Cell Res 27, 1083-1099.) Change in pH may influence survival, differentiation, migration and cellular metabolism in a cell-type specific manner. (Hajj ar and Zhou, Trends Immunol. 44, 807-825.)
[0151] The Examples of the present disclosure explored immune cells that may sense changes in pH and influence tissue activity by studying macrophages, given their role as tissue sentinels. (Wynn, et al., Nature 496, 445-455; Davies et al., Nat. Immunol. 14, 986-995.) In response to cues associated with microbial infections, macrophages regulate the expression of thousands of genes important for tissue homeostasis, innate host defense, antiviral response, and coordination with adaptive immune system. (Smale and Natoli, Cold Spring Harb. Perspect. Biol. 6, aO 16261.) The Examples provided herein study, amongst other things, how detecting pH changes in macrophages regulates the inflammatory response to pathogens.
[0152] Inflammation is an essential defense response but operates at the cost of normal tissue functions. Acidification of the tissue microenvironment is associated with inflammation. The Examples provided herein demonstrate that acidic pH restructured the inflammatory response of macrophages in a gene-specific manner. Mammalian BRD4 was identified as a novel intracellular pH sensor. Acidic pH disrupts transcription condensates containing BRD4 and MED1, via histidine-enriched intrinsically disordered regions. Crucially, a decrease in macrophage intracellular pH was necessary and sufficient to regulate transcriptional condensates in vitro and in vivo, acting as negative feedback to regulate the inflammatory response.
[0153] Collectively, the present Examples demonstrate the discovery of a pH-dependent switch in transcriptional condensates that enables environment dependent control of inflammation, with a broader implication for calibrating the magnitude and quality of inflammation by the inflammatory cost.
[0154] Transcription Condensates and BRD4
[0155] Recent studies revealed that proteins can form biomolecular condensates of fundamental roles in cellular organization, signaling, stress response and gene regulation. (Alberti and Hyman, Nat. Rev. Mol. Cell Biol. 22, 196-213; Banani et al., Nat. Rev. Mol. Cell Biol. 18, 285-298.) (Shin, et al., Science 357, 56; Hnisz, et al., Cell 169, 13-23; Xiao, et al., Nat. Rev.
[0156] Immunol., 1-12; Cramer, P., Nature 573, 45-54.) In particular, critical factors involved in gene transcription tend to concentrate in distinct and dynamic nuclear foci referred to as transcriptional “hubs” or “condensates”. These mechanisms represent crucial biochemical controls of gene expression, transcription burst and compartmentalization of opposing regulators. (Lyons, et al., Cell 186, 327-345; Chong, et al., S., Mol. Cell 82, 2084-2097; Patil, et al., Cell., vol. 186, Issue 22; Du, et al., Cell 187, 2595-2598; Chong, et al., Science 361. Issue 6400;Attorney Docket No. 167705-038401PCT
[0157] Sabari, et al., Science 361, eaar3958.) The proteins identified within these foci, including BRD4, MED1, Pol II, YAP / TAZ, TBP, P300, pTEFb, typically contain intrinsically disordered regions (IDRs) that favor weak and multivalent interactions. (Chong, et al., Science 361. Issue 6400; Sabari, et al., Science 361, eaar3958; Basu, et al., Cell 181, 1062-1079. e30; Cai, et al., Nat. Cell Biol. 21, 1578-1589; Lu, et al., Nature 558, 318-323; Lu, et al., Nat. Cell Biol. 22, 453-464; Gibson, et al., Cell 179, 470-484. e21; Cho, et al., Science 361, 412-415.) Specifically, BRD4 is a member of the bromodomain and extraterminal (BET) protein family that recognizes histone lysine acetylation associated with active transcription. (Dey, et al., Proc. Natl. Acad. Sci. 100, 8758-8763; Strom, et al., Mol. Biol. Cell, mbcE24010046.) It interacts and recruits the mediator complex, pTEFb and other transcription machinery, as an essential regulator of Pol Il-dependent transcription. (Yang, et al., Mol. Cell 19, 535-545; Jang, et al., Mol. Cell 19, 523-534.) In macrophages and in mice, inhibition of BRD4 reduces inflammatory response and prevents lethality in severe sepsis, (Nicodeme, et al., Nature 468, 1119-1123.) suggesting that BRD4 function is vital for the activation of inflammatory response.
[0158] Despite the increasing examples of transcriptional condensates in gene regulation, control of transcriptional condensate formation and their roles in the immune system are not well understood.
[0159] Without intending to be bound by theory, the Examples provided herein demonstrated that pH deviation by the immune system acts as a feedback mechanism to balance the protective benefits of immune response against their potentially pathological impact (FIG. 1A). Using the innate immune response to gram-positive bacterial cell wall component lipopolysaccharide (LPS) via Toll-like receptor 4 (TLR4) in macrophages, it was found that acidic pH regulates inflammatory response in a gene-specific manner and independent of well-known pH-sensor pathways. Employing bioinformatic analysis and experimental validation, BRD4 was identified as a novel intracellular pH sensor. The BRD4-containing transcription condensates are pH-sensitive, regulated by evolutionary conserved histidine-enriched IDRs. The inflammatory activation of macrophages triggers intracellular acidification and alters transcriptional condensates in vitro and in vivo. Thus, the Examples provided herein unveiled a novel regulatory mechanism of inflammation, where transcriptional condensates integrate extracellular and intracellular pH via BRD4 and / or a series of histidines to elicit gene-specific inflammatory response based microenvironment.
[0160] In embodiments, compositions and methods of the present disclosure may be used to modulate immune responses. In embodiments, such immune responses may include adaptive or innate immunity. Without intending to be bound by theory, it is expected that disruption of BRD4 transcriptional condensates in cells (e.g., macrophages, T cells, or B cells) will lead to theAttorney Docket No. 167705-038401PCT
[0161] disruption of transcription of genes dependent on BRD4 transcriptional condensates (e.g., genes involved in immune response). Accordingly, compositions and methods of the present disclosure may be used to disrupt BRD4 condensates, to induce BRD4 condensates to form under conditions (e.g., low pH) that BRD4 condensates would normally be disrupted, or to modulate the transcription of genes dependent on BRD4 condensates in the absence of condensate formation. In embodiments, modulation of the formation of BRD4 condensates, or modulation of the transcription of genes associated with immune response that are dependent on BRD4 condensates in the absence of BRD4 condensates modulates immune response (e.g., through the modulation of the transcription of any of the immune response associated genes).
[0162] The Examples provided herein demonstrate that the pH sensitivity of BRD4 condensates provides a feedback mechanism for immune response (e.g., lowering intracellular pH was demonstrated to provide negative feedback to the immune response). Accordingly, in some embodiments, BRD4 condensates are restored under low pH conditions (e.g., pH < 7.4 or 7.0, about 6.5, or below 6.5) to modulate immune responses under low pH conditions. In some embodiments, the transcription of BRD4 transcriptional condensate dependent genes is modulated under low pH conditions, with or without the restoration of BRD4 condensates. In embodiments, administration of or contacting a cell with a polypeptide comprising a BRD4-IDR polypeptide sequence (e.g., an IDRBRD4sequence of Table 6), a polynucleotide encoding such polypeptide, or an expression vector encoding such polynucleotide is sufficient to at least partially restore the formation of BRD4 transcriptional condensates and / or upregulate the transcription of BRD4 transcriptional condensate associated genes (e.g., a gene of Tables 1-4) under low pH conditions (e.g., pH < 7.4 or 7.0, about 6.5, or below 6.5), as compared to a reference. In embodiments, the reference is the level of BRD4 condensate formation, or the level of gene expression under low pH conditions in an untreated subject or cell. In some embodiments, the restoration of BRD4 condensates, or the upregulation of transcription of BRD4 transcriptional condensate associated genes (e.g., a gene of Tables 1-4) under low pH conditions (e.g., pH < 7.4 or 7.0, about 6.5, or below 6.5), as compared to a reference, is effective to modulate and / or increase an immune response under the low pH conditions.
[0163] In some embodiments, immune responses are modulated by the disruption of condensates (e.g., BRD4 condensates). In embodiments, administration of or contacting a cell with a polypeptide comprising a BRD4-IDR polypeptide sequence (e.g., an IDRBRD4sequence of Table 6), a polynucleotide encoding such polypeptide, or an expression vector encoding such polynucleotide is sufficient to disrupt the formation of BRD4 transcriptional condensates. In embodiments, the disruption of BRD4 condensates is effective to modulate and / or decrease theAttorney Docket No. 167705-038401PCT
[0164] transcription and / or expression of genes dependent on BRD4 condensates (e.g., a gene of Tables 1-4).
[0165] Table 1 below provides a list of genes involved in adaptive immunity that are dependent on pH through BRD4 transcriptional condensates in macrophages.
[0166] Table 1 - Adaptive Immunity Associated Genes Dependent on BRD4 Transcriptional Condensates
[0167]
[0168] Attorney Docket No. 167705-038401PCT
[0169]
[0170] Tables 2-4, below, provides a list of secreted factors that are dependent on BRD4 condensates.
[0171] Table 2: Cytokines Dependent on BRD4 Condensates
[0172]
[0173] Attorney Docket No. 167705-038401PCT
[0174]
[0175] Table 3: Chemokines Dependent on BRD4 Condensates
[0176]
[0177] Table 4: Other Secreted / Extracellular Factors Dependent on BRD4 Condensates
[0178]
[0179] Attorney Docket No. 167705-038401PCT
[0180]
[0181] In embodiments, the present disclosure provides fusion proteins comprising an IDR (e.g., a BRD4 IDR such as a sequence of Table 6) fused to a heterologous polypeptide.
[0182] pH-Sensing Polypeptides
[0183] In some aspects or embodiments, the present disclosure provides for a polypeptide comprising a series of histidines and / or a pH sensitive IDR. In embodiments, the IDR is enriched for histidine residues. In embodiments, the IDR is a polypeptide having at least at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to any of the IDR sequences disclosed herein (e.g., a BRD4 IDR, or a polypeptide of Table 6). In some embodiments, the series of histidines comprises at least about 6 histidines. In some embodiments, the series of histidines comprises about 6-25 histidines (e.g., 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25). In some embodiments, the series of histidines comprises between about 6-12 histidines (e.g., 6, 7, 8, 9, 10, 11, 12).
[0184] In embodiments, the series of histidines is proximal to the IDR sequence. In embodiments, the series of histidines includes at least 9, 10, 11, 12, or more histidines. Without intending to be bound by theory, it is expected that enriching and / or fusing a series of histidines to an IDR sequence will confer pH sensitivity to the IDR sequence.
[0185] In embodiments, the series of histidines is proximal to a series of proline and / or glutamine residues. In embodiments, the series of histidines is proximal to at least 15, 16, 17, 18, 19, 20, or more proline and / or glutamine residues. Without intending to be bound by theory, it is expected that having a series of histidines proximal to a series of proline and / or glutamine residues and / or enriching a portion of an IDR sequence proximal to a series of proline and / or glutamine residues with histidines confers pH sensitivity to the IDR sequence. In an embodiment, the series of histidines includes at least 4, 5, 6, 7, 8, or more histidines. In an embodiment, the series of proline and / or glutamine residues includes about the same number of proline and glutamine residues, the number of proline residues is within 1, 2, 3, 4, or 5 of the number of glutamine residues, or the number of glutamine residues is within 1, 2, 3, 4, or 5 of the number of proline residues.Attorney Docket No. 167705-038401PCT
[0186] Without intending to be bound by theory, it is expected that protonation of histidine side chains in response to decreasing pH will alter and / or disrupt protein interactions and / or disrupt polypeptide conformation. Accordingly, pH sensitive IDRs of the present disclosure are expected to confer pH sensitivity to polypeptides comprising these sequences.
[0187] In some embodiments, the compositions and methods of the present disclosure include wild-type versions of an IDR (e.g., a BRD4 IDR), fragments thereof, or polynucleotides encoding the same. Without intending to be bound by theory, it is expected that increasing the expression of a wild-type IDR (e.g., a BRD4 IDR) can increase the transcription and / or expression of genes dependent on the formation of transcriptional condensates associated with the IDR (e.g., through the recruitment of transcriptional machinery such as pTEFb or an RNA polymerase such as PolII) by the IDR, independently of the formation of transcriptional condensates. Accordingly, in some embodiments, the present disclosure provides compositions and methods for increasing the transcription and / or expression of a gene dependent on BRD4 condensate associated transcription (e.g., a gene of Tables 1-4) including wild-type IDRs (e.g., a BRD4 IDR), fragments thereof, or polynucleotides encoding the same. In embodiments, the transcription and / or expression of the gene dependent on BRD4 condensate associated transcription (e.g., a gene of Tables 1-4) is increased under low and / or acidic intracellular pH conditions (e.g., pH < 7.4 or 7.0, about 6.5, or below 6.5), as compared to a reference. In embodiments, the reference is the level of gene expression and / or transcription under low pH conditions conditions (e.g., pH < 7.4 or 7.0, about 6.5, or below 6.5) in an untreated subject or cell. In some embodiments, the conditions are hypoxic conditions. In some embodiments, the intracellular conditions comprise hypoxic conditions.
[0188] In some embodiments, compositions and methods of the present disclosure include IDRs that are mutated to be pH-insensitive. For example, histidine residues of a pH sensitive IDR may be mutated, in some embodiments, to other amino acids that do not become charged under low or acidic pH conditions (e.g., alanine). In embodiments, the histidine residue to be mutated is in a series of histidines. In embodiments, the series of histidines includes at least 4-12 residues. In embodiments, the IDR includes a plurality of series of histidines. In embodiments, the histidine to be mutated is located, in order from the N terminus of the IDR to the C terminus of the IDR, in the 1st, 2nd, or 3rdseries of histidines. Without intending to be bound by theory, it is expected that the mutated pH-insensitive IDRs can cause condensate formation (e.g., formation of BRD4 transcriptional condensates) and / or increase the transcription and / or expression of genes dependent on the formation of transcriptional condensates associated with the IDR regardless of intracellular pH (e.g., at low / acidic pH conditions). Accordingly, in some embodiments, the present disclosure provides compositions and methods for increasing the transcription and / orAttorney Docket No. 167705-038401PCT
[0189] expression of a gene dependent on BRD4 condensate associated transcription (e.g., a gene of Tables 1-4) including IDRs mutated to be pH-insensitive (e.g., an IDR of Table 6), fragments thereof, or polynucleotides encoding the same. In embodiments, the transcription and / or expression of the gene dependent on BRD4 condensate associated transcription (e.g., a gene of Tables 1-4) is increased under low and / or acidic intracellular pH conditions (e.g., pH < 7.4 or 7.0, about 6.5, or below 6.5), as compared to a reference. In embodiments, the reference is the level of gene expression and / or transcription under low pH conditions conditions (e.g., pH < 7.4 or 7.0, about 6.5, or below 6.5) in an untreated subject or cell.
[0190] In some embodiments, compositions and methods of the present disclosure include polypeptides comprising a histidine to arginine mutation in an IDR sequence of the polypeptide. In embodiments, the histidine residue to be mutated is in a series of histidines. In embodiments, the series of histidines includes at least 4-12 residues. In embodiments, the IDR includes a plurality of series of histidines. In embodiments, the histidine to be mutated is located, in order from the N terminus of the IDR to the C terminus of the IDR, in the 1st, 2nd, or 3rdseries of histidines. Without intending to be bound by theory, it is expected that the IDRs including a histidine to arginine mutation have reduced capacity for forming condensates and / or are expected to interfere (e.g., competitively interfere) with condensate-dependent transcription (e.g., BRD4 condensate transcription). Accordingly, in some embodiments, the present disclosure provides compositions and methods for decreasing the transcription and / or expression of a gene dependent on BRD4 condensate associated transcription (e.g., a gene of Tables 1-4) including an IDR sequence including a histidine to arginine mutation. In embodiments, the transcription and / or expression of the gene dependent on BRD4 condensate associated transcription (e.g., a gene of Tables 1-4) is decreased as compared to a reference. In embodiments, the reference is the level of gene expression and / or transcription in an untreated cell and / or subject, or the level of gene expression and / or transcription under non-acidic conditions (e.g., pH>7.5 or 7.0, between 7.0 and 7.5, or about 7.0 or 7.4).
[0191] In some embodiments, compositions and methods of the present disclosure include polypeptides comprising an IDR sequence that lacks at least a part of a domain which interacts with one or more polypeptides or polynucleotides associated with transcription (e.g., a C-terminal domain associated with transcription). Without intending to be bound by theory, IDR fragments lacking at least a part of a domain which interacts with one or more polypeptides or polynucleotides associated with transcription (e.g., a C-terminal domain associated with transcription) are expected to interfere (e.g., competitively interfere) with condensate-dependent transcription (e.g., BRD4 condensate transcription). Accordingly, in some embodiments, the present disclosure provides compositions and methods for decreasing the transcription and / orAttorney Docket No. 167705-038401PCT
[0192] expression of a gene dependent on BRD4 condensate associated transcription (e.g., a gene of Tables 1-4) including an IDR sequence that lacks at least a part of a domain which interacts with one or more polypeptides or polynucleotides associated with transcription (e.g., an IDR of Table 6), fragments thereof, or polynucleotides encoding the same. In embodiments, the transcription and / or expression of the gene dependent on BRD4 condensate associated transcription (e.g., a gene of Tables 1-4) is decreased as compared to a reference. In embodiments, the reference is the level of gene expression and / or transcription in an untreated cell and / or subject, or the level of gene expression and / or transcription under non-acidic conditions (e.g., pH>7.5 or 7.0, between 7.0 and 7.5, or about 7.0 or 7.4).
[0193] Polynucleotides encoding the pH-sensing polypeptides are also contemplated. These polynucleotide sequences may be optimized or non-optimized.
[0194] Polynucleotide Delivery
[0195] Viral vectors are used to genetically alter cells of the present disclosure and their progeny. Viral vectors are used, as are the physical methods described below, to deliver one or more target genes, polynucleotides, antisense molecules, HDR cassettes, or ribozyme sequences, for example, into the cells.
[0196] Viral vectors and methods for using them to deliver DNA to cells are well known to those of skill in the art. Transducing viral vectors (e.g., retroviral vectors (e.g., lentiviral vectors), alphaviral vectors (e.g., Sindbis vectors), adenoviral vectors, herpes virus vectors, and adeno-associated viral vectors) can be used for introducing a polynucleotide to a cell, especially because of their high efficiency of infection and stable integration and expression (see, e.g., Cayouette et al., Human Gene Therapy 8:423-430, 1997; Kido et al., Current Eye Research 15:833-844, 1996; Bloomer et al., Journal of Virology 71:6641-6649, 1997; Naldini et al., Science 272:263-267, 1996; and Miyoshi et al., Proc. Natl. Acad. Sci. U. S. A. 94: 10319, 1997). For example, a polynucleotide can be cloned into a retroviral vector and expression can be driven from its endogenous promoter, from the retroviral long terminal repeat, or from a promoter specific for a target cell type of interest. In some embodiments, the promoter is an exogenous inducible promoter. In some embodiments, the promoter is a TetOn promoter.
[0197] Other viral vectors that can be used include, for example, a vaccinia virus, a bovine papilloma virus, or a herpes virus, such as Epstein-Barr Virus (also see, for example, the vectors of Miller, Human Gene Therapy 15-14, 1990; Friedman, Science 244:1275-1281, 1989; Eglitis et al., BioTechniques 6:608-614, 1988; Tolstoshev et al., Current Opinion in Biotechnology 1:55-61, 1990; Sharp, The Lancet 337:1277-1278, 1991; Cornetta et al., Nucleic Acid Research and Molecular Biology 36:311-322, 1987; Anderson, Science 226:401-409, 1984; Moen, BloodAttorney Docket No. 167705-038401PCT
[0198] Cells 17:407-416, 1991; Miller et al., Biotechnology 7:980-990, 1989; Le Gal La Salle et al., Science 259:988-990, 1993; and Johnson, Chest 107:77S-83S, 1995). Retroviral vectors are particularly well developed and have been used in clinical settings (Rosenberg et al., N. Engl. J. Med 323:370, 1990; Anderson et al., U. S. Pat. No.5,399,346). In some embodiments, the AAV vector is an AAV6 vector or an AAV-DJ vector (see, e.g., Lerch, et al. “Structure of AAV-DJ, a retargeted gene therapy vector: Cryo-Electron Microscopy at 4.5A resolution,” Structure, 20:1310-1320 (2012)).
[0199] Calcium phosphate transfection can be used to introduce plasmid DNA containing a target gene or polynucleotide into a B cell and is a standard method of DNA transfer to those of skill in the art. DEAE-dextran transfection, which is also known to those of skill in the art, may be preferred over calcium phosphate transfection where transient transfection is desired, as it is often more efficient. Since the cells of the present disclosure are isolated cells, microinjection can be particularly effective for transferring genetic material into the cells. This method is advantageous because it provides delivery of the desired genetic material directly to the nucleus, avoiding both cytoplasmic and lysosomal degradation of the injected polynucleotide. Cells of the present disclosure can also be genetically modified using electroporation.
[0200] Liposomal delivery of DNA or RNA to genetically modify the cells can be performed using cationic liposomes, which form a stable complex with the polynucleotide. For stabilization of the liposome complex, dioleoyl phosphatidylethanolamine (DOPE) or dioleoyl phosphatidylcholine (DOPC) can be added. Commercially available reagents for liposomal transfer include Lipofectin (Life Technologies). Lipofectin, for example, is a mixture of the cationic lipid N-[1-(2,3-dioleyloxy)propyl]-N-N-N- trimethyl ammonia chloride and DOPE. Liposomes can carry larger pieces of DNA, can generally protect the polynucleotide from degradation, and can be targeted to specific cells or tissues. Cationic lipid- mediated gene transfer efficiency can be enhanced by incorporating purified viral or cellular envelope components, such as the purified G glycoprotein of the vesicular stomatitis virus envelope (VSV-G). Gene transfer techniques which have been shown effective for delivery of DNA into primary and established mammalian cell lines using lipopolyamine-coated DNA can be used to introduce target DNA into the lymphatic endothelial progenitor cells described herein.
[0201] Naked plasmid DNA can be injected directly into B cells. This technique has been shown to be effective in transferring plasmid DNA to skeletal muscle tissue, where expression in mouse skeletal muscle has been observed for more than 19 months following a single intramuscular injection. More rapidly dividing cells take up naked plasmid DNA more efficiently. Therefore, it is advantageous to stimulate cell division prior to treatment with plasmid DNA. Microprojectile gene transfer can also be used to transfer genes into cells eitherAttorney Docket No. 167705-038401PCT
[0202] in vitro or in vivo. The basic procedure for microprojectile gene transfer was described by J. Wolff in Gene Therapeutics (1994), page 195. Similarly, microparticle injection techniques have been described previously, and methods are known to those of skill in the art. Signal peptides can be also attached to plasmid DNA to direct the DNA to the nucleus for more efficient expression.
[0203] Peptide or protein transfection is another method that can be used to genetically alter lymphatic endothelial progenitor cells of the disclosure and their progeny. Peptides such as Pep-1 (commercially available as Chariot®), as well as other protein transduction domains, can quickly and efficiently transport biologically active proteins, peptides, antibodies, and nucleic acids directly into cells, with an efficiency of about 60% to about 95% (Morris, M. C. et al, (2001) Nat. Biotech. 19: 1173-1176).
[0204] Cells Comprising Polypeptides or Polynucleotides
[0205] The present disclosure also provides host cells comprising polypeptides fused to a series of histidines (e.g., 6-12) or polynucleotides encoding such polypeptides. In an embodiment, the polypeptide comprises an IDR sequence. In embodiments, the series of histidines is proximal to the IDR sequence. The present disclosure also provides host cells comprising a pH-insensitive IDR polypeptide of the present disclosure (e.g., a pH-insensitive IDR polypeptide of Table 6).
[0206] In embodiments, the series of histidines includes at least 9, 10, 11, 12, or more histidines. Without intending to be bound by theory, it is expected that fusing a series of histidines to an IDR sequence will confer pH sensitivity to the IDR sequence.
[0207] In embodiments, the series of histidines is proximal to a series of proline and / or glutamine residues. In embodiments, the series of histidines is proximal to at least 15, 16, 17, 18, 19, 20, or more proline and / or glutamine residues. Without intending to be bound by theory, it is expected that having a series of histidines proximal to a series of proline and / or glutamine residues confers pH sensitivity to the IDR sequence. In an embodiment, the series of histidines includes at least 4, 5, 6, 7, 8, or more histidines.
[0208] In embodiments, the host cell may be an immune cell, such as a macrophage, T cell, or B cell. Without intending to be bound by theory, immune cells comprising a pH-insensitive IDR polypeptide of the present disclosure (e.g., a pH-insensitive IDR polypeptide of Table 6) are expected to have increased immune function and / or response, as compared to a reference, under low and / or acidic pH conditions (e.g., pH < 7.4 or 7.0, about 6.5, or below 6.5). Accordingly, the present disclosure provides compositions and methods for modulating immune response in a subject involving administering modified immune cells of the present disclosure comprising pH-insensitive IDR polypeptides of the present disclosure or polynucleotides encoding suchAttorney Docket No. 167705-038401PCT
[0209] polypeptides. In an embodiment, the immune response is modulated under low and / or acidic pH conditions (e.g., extracellular and / or intracellular conditions). In an embodiment, the low and / or acidic pH condition is a low and / or acidic pH condition associated with a disease and / or disorder. In an embodiment, the disease and / or disorder is a neoplasia. In an embodiment, the low and / or acidic pH condition is associated with a tumor microenvironment (TME).
[0210] In embodiments, the host cell may be a cell from a stromal cell line.
[0211] In embodiments, the host cell may be a cell from an epithelial cell line.
[0212] In embodiments, the host cell is transduced with fusion polypeptides or polynucleotides encoding such polypeptides in vivo, or modified ex vivo, or in vitro before being administered to a subject.
[0213] Where host cells are modified ex vivo, or in vitro before being administered to a subject, the host cells may be autologous, allogeneic, or heterologous to the subject.
[0214] Compositions
[0215] Compositions comprising at least one engineered cell of the disclosure expressing a fusion protein fused to a series of histidines (e.g., 1-12 histidines), fused to a series of histidines fused to a BRD4 IDR domain, or a BRD4 variant polypeptide IDR domain, or a polynucleotide encoding such fusion proteins, as described herein are provided. In some embodiments, the compositions further comprise a pharmaceutically acceptable carrier, diluent, excipient, or vehicle.
[0216] Pharmaceutical compositions can include, depending on the formulation desired, pharmaceutically-acceptable, non-toxic carriers of diluents, which are vehicles commonly used to formulate pharmaceutical compositions for animal or human administration The diluent is selected so as not to affect the biological activity of the combination. Examples of such diluents include, without limitation, distilled water, buffered water, physiological saline, PBS, Ringer's solution, dextrose solution, and Hank's solution. A pharmaceutical composition or formulation of the present disclosure can further include other carriers, adjuvants, or non-toxic, nontherapeutic, nonimmunogenic stabilizers, excipients and the like. The compositions can also include additional substances to approximate physiological conditions, such as pH adjusting and buffering agents, toxicity adjusting agents, wetting agents and detergents.
[0217] Further examples of formulations that are suitable for various types of administration can be found in Remington's Pharmaceutical Sciences, Mace Publishing Company, Philadelphia, Pa., 17th ed. (1985). For a brief review of methods for drug delivery, see, Langer, Science 249: 1527-1533 (1990).Attorney Docket No. 167705-038401PCT
[0218] Methods of treatment
[0219] In various aspects, the present disclosure provides a method for treating a subject having a disease characterized by an excessive immune response (e.g., excessive inflammatory response) or an inadequate immune response. Compositions and methods of the present disclosure are expected to modulate immune response, for example, by mimicking the natural homeostatic downregulation of immune response in response to pH change. Accordingly, compositions and methods of the present disclosure are expected to ameliorate diseases characterized by an undesirable immune response. In some embodiments, the disease is cancer. In some embodiments, the disease is characterized by an excessive immune response, for example, sepsis, or inflammatory bowel disease (IBD). In embodiments, the subject has a low or acidic pH. In embodiments, the subject has hypoxia. In embodiments, the subject has a low or acidic pH at or near a site associated with the disease or disorder. In embodiments, the subject has hypoxic conditions at or near a site associated with the disease or disorder.
[0220] In some embodiments, the methods herein include administering to a subject (including a human subject identified as in need of such treatment) an effective amount of engineered cells of the disclosure (e.g., immune cells expressing a series of histidines fused to a heterologous protein of interest, fused to a BRD4 polypeptide, variant thereof, or fragment thereof). The treatment methods are suitably administered to a subject, particularly a human, suffering from, susceptible to, or at risk of having cancer or another disease characterized by inflammation. In some embodiments, the subject requires modulation of an immune response. In some embodiments, the subject is administered a single dose of the engineered cells, BRD4 polypeptides, variants thereof, or fragments thereof, or polynucleotides encoding the same. In various embodiments, the engineered cells are autologous to the subject to which they are administered.
[0221] In some embodiments, the agent administered is JQ-1, which is a potent, specific, and reversible BET bromodomain inhibitor. The structure of JQ-1 follows:
[0222]
[0223] (+)-JQ-l Chemical Structure
[0224] CAS No.: 1268524-70-4Attorney Docket No. 167705-038401PCT
[0225] In some embodiments, the agent is IBET (also termed iBET or I-BET 762), which is described by Nicodeme et al., Nature 2010 Dec 23;468(7327): 1119-23. The structure of IBET follows:
[0226]
[0227] I-BET 762 Chemical Structure
[0228] CAS No.: 1260907-17-2
[0229] In some embodiments, the agent is MS645. MS645 is a bivalent BET bromodomains (BrD) inhibitor. The structure of MS645 follows:
[0230]
[0231] MS645 Chemical Structure
[0232] CAS No.: 2250091-96-2Attorney Docket No. 167705-038401PCT
[0233] Identifying a subject in need of such treatment can be based on the judgment of the subject or of a health care professional and can be subjective (e.g., opinion) or objective (e.g., measurable by a test or diagnostic method). Briefly, the determination of those subjects who are in need of treatment or who are “at risk” or “susceptible” can be made by any objective or subjective determination by a diagnostic test (e.g., blood sample, biopsy, genetic test, enzyme, or protein marker assay), marker analysis, family history, and the like, including an opinion of the subject or a health care provider. A subject undergoing treatment can be a non -human mammal, such as a veterinary subject, or a human subject (also referred to as a “patient”).
[0234] The engineered cells and / or agents of the disclosure may be administered to a subject by any of the routes normally used for introducing a cell or agent into a subject. Routes and methods of administration include, without limitation, intradermal, intramuscular, intraperitoneal, intrathecal, parenteral, such as intravenous (IV) or subcutaneous (SC), vaginal, rectal, intranasal, inhalation, intraocular, intracranial, or oral. Parenteral administration, such as subcutaneous, intravenous, or intramuscular administration, is generally achieved by injection (immunization). Injectables can be prepared in conventional forms and formulations, either as liquid solutions or suspensions, solid forms (e.g., lyophilized forms) suitable for solution or suspension in liquid prior to injection, or as emulsions. Injection solutions and suspensions can be prepared from sterile powders, granules, and tablets. Administration can be systemic or local.
[0235] The engineered cells, agents, or compositions thereof, can be administered in any suitable manner, such as with pharmaceutically acceptable carriers, diluents, or excipients as described supra. Pharmaceutically acceptable carriers are determined in part by the agents being administered, as well as by the particular method used to administer the composition.
[0236] Accordingly, a pharmaceutical composition comprising the engineered B cells or compositions thereof, can be prepared using a wide variety of suitable and physiologically and pharmaceutically acceptable formulations.
[0237] Administration of the engineered cells of the disclosure, agents, or compositions thereof, can be accomplished by single or multiple doses. It may be advantageous to administer only a single dose of engineered cells to a subject. The dose administered to a subject should be sufficient to induce a beneficial therapeutic response in a subject over time, such as to modulate an immune response or tumor microenvironment in the subject. The dose required will vary from subject to subject depending on the species, age, weight, and general condition of the subject, by the severity of the cancer being treated, by the particular composition being used and by the mode of administration. An appropriate dose can be determined by a person skilled in the art, such as a clinician or medical practitioner, using only routine experimentation. One of skill in the art is capable of determining therapeutically effective amounts of engineered cells and / orAttorney Docket No. 167705-038401PCT
[0238] agents that provide a therapeutic effect or protection against diseases associated with inflammation, cancer, or an undesirable immune response.
[0239] In various embodiments, the engineered cells administered to the subject are detectable in the subject after about or after at least about 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 3 months, 4 months, 5 months 6 months, or a year post-administration.
[0240] In some cases, administration of the engineered cells or agents to the subject is associated with an alteration in the pH of a cell or cellular environment (e.g., tumor microenvironment) relative to a reference subject. The administration of the engineered cells or agents may be associated with an increase in immune response in the subject relative to a reference subject. For example, the administration may result in a decrease in tumor volume or mass by about or at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% relative to a reference.
[0241] Kits
[0242] The instant disclosure also provides kits containing agents of this disclosure for use in the methods of the present disclosure. Kits of the instant disclosure may include one or more containers comprising an agent for treatment of a neoplasia, an undesirable immune response, inflammation, or another disease or disorder associated with an undesirable immune response. In some embodiments, the kits further include instructions for use in accordance with the methods of this disclosure. In some embodiments, these instructions comprise a description of use of the agent to treat, e.g., a neoplasia, an undesirable immune response, inflammation, or another disease or disorder, such as sepsis or IBD, according to any of the methods of this disclosure.
[0243] Instructions supplied in the kits of the instant disclosure are typically written instructions on a label or package insert (e.g., a paper sheet included in the kit), but machine-readable instructions (e.g., instructions carried on a magnetic or optical storage disk) are also acceptable. Instructions may be provided for practicing any of the methods described herein.
[0244] The kits of this disclosure are in suitable packaging. Suitable packaging includes, but is not limited to, vials, bottles, jars, flexible packaging (e.g., sealed Mylar or plastic bags), and the like. Kits may optionally provide additional components such as buffers and interpretive information. Normally, the kit comprises a container and a label or package insert(s) on or associated with the container.
[0245] The practice of the present invention employs, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology,Attorney Docket No. 167705-038401PCT
[0246] biochemistry and immunology, which are well within the purview of the skilled artisan. Such techniques are explained fully in the literature, such as, “Molecular Cloning: A Laboratory Manual”, second edition (Sambrook, 1989); “Oligonucleotide Synthesis” (Gait, 1984); “Animal Cell Culture” (Freshney, 1987); “Methods in Enzymology” “Handbook of Experimental Immunology” (Weir, 1996); “Gene Transfer Vectors for Mammalian Cells” (Miller and Calos, 1987); “Current Protocols in Molecular Biology” (Ausubel, 1987); “PCR: The Polymerase Chain Reaction”, (Mullis, 1994); “Current Protocols in Immunology” (Coligan, 1991). These techniques are applicable to the production of the polynucleotides and polypeptides of the invention, and, as such, may be considered in making and practicing the invention. Particularly useful techniques for particular embodiments will be discussed in the sections that follow.
[0247] The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the assay, screening, and therapeutic methods of the invention, and are not intended to limit the scope of what the inventors regard as their invention.
[0248] EXAMPLES
[0249] Example 1: Acidic pH modulates gene-specific inflammatory response
[0250] In a murine model of acute inflammation, intraperitoneal (i.p.) injection of a sub-lethal dose of Escherichia coli LPS in wild-type mice (WT) triggered a TLR4-dependent systemic inflammatory response. As a consequence, the blood pH decreased significantly at 6 hours postinjection (FIG. IB). Severe acidosis (< pH 6.5) was reported in various tissues at 24 h (Henry, et al., J. Nucl. Med. 61, 1361-1368.) including liver, small intestine, kidney, brain stem, hypothalamus and cortex of the brain, underscoring the link between acidic pH levels and acute inflammatory response. In vitro, WT bone marrow derived macrophages (BMDMs) acidified the extracellular environment to pH 6.5 at 24 hours after LPS stimulation (FIGs. 1C, 8A), in the presence of a physiological level buffer system (23.8 mM bicarbonate). Notably, this pH level did not adversely affect the viability of BMDMs (FIG. 8B) nor impede TLR4 internalization triggered by LPS exposure (FIG. 8C). Consequently, BMDMs were conditioned at pH 6.5 to further investigate the influence of acidic conditions on the inflammatory responses of macrophages.
[0251] The transcriptional response to LPS in macrophages is regulated by TLR4 signaling pathways, epigenetic mechanisms, and both feedback and feedforward genetic circuits. (Smale andNatoli, Cold Spring Harb. Perspect. Biol. 6, a016261; Natoli, et al., Nat. Immunol. 20, 783-792; Gatchalian, et al., Trends Immunol. 41, 126-140; Pope, et al., Mol. Cell 71, 389-397; Fitzgerald, et al. Cell 180, 1044-1066). The transcriptionally induced genes can beAttorney Docket No. 167705-038401PCT
[0252] categorized into primary response genes (PRGs) and secondary response genes (SRGs) depending on the reliance of the latter on newly synthesized proteins. (Smale and Natoli, Cold Spring Harb. Perspect. Biol. 6, a016261.) PRGs can be further subdivided into early and late response groups based on activation kinetics. To evaluate the overall impact on the inflammatory response, expression of early PRGs (Cxcll, Illb, Nfkbia, Tnf Tnfsf9'), late PRGs (IfhbT) and secondary response genes Ifitl, 116, 1112b, Saa3) were examined at 4 hours post LPS exposure. (Tong, et al., Cell 165, 165-179.) It was found that conditioning BMDMs at pH 6.5 revealed a gene-specific impact on inflammatory genes that did not correlate with the classification of PRGs and SRGs (FIG. ID). The transcription of Cxcll, Ifitl, Nfkiba, Tnf and Vcaml was relatively insensitive to pH, whereas Ednl, Illb, 116, 1112b and Saa3 were significantly repressed at pH 6.5. Remarkably, the induction of Ifnbl, Tnfsf9, Adm and 1123a was greatly enhanced, showing an average of 20-fold increase at pH 6.5.
[0253] Varying experimental conditions, including concentrations of LPS (10 to 1000 ng / mL) and duration of pH conditioning (4-12 hours) demonstrated a similar pattern of gene-specific regulation by acidic pH (FIGs. 8D, 8E), independent of inflammasome activity (FIG. 8F).
[0254] Furthermore, analysis of gene expression over time revealed a switch-like pattern among pH-regulated genes (FIG. IE), and such pH-dependent gene expression translated into protein-level responses (FIGs. IF and 8G-H) In particular, interferon-β production was significantly elevated at pH 6.5, and the conditioned medium of LPS-treated BMDMs at pH 6.5 stimulated stronger STAT1 phosphorylation (FIG. 81), suggesting that the pH-dependent transcriptional response controls functionally distinct inflammatory programs. Notably, Ednl and Adm, which encode endothelin-1 and adrenomedullin, respectively, have antagonistic effects on blood vessels through vasoconstriction and vasodilation and exhibit differential activation at pH 7.4 and 6.5. (Hinson, Endocr. Rev. 21, 138-167.) The gene-specific sensitivity to pH and the regulation of opposing physiological functions indicated that macrophages orchestrate a qualitatively different type of inflammatory response based on microenvironment, rather than merely adjusting the magnitude of immune activation.
[0255] Example 2: Common pH sensors cannot account for pH-dependent inflammatory response Among the known pH sensors, Gpr65, Gpr68, Hifla, Hif2a are abundantly expressed in BMDMs and tissue resident macrophages (FIGs. 1G, 8J). (Lavin, Y., et al., Cell 159, 1312— 1326.) Whether pH-dependent inflammatory responses in BMDMs differentiated from Gpr65-I-, Gpr68-!-, Hiflaflox / flox lyz2Cre and Hif2aflox / flox lyz2Cre was investigated in mice in vitro.
[0256] However, the results indicated that neither Gpr65, Gpr68, Hifla nor Hif2a alone was essential for the observed gene-specific, pH-dependent regulation (FIGs. 1H-I). At pH 6.5, bothAttorney Docket No. 167705-038401PCT
[0257] GPR65 and GPR68 activated the production of cyclic AMP (cAMP). (Huang et al., Nature 527, 477-483.) To exclude the possibility of receptor redundancy, BMDMs were treated with 100 pM dibutyryl-cAMP, a cell-permeable analog of cAMP, and little effect on pH-dependent gene expression was observed (FIG. 8K). Although acidic pH may broadly affect biochemical reactions and protein interactions, the activation and repression of selective genes at pH 6.5 indicated that a general interference with transcription was unlikely. To further test this, BMDMs were treated with a-amanitin, a potent RNA Polymerase II inhibitor, and it was found that a-amanitin suppressed the activation of both pH-insensitive and pH-sensitive genes (FIG. I J). A similar effect was observed with camptothecin (FIG. 8L), a DNA topoisomerase I inhibitor known to broadly repress the inflammatory response of macrophages by inhibiting Pol II elongation. (Rialdi, A., et al., Science 352, aad7993.) In contrast, acidic pH mildly inhibited the cell cycle (FIG. 8M), but treating BMDMs with DNA polymerase inhibitor aphidicolin had minimal impact on the activation of inflammatory genes (FIG. 1 J). These results confirmed that gene-specific transcriptional control was required for the pH-dependent inflammatory response. Collectively, these findings indicated that the observed response was not dependent on established pH sensing mechanisms. Thus, it was demonstrated that a novel specific pH-sensing mechanism controls inflammatory gene expression.
[0258] Example 3: A deconvolution model reveals pH-dependent inflammatory programs Bulk RNA-seq of BMDMs was compared at pH 7.4, pH 7.4 LPS 4 h, pH 6.5, and pH 6.5 LPS 4 h (FIG. 2A) to comprehensively characterize the pH-dependent and pH-independent inflammatory response. Applying a stringent threshold (Fold change > 3 and q-value < 0.05), 522 genes were identified that uniquely induced at pH 7.4 and 85 genes were identified that uniquely induced at pH 6.5, underscoring the gene-specific inflammatory response by acidic pH. However, among 308 genes induced at both pH 7.4 and pH 6.5, many differed in their fold activation and expression counts (FIG. 9A). To gain a quantitative understanding of how the inflammatory response is regulated by acidic pH, a linear deconvolution model originally developed to dissect regulatory interactions among transcription factors was employed (Zhou, et al., Mol. Cell 42, 826-836; Zhou, et al., eLife 5, el 6970.). This model conceptualized that two signals, such as LPS stimulation and acidic pH, could control gene expression through three possible logics: LPS regulation independent of pH (LPS), pH regulation independent of LPS (pH), and the regulation dependent on the synergistic or antagonistic interactions between LPS and pH (INT). The combinations of these regulations (referred to as “expression components”) contributed to differential expression among all experimental conditions (FIG. 2B), and applying the linear deconvolution model allowed for assessing them simultaneously for each gene (FIG.Attorney Docket No. 167705-038401PCT
[0259] 9B) An expression component close to 0 indicated a lack of regulation, while a positive or a negative value indicated activation or repression, or that LPS and acidic pH acted synergistically or antagonistically.
[0260] Overall, more than 92% of differentially expressed genes (FIG. 9C) were well captured using the 3-component linear model (R2 > 0.9) (FIG. 2C). 1620 genes had at least one significant expression component (p<0.05, null hypothesis component > 2-fold), forming 20 clusters with at least 5 genes each (FIGs. 2D, 9D). Among genes regulated by LPS and pH independently (cluster 1-8), cluster 1-4 represented independent activation or repression by only acidic pH or LPS, while Clusters 5-8 represented combinations of these independent regulations. For example, Cluster 3 included Nfkbib, Nfkbid, Nfkbie, and Cluster 5 included Nfkbia and Nkfbiz. These were all induced by LPS independent of pH despite having differences in pH-dependent basal expression (FIG. 9F). Cluster 9-14 included genes regulated antagonistically by pH and LPS (a positive LPS and a negative INT expression component), including inflammatory cytokines (116, 1112a, 1112b, 1118), chemokines (Ccl5, Ccl8, Ccll2, Cxcl9, CxcllO, Cxclll), acute phase proteins (Oasl, Oas2, Oas3, Saa3) and inflammatory effectors (Ednl, Nos2). Finally, group 15-18 included genes synergistically regulated by LPS and acidic pH, such as Adm, Ifnbl, Tnfsf9, 1123a and Adora2b. To examine potential immune functions enriched in pH-dependent and independent responses, the 20 clusters were merged into groups characterized as pH-insensitive (non-significant INT), pH-antagonistic (opposite signs between LPS and INT) or pH-synergistic (both positive or both negative for LPS and INT) (FIG. 9D). Overall, approximately 40% of LPS-regulated genes were pH-insensitive. Among pH-regulated genes, an antagonistic effect predominated in both LPS-induced and LPS-repressed responses (88% and 86% respectively, FIG. 9E). Since LPS induced transcriptional program served as a model system for innate inflammatory response, the three groups of LPS induced genes: pH-insensitive (pHIN), pH-repressed (pHANTI) and pH-synergistic genes (pHSYN) were studied. pHINgenes were uniquely enriched in TLR signaling, T cell activation, integrin interactions, and showed strongest enrichment in innate immune response and antimicrobial defense (FIG. 2E).
[0261] The majority of LPS-induced integrins and NF-kB regulators were regulated by LPS independent of pH (FIG. 2F). On the contrary, pHANTIgenes were uniquely enriched in MHC I presentation, IL-1 signaling, chemotaxis, and showed the strongest enrichment in cytokine receptor interactions, antiviral and adaptive immune response (FIG. 2E). The activation of most antigen presentation genes and cytokines were strongly repressed by acidic pH (FIG. 2F).
[0262] Interestingly, pHSYNgenes, although fewest in number, were enriched in blood vessel morphogenesis and T cell differentiation (FIG. 2E). These analyses revealed that the activationAttorney Docket No. 167705-038401PCT
[0263] of innate defense programs is relatively insensitive to pH, while the coordination and recruitment of other branches of the immune system were dependent on the tissue microenvironment.
[0264] TLR4-induced genes were regulated by two signaling adaptors, MyD88 and TRIF (FIG.
[0265] 2G). (Fitzgerald, et al. Cell 180, 1044-1066.) MyD88 recruits IL-1 receptor-associated kinases (IRAKs) and TRAF6, initiating the activation of the transcriptional activator NF -kB. Conversely, TRIF facilitates TRAF3 -dependent activation of TBK1, which phosphorylates the transcription factor IRF3 to regulate interferon beta and other interferon-induced genes. It was found that the consensus binding motif of p65 (NF-kB) was enriched in both pHINand pHANTIgenes, whereas the IRF3 motif was only enriched in pHANTIgenes (FIG. 2G). However, LPS-induced degradation of the NF-kB inhibitory regulator IkBa, IRF3 phosphorylation as well as autocrine type-I Interferon (induced by both NF-kB and IRF3) signaling via STAT1 phosphorylation, all displayed comparable kinetics between pH 7.4 and pH 6.5 in BMDMs (FIG. 2H). Furthermore, the nuclear localization of p65 and IRF3 was found comparable at both pH levels (FIG. 21). Of note, several Interferon-stimulated genes (ISGs) were repressed despite a higher level of Interferon-b at pH 6.5. This was not due to the inhibition of Interferon-b signaling (FIGs. 9G, 9H) nor the inhibition of interferoninduced ISG expression (FIG. 91). These findings indicated that pH-sensitive and pH-insensitive genes were differentially regulated at the level of transcriptional activation rather than signal transduction.
[0266] Example 4: pH regulates gene expression at the chromatin level
[0267] IRF3 exhibited a delayed activation kinetics compared to NF-kB (FIG. 2H). The observed enrichment of IRF3 motifs indicated possible differences in activation kinetics between pHINand pHANTIgenes. At pH 7.4, it was found that pHINgenes reached full activation within 2 hours after LPS stimulation, whereas pHANTIgenes showed minimal induction, only peaking at 4 hours (FIG. 3A). Interestingly, pHSYNgenes demonstrated the most rapid and transient activation (FIGs. 3A, 10A). The LPS-repressed genes also displayed a similar pH-dependent kinetics (FIG. 10B) Therefore, acidic pH was shown to act on a timelimiting step required for the activation of the pHANTIgenes. LPS-induced SRGs typically have delayed activation due to the requirement for new protein synthesis (Tong, et al., Cell 165, 165-179.) and were found to have a strong pH-dependence compared to PRGs in the data (FIG. 10C). However, blocking protein synthesis in BMDMs with cycloheximide (CHX) did not affect pHANTIgenes to the same extent as acidic pH (FIGs. 3B, 10D). On the other hand, the activation of pHSYNgenes was almost completely replicated by blocking protein synthesis (FIGs. 3B, 10D), indicating that the induction of potential transcriptional repressors was suppressed by acidic pH, thereby facilitating the elevated activation of pHSYNgenes.Attorney Docket No. 167705-038401PCT
[0268] A second possibility of a delayed activation kinetics involves chromatin remodeling. Given that acidic pH has been linked to modulation of histone acetylation and metabolism in cell lines (McBrian, et al., Mol. Cell 49, 310-321; Corbet, et al., Cell Metab. 24, 311-323.) ATAC-seq and ChlP-seq was performed to examine chromatin accessibility and histone modifications (H3K27ac and H3K4me3) associated with transcriptional activation. On average, 214,808 peaks were identified across the four conditions (pH 7.4, pH7.4 LPS, pH 6.5 and pH 6.5 LPS) (FIG. 10E). ATACseq peaks were identified that were either significantly induced by LPS (> 4-fold, pH 7.4 LPS vs pH 7.4) or homeostatically maintained at pH 7.4 (< 2-fold, pH 7.4 LPS vs pH 7.4) across two biological replicates. At the LPS-induced peaks, a comparable increase in ATAC-seq, H3K27ac and H3K4me3 was observed after LPS between pH 7.4 and 6.5, while the homeostatic peaks remained unchanged among all examined conditions (FIG. 10F). Intriguingly, ATAC-seq signals were mildly elevated at pH 6.5 independently of LPS stimulation (FIG. 10F), suggesting that acidic pH did not restrict chromatin accessibility. The global levels of H3K27ac and H3K4me3 were consistent across conditions, aligning with genespecific control at pH 6.5. To probe pH-dependent transcriptional mechanisms, the enrichment of transcription factor motifs in ATACseq peaks associated with pH-dependent activity was analyzed genome-wide. Among peaks with differential H3K27ac (> 2-fold) between pH 7.4 and pH 6.5, or LPS-induced peaks with differential H3K27ac (> 2-fold) between pH 7.4 LPS and pH 6.5 LPS, enrichment was observed for similar DNA sequence motifs (FIGs. 10G, 10H). The surprising absence of the association between unique transcriptional factor and pH-dependent activity suggested that transcription factor activity was not a key determinant of pH-dependent inflammatory responses. To identify clues for pH-dependent regulation, chromatin changes specific to pHIN, pHANTIand pHSYNgenes (FIG. 3C) was further examined. Consistent with the genomic profile, ATAC-seq signals at TSS were elevated at pH 6.5 across all three gene groups and demonstrated a similar increase after LPS between pH 7.4 and 6.5. A consistent difference in H3K27ac was not observed. Interestingly, the increase of H3K4me3 was selectively reduced in pHANTIgenes after LPS stimulation at pH 6.5, particularly within the gene body immediately downstream of TSS (FIGs. 3C, 3D), consistent with reduced transcriptional activity.
[0269] Intriguingly, the pHANTIgenes exhibited lower H3K27ac and H3K4me3 signals at baseline as well as lower enrichment of CpG islands (p = 0.002, Chi-squared test), albeit similar levels of expression and chromatin accessibility (FIG. 101). Overall, both the lack of pH-dependent difference in global histone modifications and the comparable regulation of chromatin accessibility at TSS indicated that acidic pH may primarily affect distal regulatory elements to control gene activation.Attorney Docket No. 167705-038401PCT
[0270] By assigning ATACseq peaks to their nearest genes, it was found that enhancers associated with pHANTIgenes were enriched for both IRF and NF-kB motifs, whereas enhancers associated with pHINgenes were enriched for NF-kB motifs (FIG. 10J), consistent with similar findings from the promoter analysis (FIG. 2G). However, the average profiles of ATACseq, H3K27ac, and H3K4me3 signals at these enhancers did not reveal a clear trend (FIG. 13E). Thus, examples of pH-dependent and independent genes were examined. At 116 and Ednl loci, two representative pHANTIgenes, transcriptional induction was correlated with the activation of multiple distal enhancers spanning hundreds of thousands of base pairs — marked by increased ATAC-seq and broadened H3K27ac peaks at pH 7.4 following 4 hours of LPS stimulation (FIG.
[0271] 3E). Notably, the H3K27ac signals at these enhancers were completely abolished at pH 6.5, along with a reduction in chromatin accessibility and binding of p65 and IRF3 by ChlP-seq. In contrast, the pHINgene Nfkbia displayed consistent epigenetic marks across pH conditions, and the pHSYNgene7 / Z>7 exhibited elevated H3K27ac and H3K4me3 at gene TSS, as well as enhanced IRF3 binding at a -15kb enhancer (FIG. 3E), arguing against the possibility that acidic pH pleiotropically blocks histone modification or epigenetic remodeling.
[0272] To probe this further, histone acetyltransferase (HAT) p300 was inhibited with C646 and histone deacetylases (HDACs) we reinhibited with pan-inhibitor TSA (Finnin, et al., Nature 401, 188-193; Bowers, et al., Chem. Biol. 17, 471-482.). Overall, HAT inhibition resulted in a less profound effect than HD AC inhibition, yet both differed from the influence of acidic pH (FIG. 10K). For instance, TSA strongly inhibited both pHINand pHSYNgenes (FIG. 10D), and the activation of pHANTIgenes required both HAT and HD AC activity (FIG. 10K). Thus, combining epigenetic profiling and pharmacological perturbations, our data indicated that a pH-sensitive epigenetic mechanism specifically impacted the activation of inflammatory genes. Genes induced immediately by TLR signaling are insensitive to pH difference, while genes dependent on the activation of NF-kB, IRF3 and distal enhancers are more likely to be influenced by the tissue microenvironment. Putative transcriptionally induced repressors belonging to the pHANTIgroup may be necessary to deactivate Ifnbl, Adm and other pHSYNgenes at pH 7.4; its absence at pH 6.5 leads to their prolonged and heightened activation. It was found that transcription factor IRF2, a transcriptional repressor of the interferon regulatory family (Lukhele, et al., Immunity 55, 2369-2385. elO. 59) was induced by LPS and repressed by acidic pH at both mRNA and protein levels (FIGs. 10L, 10M). CRISPR knock-outs of Irf2 in an immortalized BMDM cell line (iBMDM) significantly enhanced the induction of Ifnbl mRNA (FIGs. ION, 100), and Irf2 deficiency abolished synergistic induction of Ifnbl at pH 6.5 (FIG.
[0273] 10P) These data uncovered IRF2 as one of the negative feedback regulations underlying the switch between pHANTIand pHSYNresponses (FIG. 3F).Attorney Docket No. 167705-038401PCT
[0274] TLR4 and nucleic acid sensors induce both IRF3 -dependent genes and ISGs (STATl / STAT2 / IRF9-dependent genes). The data indicated that these two groups of genes were differentially regulated by pH, with some IRF3 -dependent genes being repressed, and a few genes, including Ifnbl, being hyperinduced. Intriguingly, acidic pH did not significantly repress STAT 1 -dependent Interferon-b response, and in some cases, even enhanced Interferon-induced ISG expression (FIG. HA). Thus, the IRF3 -dependent and STAT 1 -dependent regulatory mechanisms generated differential antiviral programs based on pH.
[0275] Example 5: Transcriptional condensates of BRD4 are sensitive to acidic pH
[0276] The budding yeast Snf5, a core component of SWI / SNF chromatin remodeling complex, was recently found to be sensitive to intracellular pH (pHi) (Gutierrez, et al., eLife 77, e70344.). Two histidine residues on a disordered loop of S. cerevisiae Snf5 become protonated at pH 6.5 and this protonation disrupts the electrostatic interactions with nucleosomes and transcription factors (Gutierrez, et al., eLife 77, e70344.). However, this disordered loop is only present in fungi. Guided by its biochemical properties, a bioinformatic screening was performed to identify putative pH sensors that could mediate pH-dependent transcriptional response in macrophages. The screening was based on three assumptions: 1) a pH-sensitive protein must carry a peptide region with a significant difference in protonation between pH 7.4 and 6.5 (Acharge), 2) this region is near uncharged residues or disordered sequences, with minimal prior structural constraints, and 3) this region is enriched in prolines (P) and glutamines (Q), similar to the disordered loop in yeast SNF5. 50,961 annotated proteins were scanned in the mouse genome (UniProt) to identify putative regions with significant Acharge (> 1 histidine residues in a stretch of 20 amino acids). The results were then filtered based on IDR consensus score (Emenecker, et al., Biophys. J. 120, 4312-4319.) and PQenrichment, and gene expression in BMDMs (FIG. 4A). BRD4, a BET family member known for recognizing acetylated histones and regulating transcriptional programs in development and inflammation, (Henry, et al., J. Nucl. Med. 61, 1361-1368) was identified as a top candidate. BRD4 has two regions enriched for histidine, proline, and glutamine (HPQ) (FIG. 4A): AA 721-800, featuring a stretch of six consecutive histidine residues resembling an endogenous His-tag motif adjacent to a 40-residue non-polar region with 90% poly-PQ, and AA 1001-1080, containing nine histidine and 39 proline or glutamine residues. These regions had a minimal net charge (FIG. 11B) and were within the C-terminal Intrinsically Disordered Region (IDR) of BRD4 (IDRBRD4). The IDR-containing full length BRD4 was the most abundant isoform expressed in BMDMs (FIGs. 11C, HD).
[0277] Using a pH-sensitive fluorescent dye SNARF (Hunter, et al., Appl. Environ. Microbiol.
[0278] 71, 2501-2510.) and a nuclear-localized pH-sensitive fluorescent reporter (Liu, et al., Nat.Attorney Docket No. 167705-038401PCT
[0279] Commun. 14, 3745.), it was found that the intracellular pH (pHi) as well as nuclear pH of macrophages, decreased to pH 6.6 in pH 6.5 medium (FIGs. 4B, 4C, and HE), exposing BRD4 directly to an acidic environment. Since BRD4 forms transcriptional condensates via its hydrophobic IDR, (Sabari, et al., Science 361, eaar3958.) it was hypothesized that pH-dependent protonation of histidine residues may disrupt the hydrophobic interactions critical for condensate formation. At pH 7.4, endogenous BRD4 formed small and distinct foci in BMDMs, and these foci were substantially reduced at pH 6.5 by confocal microscopy (FIG. 4D, E).
[0280] Treatment with 10% 1,6-hexanediol (1,6-HD), a chemical known to disrupt weak hydrophobic macromolecular interactions, reduced BRD4 foci similarly to acidic pH. Given that the size of transcriptional condensates approached the resolution limit of confocal microscopy, Stimulated Emission Depletion (STED) microscopy was utilized to better characterize pH-dependent changes in BRD4 condensates, up to a 25-nm resolution (FIG. 4F). At pH 7.4, the diameter of BRD4 condensates ranged from 70 - 200 nm in BMDMs, and congregated at a few discrete sizes (FIGs. 4G-H) At pH 6.5, the remaining BRD4 condensates exhibited a similar size distribution but showed substantially reduced intensity, forming an almost bimodal distribution compared to condensate intensities at pH 7.4 (FIGs. 4G-H). Fluorescence Recovery After Photobleaching (FRAP) analyses measured comparable recovery of BRD4 condensates near completion within 5-6 seconds at pH 7.4 and pH 6.5 (FIG. 41), exhibiting liquid-like properties similar to previous reports (Sabari, et al., Science 361, eaar3958.). Both BRD4 mRNA and protein expression remained stable at pH 6.5 (FIGs. HF, 11G), demonstrating that condensates rather than BRD4 expression were regulated by pH. To discern potential roles of signaling and cytoplasmic contents, BMDM nuclei were isolated after gently lysing the plasma membrane and were incubated at pH 7.4 or 6.5 for 0.5 hours, followed by fixation and imaging (FIG. 11H).
[0281] Endogenous BRD4 could form distinct foci in isolated nuclei, although fewer in quantities than in living cells. Despite the morphological difference, it was found that BRD4 foci significantly decreased in acidic pH (FIG. 4J), demonstrating nuclear intrinsic roles in regulating pH-dependent BRD4 condensates.
[0282] To further investigate the dynamics of BRD4 condensates, a stable 293 T cell line was generated expressing a murine mCherry-BRD4 fusion protein for live-cell imaging. Initially, heterogeneous response in mCherry-BRD4 was shown, likely due to variability in pH buffering capacity between cells. Treating 293T cells with a proton ionophore 2-4-Dinitrophenol (2,4-DNP) equilibrated extracellular and intracellular pH, (Dechant, et al., EMBO J. 29, 2515- 2526.) and significantly reduced the heterogeneity in BRD4 condensates (FIG. HI). To monitor the dynamic changes, these cells were treated with 2,4-DNP for 30 min at pH 7.4 and then the medium was abruptly switched to pH 6.5. Remarkably, BRD4 condensates were significantlyAttorney Docket No. 167705-038401PCT
[0283] reduced within 10-12 minutes, and upon returning to pH 7.4, the condensates reappeared and recovered in 1 hour (FIGs. 4K, 11 J). In contrast, cells expressing only mCherry showed constant fluorescent signals unaffected by pH (FIG. 11K). (Rennick, et al., Nat. Commun. 73, 6023.) Collectively, these findings demonstrated that BRD4 condensates were dynamically regulated in a pH-dependent manner within live cells, highlighting their role in regulating cellular responses to environmental shifts.
[0284] Example 6: Histidine-rich IDR mediates pH-dependent regulation of BRD4
[0285] Given that pH-dependent changes in BRD4 condensates were reversible, whether the impact on inflammatory responses could be reversed after normalizing pH was investigated. BRD4 condensates were significantly reduced after overnight incubation at pH 6.5 and were fully restored after 4 hours at pH 7.4 (FIGs. 5A, 5B). Alongside the changes in BRD4 condensates, pH-repressed genes regained activation nearly completely after re-conditioning at pH 7.4 with the exception of only a few genes (FIG. 5C), representing possible imprinting by the environment (FIG. 12A). To test whether pH-dependent genes were regulated by BRD4, the transcriptional response to LPS in Brd4-I- BMDMs was analyzed. (Dey, et al., EMBO J. 38, el00293.) The deconvolution model was applied to identify LPS-induced genes that were BRD4-dependent and independent, and it was found that the BRD4-dependent genes were more repressed under acidic conditions (FIG. 12B). Similarly, competitive inhibitors targeting the bromodomains of BRD4 (JQ-1, iBET, and MS-645), or disrupting condensates with 1% 1,6-HD, consistently repressed pHANTIgenes (FIG. 5D). Thus, the pH-dependent inflammatory regulation was demonstrated to be functionally linked to BRD4 condensates.
[0286] Histidine is responsible for the majority of protonation around physiological pH. It was found that IDRBRD4was uniquely enriched for histidine (FIGs. 5E, 12C), as both full length BRD4 (FIG. 12D) and IDRs from mouse proteome (FIG. 12E) lacked histidine enrichment. Moreover, the two identified HPQ regions were highly conserved among vertebrates (FIG. 5F), suggesting potential biological significance of these sequence features. To investigate whether histidine residues directly contributed to pH-dependent condensates, a BRD4HAmutant was synthesized by swapping 33 histidine residues within IDRBRD4to alanine to eliminate most pH-dependent Acharge. 293T cell lines were established expressing comparable levels of murine mCherry -BRD4WTor mCherry -BRD4HA(FIG. 12F), where both BRD4 variants appeared in condensates, likely due to high sequence homology between mouse and human. To minimize the complication of endogenous human BRD4, all live-cell imaging was performed at 24 hours after siRNA knock-down of hBRD4. In these experiments, it was observed that the number of BRD4WTcondensates (36 cells) began to decrease between 2-5 minutes at pH 6.5, stabilizing atAttorney Docket No. 167705-038401PCT
[0287] -25% of their original quantity by half an hour; in contrast, these pH-dependent changes were completely abolished for BRD4HA(45 cells) (FIG. 5G). These data indicated that BRD4 directly sensed intracellular pH via its histidine-rich IDR, and thus dynamically regulated transcriptional condensates to control gene expression.
[0288] To further investigate how the histidine-rich IDR mediated pH-dependent condensates, histidine was replaced with alanine in four segments along BRD4-IDR (FIG. 5H). Three out of four segment mutants (AHHH, HAHH, HHAH) were able to rescue proliferation in BRD4 deficient cells to levels comparable to wild-type BRD4 (FIG. 12G), suggesting proper functions of these segment mutants. Among them, it was found that mutated histidine residues in AHHH and HHAH were required for pH-dependent regulation (FIG. 5H). These two segments also overlapped with the two putative pH-sensitive regions in the bioinformatic screen (FIG. 4A), indicating that the size and distribution of the histidine cluster, along with the neighboring amino acid composition, were critical for pH sensing. To test sufficiency of histidine clusters in pH-dependent condensate regulation, synthetic IDRs were constructed by fusing 6X or 12X histidine with the N-terminal IDR of the FUS protein. IDRFUSlacks histidine and charged residues, and forms small nuclear condensates phenotypically similar to BRD4 condensates in BMDMs (Lyons, et al., Cell 186, 327-345.) Over-expression of mCherry-IDRFUSproduced condensates in both the nucleus and cytosol (FIG. 12H) that were insensitive to pH shifts from 7.4 to 6.5 (FIG.
[0289] 5H). Notably, introducing 12X-histidine but not 6X-histidine disrupted FUS condensates at pH below 6.5 without affecting their expression levels (FIGs. 51, 121-12 J), demonstrating that pH-sensitivity can be tuned by the size of histidine clusters. Thus, histidine clusters in uncharged IDRs were both necessary and sufficient to control pH-dependent phase condensates.
[0290] Example 7: Gene-specific mechanisms for pH-dependent regulation
[0291] BRD4 was shown to bind to and regulate both pH-sensitive and pH-insensitive genes (FIG. 5D). It was thus studied how pH-dependent BRD4 condensates could specifically influence a subset of inflammatory genes. The mainstream model of BRD4-dependent gene activation illustrates that BRD4 recognizes histone acetylation via its bromodomains and recruits mediator complexes to active enhancers, facilitating the interaction between distal enhancers and promoters to activate transcriptional machinery. (Cho, et al., Science 361, 412-415.) Given the distinct changes at enhancers of pH-sensitive genes, it was hypothesized that pH-dependent condensates facilitated remodeling and activation of enhancers, and thus controlled gene activation that strongly depends on these processes.
[0292] First, bridging enhancer activation to gene promoters requires mediators. (Malik, et al., Nat. Rev. Genet. 11, 761-772.) Both BRD4 and MED1 form liquid-liquid phase condensatesAttorney Docket No. 167705-038401PCT
[0293] and co-localize at distinct nuclear foci to recruit RNA polymerase II. (Sabari, et al., Science 361, eaar3958.) At pH 7.4, endogenous MED1 formed condensates and co-localized with BRD4 in BMDMs (FIG. 6A). At pH 6.5, however, these condensates were substantially reduced, despite MED1 lacking an HPQ-enriched IDR (FIGs. 13A, 13B). Notably, the remaining puncta of BRD4 and MED1 were partitioned spatially, contrasting with the strong colocalization seen at pH 7.4 (FIGs. 6A, 6B). These pH-dependent changes were also aligned with the chemical disruption of condensates by 1,6-HD (FIGs. 6A, 6B). STED imaging further confirmed pH-dependent regulation of MED 1 condensates and uncovered detailed differences in the colocalization and interaction among BRD4 and MED1 condensates (FIG. 6C). Interestingly, a kinetic increase was observed in both BRD4 and MED1 condensates at 4 hours after LPS stimulation, temporally coupling the changes of transcriptional condensates and the activation kinetics of pH-sensitive genes (FIG. 13C). Since the reduction of H3K27ac at acidic pH was observed at the enhancers of pH-sensitive genes, it was thus tested whether interfering with binding to histone acetylation would result in a similar perturbation of BRD4 condensates.
[0294] Surprisingly, BRD4 and MED1 condensates were differentially affected by the bromodomain competitive inhibitors JQ1, iBET, and MS645, although all of them inhibited BRD4 functions (FIG. 5E). The contrasting phenotypes between acidic pH and BRD4 inhibitors also indicated that altered chromatin recruitment was not the cause for pH-dependent dissolution of transcription condensates. This was corroborated by comparable levels of global histone acetylation (FIG. 13F) and binding of BRD4 at house-keeping genes (FIG. 13D), which was consistent with previous findings that the reliance of condensates on histone acetylation may vary by cell type. (Sabari, et al., Science 361, eaar3958; Strom, et al., Mol. Biol. Cell, mbcE24010046; Han, et al., Nat. Struct. Mol. Biol. 27, 333-341.). Thus, acidic pH disrupted the formation of transcriptional condensates containing both BRD4 and MED1, two essential components of enhancer-regulated transcriptional activation.
[0295] Second, enhancer activation often requires chromatin remodeling. Bromodomaincontaining protein 9 (BRD9), a subunit of the noncanonical SWI / SNF chromatin remodeling complex (ncBAF), was found to co-localize with BRD4 at the enhancers and promoters enriched with both NF-kB and IRF3 binding motifs. (Ahmed, et al., Proc. National Acad. Sci. 119, e2110812119.) The inhibition of BRD4 with JQ1 displaces BRD9 in both BMDMs and embryonic stem cells (Ahmed, et al., Proc. National Acad. Sci. 119, e2110812119.) (Gatchalian, et al., Nat. Commun. 9, 5139.) without directly inhibiting BRD9 in vitro. (Filippakopoulos, et al., Nature 468, 1067-1073.) These findings suggested that BRD4 may directly interact with BRD9-containing ncBAF complex to activate enhancers. It was thus hypothesized that disruption of BRD4 condensates impacts BRD9 function to regulate enhancer activation in pH-sensitiveAttorney Docket No. 167705-038401PCT
[0296] genes. In the presence of a specific BRD9 inhibitor (BRD9i) or a BRD9 degrader (dBRD9), pHANTIgenes exhibited a significantly reduced activation in comparison to pHINgenes (FIGs.
[0297] 6D, 11K-11L). (Ahmed, et al., Proc. National Acad. Sci. 119 e2110812119.) Effective size analysis further revealed that a majority of pH-dependent regulation could be explained by the inhibition of either BRD4 or BRD9 (FIG. 6E). At inflammatory gene loci, ChlP-seq analysis of BRD4 and BRD9 revealed a significant reduction in LPS-induced recruitment at the enhancers and promoters at pH 6.5 for pH-sensitive genes, such as 116, 1112b, Saa3, Ednl (FIG. 6F). At genome-wide, BRD4 was significantly recruited to the enhancers associated with pHANTIgenes after LPS activation, but not at enhancers associated with pHINor pHSYNgenes (FIG. 6G), suggesting a differential requirement of BRD4 and chromatin remodeling. The enhancers of pHANTIgenes may be particularly sensitive to the control of transcriptional condensates.
[0298] Correspondingly, the recruitment of BRD4 was substantially reduced at pH 6.5 (FIG. 13E). Interestingly, it was found that BRD4 inhibition with JQ1 also had a profound impact on several pHINgenes (FIG. 13G), but these genes were significantly less sensitive to BRD4 inhibition than pHANTIgenes (FIGs. 13H, 131). However, BRD9 binding was indistinguishable between gene groups, indicating alternative mechanisms for BRD9 recruitment (FIG. 13E). Among BET family proteins, only BRD4 contains HPQ regions, and this was consistent with the pH-dependent BRD4 recruitment but not BRD9 recruitment shown in the data (FIGs. 13A, 13B). A recent proteomic analysis comparing different BRD4 isoforms suggested that the c-terminal IDRBRD4may directly interact with BRD9. (Wu, et al., Mol. Cell 84, 202-220. el 5.) FLAG-mCherry-IDRBRD4was thus expressed to test whether the interaction with BRD9 was affected by pH. It was observed that FLAG-mCherry-IDRBRD4was integrated into endogenous BRD4 condensates (FIG. 13F). Using Co-immunoprecipitation (Co-IP), it was found that the coassociation of BRD9 to BRD4 was substantially reduced at pH 6.5 (FIG. 13H). In connection with the differential regulation of distal enhancers of pH-sensitive genes (FIGs. 3F, 3G), these data indicated that pH-dependent BRD4 condensates regulate a subset of inflammatory response in macrophages by directly interacting with the non-classic BAF complex to activate enhancers.
[0299] BRD4, MED1 and enhancer activation are crucial for RNA Pol II elongation. It was hypothesized that Pol II elongation at pH-sensitive genes was selectively inhibited at acidic pH conditions, and activating elongation would mitigate the suppressive inflammatory response. The C-terminal fragment of BRD4 was found sufficient to release paused Pol II independent of the BET bromodomains. (Zheng, et al., Mol. Cell., Vol. 83, Issue 16.) The possibility of rescuing pH-dependent repression using IDRBRD4was thus tested. In iBMDMs, pH sensitive genes consistently regulated with BMDMs were identified (FIG. 13J). Over-expression of FLAG-mCherry-IDRBRD4significantly reversed the pH-dependent repression and reduced theAttorney Docket No. 167705-038401PCT
[0300] synergistic induction of Ifnbl, while maintaining proper activation of pH-insensitive genes (FIG.
[0301] 61). This data indicated that transcription condensates integrated environmental signals to orchestrate a gene-specific regulation of inflammatory response facilitated by chromatin remodeling (FIG. 6J). Leveraging BRD4-IDR could reverse environment-dependent repression of inflammatory responses based on this data.
[0302] Whether pH-dependent repression could be mitigated through control of intracellular pH was also tested. Macrophages (iBMDM) were transfected either with a vector encoding Hvl, a voltage-gated outwards proton pump, or with an empty (negative) control vector. After transfection, cells were stimulated with LPS, and the pH of the extracellular environment was set to either 7.4 or 6.5. The results showed that by controlling intracellular pH by using Hvl, pH-dependent control (based on the acidification of the extracellular environment) of the expression of transcriptional targets of BRD4 condensates was reversed (FIG. 15). These results were similar to the results of over-expression of IDRBRD4.
[0303] Example 8: pH sensing by BRD4 mediates feedback control of inflammatory activation To understand the potential functions of pH-dependent transcriptional condensates during inflammation, the change of pH upon stimulation with LPS was revisited. Interestingly, it was found that the pHi of BMDMs quickly decreased and plateaued after 8 hours (FIG. 14A), in addition to acidifying the extracellular environment (FIG. IB). The decrease in pHi cannot be simply restored by conditioning LPS-stimulated BMDMs in pH 7.4 medium (FIG. 7A), suggesting that LPS activates an intrinsic program to maintain a different intracellular state. Consequently, BRD4 and MED1 condensates were significantly reduced simply by the activation of innate sensing pathways (FIGs. 7B and 7C). It was found that subjecting LPS-treated BMDMs to a 5 min pulse of 10 pM nigericin and 100 mM KC1 followed by conditioning at pH 7.4 was able to largely restore the pHi to 7.0 (FIG. 7A). Following this treatment, the increase in pHi restored both BRD4 and MED1 condensates as well as their colocalization (FIGs. 7B and 7C), and demonstrated that low pHi induced by LPS in vitro was sufficient and necessary to inhibit transcriptional condensates. In vivo, the response of thioglycolate-induced peritoneal macrophages (pMac) to i.p. Injection of LPS was examined. Thioglycolate was shown to induce the expansion of CD1 lbIntF4 / 80lowMHC-II+ pMac (FIG. 14B). (Ghosn, et al., Proc. Natl. Acad. Sci. 107, 2568-2573.) Although the number of pMac decreased after LPS treatment, the remaining pMac from peritoneal cavity displayed a significant reduction in pHi and BRD4 condensates, compared to the PBS-treated controls (FIGs. 7D, 7E). Altogether, these data demonstrated that inflammatory activation of macrophages in vitro and in vivo adopted an acidic intracellular environment that was necessary and sufficient to regulate transcriptionAttorney Docket No. 167705-038401PCT
[0304] condensates. Since acidic pH represses the inflammatory response in macrophages, the data indicated that sensing pH via BRD4-containing transcription condensates functioned as negative feedback to control the inflammatory response.
[0305] To explore the role of pH-sensing by BRD4 in a broader cellular physiology, it was hypothesized that a pH sensor may regulate cellular processes to control pHi, similar to a homeostatic controller (FIG. 14C). (Meizlish et al., Annu Rev Immunol 39, 1-25; Hajjar and Zhou, Trends Immunol. 44, 807-825.) Thus, it was tested whether BRD4 regulates LPS-induced intracellular acidification. Interestingly, JQ-1 treatment alleviated LPS-induced acidification in BMDMs by 0.23 pH unit (1.44-fold of protons) without impacting the pHi in naive BMDMs (FIG. 7F). Using seahorse assay, it was observed that the LPS-induced increase in both glycolytic capacity and glycolytic rate was impaired by JQ-1 (FIG. 7G, 7H), similar to BMDMs activated at pH 6.5 (FIG. 14D). Mechanistically, it was found that hexokinases (HK1, HK2, HK3) that catalyze the phosphorylation from glucose to phopho-6-glucose, the first chemical reaction of converting glucose to energy, were transcriptionally induced by LPS in BMDMs in a BRD4-dependent manner (FIG. 14E). Thus, BRD4 was demonstrated to act as a sensor for pHi to modulate both transcriptional and metabolic inflammatory response.
[0306] Example 9: pH-dependent transcription condensate is a universal mechanism
[0307] Finally, given the broad expression and crucial role of BRD4 in many cell types, it was investigated if pH-dependent condensates were a general phenomenon across various cell types and species. It was observed that murine and human primary macrophages, as well as stromal and epithelial cell lines, all exhibited pH-dependent regulation of BRD4 condensates (FIG. 71).
[0308] In particular, BRD4 and MED1 in human macrophages derived from peripheral blood mononuclear cells displayed extremely strong pH dependence (FIG. 7J, 7K). It was noted that different cell types may differ in their sensitivity to extracellular pH and likely exhibit cell-type dependent response under acidic environment in vivo. pH-dependent condensates were also seen in T cells and B cells. BRD4 condensates in macrophages, T cells, and B cells were disrupted by lowering the pH to 6.5, and subsequently rescued by raising the extracellular pH to 7.4, and administering the proton ionophore 2-4-Dinitrophenol (2,4-DNP / DNP) to equilibrate extracellular and intracellular pH (FIG. 16).
[0309] Moreover, it was found that other types of nuclear condensates, such as RNA granules and stress granules were not sensitive to the pH conditions examined here (FIG. 7L). Thus, pH-sensing by BRD4 condensates was shown to establish a unique mechanism to integrate extracellular and intracellular environments in regulating inflammatory response and beyond.Attorney Docket No. 167705-038401PCT
[0310] Example 10: Acidic environment reduces antigen presentation by macrophages
[0311] It was next tested whether the pH-dependent repression of genes associated with antigen presentation in macrophages led to a reduction in antigen presentation by the macrophages.
[0312] Macrophages were placed in culture at pH 7.4, pH 7.4 in the presence of JQ1, a BRD4 inhibitor, or at pH 6.5, and then stimulated with the addition of E. coli expressing ovalbumin (OVA) to induce presentation of OVA antigens to OVA-specific T cells (OT1 T cells). OT1 T cells release interfereon-y (IFNg) in response to antigen presentation, so IFNg levels were recorded as a measurement of antigen-presentation levels. The results indicated that lowering the pH to 6.5 significantly reduced antigen presentation by macrophages as compared to pH 7.4 (FIG. 17). This effect was associated with the disruption of BRD4 condensates, since JQ1 administration at pH 7.4 had a similar effect on antigen presentation by macrophages.
[0313] Example 11: Putative Proteins Sensitive to pH
[0314] The mouse proteome from UniProt (50,961) was analyzed for putative proteins that were sensitive to a pH shift from 7.4 to 6.5. As most amino acids had minimal differences in protonation state at this pH range, the expected charge shift of peptide sequences was evaluated by focusing on histidine residues. A gaussian filter spanning 20 residues (Full Width at Half Maximum = 5; σ = 2.12) was applied on the histidine distribution to identify regions locally enriched with pH-sensitive residues. The peaks of the gaussian smoothed charge profile corresponded to the value of ACharge. All peptide regions that contained ACharge > 1 within a window of 20 AA (18596 regions) were selected. For each region, the window was extended 50 amino acid residues to the N-terminal side and to the C-terminal side of the ACharge peak. The metapredict function was used to calculate the consensus disorder score of this extended peptide region (~100 AA) to evaluate overall disordered features. To ease the selection, an extended peptide region as considered as disordered if either N-terminal or C-terminal side had a consensus disordered score > 0.3 (12168 regions). Within these regions, the enrichment of proline and glutamine was calculated by inferring a PQ-score, as the peak value of the overall PQ density by summing of the gaussian smoothed (the same filter as above) densities of proline or glutamine individually. Similarly, the higher score between N- and C-terminal side of the ACharge peak was determined as the PQ score of the region. Applying gaussian filters to the charge distribution, proline or glutamine distributions helped identify regions containing clusters of residues with the desired features.
[0315] Table 5, below, provides a list of discovered putative pH sensitive proteins.Table 5: Putative pH Sensitive Proteins
[0316]
[0317]
[0318]
[0319]
[0320]
[0321]
[0322]
[0323]
[0324]
[0325] Attorney Docket No. 167705-038401PCT
[0326] During inflammation, extreme perturbations in cellular or tissue microenvironment signals strong deviation from tissue homeostasis. Adjusting immune responses to the changes in the microenvironment may provide an adaptable strategy for the immune system to calibrate inflammatory responses to the consequences of inflammation (Medzhitov, Science 374, 1070-1075; Hajjar and Zhou, Trends Immunol. 44, 807-825.). Inflammatory response leads to acidification of both tissue and cellular microenvironment. In the above provided Examples, it was demonstrated that tissue pH regulated a switch-like transcriptional response in macrophages. Mechanistically, acidic pH disrupted transcription condensates of BRD4 and MED1 that were crucial for activating a sub-set of inflammatory genes requiring enhancer-dependent transcriptional activation. The acidification triggered by microbial cues was both necessary and sufficient to disrupt BRD4 condensates in vitro and in vivo. Thus, pH-dependent control of transcriptional condensates was shown to establish a new mode of inflammatory regulation, that allowed tissue sentinels to directly integrate environmental information to adjust the magnitude and quality of an inflammatory response.
[0327] Changes in gene expression in response to external signals are thought to be driven primarily by transcription factors. Thus, macrophage response to LPS is mediated by several transcription factors that cause dramatic changes in gene expression. (Smale and Natoli, Cold Spring Harb. Perspect. Biol. 6, a016261; Natoli, et al., Nat. Immunol. 20, 783-792.) Upon activation, transcription factors immediately downstream of TLR4 signaling orchestrate waves of sequentially induced autocrine signals along with feedforward or feedback transcriptional regulators, culminating in a dynamic and robust transcriptional response within the first few hours (Tong, et al., Cell 165, 165-179; Escoubet-Lozach, et al., PLoS Genet. 7, e1002408). The LPS-response is comprised of multiple related and coordinated inflammatory functions related to host defense (Pope, et al., Mol. Cell 71, 389-397.) However, the above Examples demonstrated extensive transcriptional reprogramming and switch-like expression patterns in macrophages at different pH levels, without apparent difference in TLR signaling. This observation indicated that innate immunity can be highly adaptable and tunable by the tissue microenvironment. Interestingly, pH-insensitive and pH-sensitive genes appeared to partition into functions associated with the kinetics and magnitude of inflammatory response. The early and pH-independent response triggered by LPS primarily involves antimicrobial defense, likely regulated directly by TLR signaling to scale with the inflammatory demand. On the contrary, genes amplifying the inflammatory cascade - such as chemokines, cytokines, antigen presentation molecules and acute phase proteins - were pH-sensitive, executing tasks that may impose a significant negative impact on tissues. The attenuated activation of these genes under inflammatory conditions that significantly induce changes in tissue state, is a strategy that likelyAttorney Docket No. 167705-038401PCT
[0328] evolved to limit the cost of inflammation. Thus, the pH-dependent regulation of inflammatory response in macrophages highlighted a strategy to decouple the demand of inflammatory response from the cost of inflammation.
[0329] Several stress-induced biomolecular condensates are regulated by acidic pH. In the budding yeast, RNA binding proteins Publ and Pabl, and prion-like protein Sup35, form condensates at a pH range of 5 to 6, mediated by disordered sequences enriched for negatively charged amino acids (glutamate pKa~4.25 and aspartic acid~3.86). (Kroschwald, et al., Cell Rep.
[0330] 23, 3327-3339.) (Riback, et al., Cell 168, 1028-1040.el9.).
[0331] A similar mechanism was found in mammalian stress granule protein G3BP1, suggesting a conserved feature to partition macromolecules under extreme conditions (Guillen-Boixet, et al., Cell 181, 346-361. el7.). Other condensate proteins, including 53BP1, FUS and a-synuclein, can transit from a soluble phase to a liquid-liquid phase separation or a condensate state at a similar acidic pH range, but the molecular underpinning of such transition is not well understood (Kilic, et al., EMBO J. 38, el01379; Ray, et al., Nat. Chem. 12, 705-716). The above Examples identified that histidine-enriched IDR of BRD4 functions to regulate transcriptional condensates under physiological pH range in vitro and in vivo. Notably, a motif of consecutive or concentrated histidine residues (H-block) surrounded by a stretch of proline and glutamine residues (PQ-block), was shown to mediate pH-sensing capacity of IDRBRD4. The abundant proline and glutamine residues may establish an unstructured and neutral environment that is necessary for the condensate formation of BRD4 at normal pH, and at the same time, signify any change of the electrostatic interactions created by histidine ionization. At pH 6.5, the positively charged H-block destabilized the multivalent interactions of IDR, leading to a phase transition in transcriptional condensates. Interestingly, H- and PQ-blocks in IDRBRD4present a unique sequence feature contrasting histidine-rich phase-separating proteins. For instance, the formation of filaggrin-containing keratohyalin granules during keratinocyte differentiation is dependent on liquid-liquid phase separation of histidine-rich filaggrin, but in this case, acidic pH promotes droplet formation rather than disrupting it (Quiroz, et al., Science 367, Issue 6483). In Drosophila, a 31 -residue peptide (7 Hs, 21 Qs, 0 P) in the neuronal amyloid protein Orb2 forms a beta sheet structure that assembles into stable amyloid fibers as a mechanism of long-term memory (Hervas, et al., Science 367, 1230-1234.). As proline strongly disfavors the formation of a beta sheet, the HPQ region found in IDRBRD4may enable dynamic assembly and disassembly of transcription condensates that are necessary for gene activation, while maintaining environment sensitivity. In fact, H-blocks can be used to engineer synthetic peptides that are sensitive to a pH shift of just 0.3 units (Shen, et al., Nat. Nanotechnol., 1-6.). The sequence feature uncovered here may provide guidance for the discovery of additional pH-Attorney Docket No. 167705-038401PCT
[0332] sensitive proteins and synthetic design of pH-dependent regulators. The ability to form molecular condensates have emerged as a unique feature of many transcription and chromatin regulators (Shin, et al., Science 357, 56; Hnisz, et al., Cell 169, 13-23; Cramer, P., Nature 573, 45-54.) Recent studies begun to shed light on the regulation of these condensates and their specific roles in gene expression. The IDR of MED 1 features alternating blocks of positively and negatively charged residues, which recruit subunits of RNA Pol II and exclude negative transcription regulators to promote transcription (Lyons, et al., Cell 186, 327-345.). The chromatin remodeler cBAF subunit ARID1A / B contains blocks of alanine, glycine, and glutamine that are essential to interact with a network of transcriptional regulators (Patil, et al., Cell., vol. 186, Issue 22.). These findings suggest that transcriptional condensates are heterogenous, partitioned and self-regulated to carry out essential gene expression programs. However, whether such crucial process in cells is regulated by internal or external environment remains unknown.
[0333] The present disclosure demonstrated that pH controlled the formation of transcriptional condensates in primary human and mouse cells. BRD4 acted as a pH-dependent switch that integrated both extracellular environment and intracellular metabolic state to control the expression of inflammatory genes. The above provided Examples established the environmentdependent transcriptional condensates as a new mode of gene regulation parallel to the classic paradigm driven by receptor signaling, transcriptional factors and chromatin accessibility.
[0334] pH-dependent transcriptional response only partially overlaps with BRD4-dependent transcriptional response. Many BRD4-dependent genes are insensitive to acidic pH, suggesting that the transcriptional functions related to transcription condensates per se may be distinct from the functions of condensate components. This is supported by the above data showing that pH-sensitive genes were more sensitive to BRD4 inhibition than pH-insensitive genes, consistent with an earlier model prediction of high valency dependence for condensate-regulated enhancers (Hnisz, et al., Cell 169, 13-23. )1 Moreover, it was also observed that inflammatory genes relying on chromatin remodeling at distal enhancers were most sensitive to pH and BRD4 condensates (e.g., 116, 1112b, Edni These genes have multiple enhancers or a long stretch of enhancer regions, specifically after LPS stimulation, mimicking super-enhancers found at the lineage determining genes. These enhancers are likely responsible for establishing inducible microdomains via chromatin loops with gene promoters. The Examples of the present disclosure support a model that BRD4-containing transcriptional condensates are crucial for remodeling and activating distal enhancers, thereby establishing new enhancer-promoter contacts that facilitate efficient transcriptional elongation. The power to reverse pH-dependent geneAttorney Docket No. 167705-038401PCT
[0335] regulation by IDRBRD4indicates that targeting pH-dependent condensate may be a viable strategy to reverse immune suppression associated with acidic tissue microenvironment.
[0336] Last, since BRD4 is ubiquitously expressed, pH-dependent regulation of transcriptional condensates is applicable to mediate cellular responses under acidic environments in various mammalian cell types. In the immune system, such mechanisms may impact broadly the specific types of activation, differentiation, and polarization programs, as well as the memory of the environmental experience. In nonimmune cells, it may selectively diminish the response to inflammatory cues, potentially allowing cells to tolerate a higher level of inflammatory environment that would otherwise be detrimental. Elucidating pH-dependent regulatory mechanisms may uncover new ways to combat diseases such as chronic inflammation and cancer.
[0337] The following methods were employed in the above examples.
[0338] Constructs
[0339] The fragment of mCherry-Brd4 was directly amplified by PCR, using pEG( / Y)FP- Cl_mCherry-BRD4 (addgene, #183939) as the template and sub-cloned into either a Piggybac or Lentiviral vector with NEBuilder HiFi DNA assembly master mix (NEB, #E2621L).
[0340] The IDR sequence of BRD4 with Histidine to alanine mutations (HA IDR) was synthesized by GenScript (USA). The HA IDR fragment was then amplified through PCR and introduced into full-length BRD4 by overlapped PCR, to build full length BRD4-HA mutant. Finally, BRD4-HA was cloned into a Piggybac or a lentiviral vector with NEBuilder HiFi DNA assembly master mix.
[0341] Exemplary sequences of constructs are provided in Tables 6 and 7, below:
[0342] Table 6: Exemplary Polypeptide Sequences
[0343]
[0344] Attorney Docket No. 167705-038401PCT
[0345]
[0346] Attorney Docket No. 167705-038401PCT
[0347]
[0348] Attorney Docket No. 167705-038401PCT
[0349]
[0350] Attorney Docket No. 167705-038401PCT
[0351]
[0352] Attorney Docket No. 167705-038401PCT
[0353]
[0354] Attorney Docket No. 167705-038401PCT
[0355]
[0356] Asterisks indicate the end of a polypeptide sequence.
[0357] Table 7: Exemplary Polynucleotide Sequences
[0358]
[0359] Attorney Docket No. 167705-038401PCT
[0360]
[0361] Attorney Docket No. 167705-038401PCT
[0362]
[0363] Attorney Docket No. 167705-038401PCT
[0364]
[0365] Attorney Docket No. 167705-038401PCT
[0366]
[0367] Attorney Docket No. 167705-038401PCT
[0368]
[0369] Attorney Docket No. 167705-038401PCT
[0370]
[0371] Attorney Docket No. 167705-038401PCT
[0372]
[0373] Attorney Docket No. 167705-038401PCT
[0374]
[0375] Attorney Docket No. 167705-038401PCT
[0376]
[0377] Attorney Docket No. 167705-038401PCT
[0378]
[0379] Mice
[0380] Male and female C57BL / 6J were bred and housed under specific pathogen free (SPF) facilities. All animal experiments were approved by Yale University or Boston Children’s Hospital Animal Care and Use Committee. C57BL / 6J wild type, Hifla. fl / fl, Hif2a. fl / fl and Lyz2- Cre mice were purchased from Jackson Laboratory. Gpr65- / - and Gpr68- / ~ were purchased from KOMP repository and were crossed with C57BL / 6J for at least 5 generations. Macrophagespecific HIF la-deficient or HIF2a-deficient mice were created by crossing Lyz2-Cre and Hiflafl / fl or Hif2afl / fl mice. All mice were maintained in a specific pathogen-free facility and animal experimentation was conducted in accordance with institutional guidelines.
[0381] Cell Culturing
[0382] All cell lines were cultured at 37°C with 5% CO₂. HEK293T, 3T3, iBMDM cell lines were grown in DMEM media supplemented with 10% FBS, lx GlutaMAX, 100 U / mL Penicillin- Streptomycin, 1 mM Sodium Pyruvate, and 10 mM HEPES. L929 cells were cultured in RPMI media supplemented with 10% FBS, lx GlutaMAX, 100 U / mL Penicillin-Streptomycin, 1 mM Sodium Pyruvate, and 10 mM HEPES. Bone marrow-derived macrophages were differentiatedAttorney Docket No. 167705-038401PCT
[0383] from bone marrow cells and cultured in macrophage growth medium (MGM) (RPMI + 2 mM L-glutamine, 1 mM sodium pyruvate, 10 mM HEPES, 200 U / mL penicillin / streptomycin, 10% FBS, 50 μM 2-mercaptoethanol and 30% L929-conditioned media).
[0384] Preparation of primary cells
[0385] For BMDMs, the fresh isolated bone marrow cells from femurs and tibias were resuspended in MGM. The nonadherent cells were harvested next day (Day 1) and replated in 15 cm non-TC treated Petri dishes at 37°C in a 5% CO2 incubator. Cells were refed on day 4 with another 15 ml fresh MGM. Cells were collected with 3 mM ice-cold PBS-EDTA on day 6-7. For thioglycolate-induced peritoneal macrophages, mice were injected with 1 mL autoclaved 3% brewer thioglycolate broth intraperitoneally. After 4 days, mice were injected intraperitoneally with 2 mg / kg LPS or PBS for 24 hours. The peritoneal macrophages were collected from peritoneal cavity with 6-9 mL cold PBS. The cells were immediately analyzed by flow cytometry for measuring intracellular pH. For imaging, cells were immediately plated onto 1% gelatin (Sigma) coated glass coverslips for immunofluorescence analysis.
[0386] For human PBMC-derived macrophages, human blood was collected from two healthy donors under the Boston Children’s Hospital Normal Blood Donor Services program. PBMCs were purified from whole blood by Ficoll gradient centrifugation. Briefly, whole blood was diluted 1:3 in RPMI 1640, and 30 mL of diluted blood was slowly layered over 15 mL of Ficoll-Paque (GE Healthcare, Piscataway, NJ), and centrifuged at 800 x g for 30 minutes at room temperature. PBMCs were collected, washed in RPMI- 1640, and plated in tissue culture dishes for 24 hours to remove adherent cells. Next day, the floating cells were collected and seeded at 1 million cells in a 12-well plate with glass coverslip. Cells were differentiated in RPMI supplemented with 2 mM L-glutamine, 1 mM sodium pyruvate, 10 mM HEPES, 200 U / mL penicillin / streptomycin, 10% FBS, 50 μM 2-mercaptoethanol, and 50 ng / mL recombinant human CSF1. After 4 days, cells were refed with fresh growth medium. On day 7-10, the differentiated macrophages were used for experiments.
[0387] Cell lines, Transfection, and lentiviral Transduction
[0388] PiggyBac vectors were used to generate stable cell lines expressing wild-type murine BRD4 and BRD4 histidine variants. To construct PB-mCherry-Brd4WT, the full-length mCherry-Brd4 was amplified directly from pEG( / Y) FP-C1 mCherry-Brd4 (Addgene #183939). To construct PB-mCherry-Brd4HA, where 33 histidine residues within BRD4-IDR were replaced with alanine, a fragment assembly method was employed. The coding sequence of the IDR of Brd4HAmutant (IDRHA) was commercially synthesized by Genscript. The full-length Brd4HAwasAttorney Docket No. 167705-038401PCT
[0389] then assembled through overlapping PCR, between IDRHAand the N-terminal portion of mCherry (excluding IDR) via 20 bp overlapping sequences. The resulting full-length mCherry and mCherry-Brd4HAfragments were purified and cloned into a piggyBac backbone (Addgene #159095) using NEBuilder HiFi DNA assembly.
[0390] To generate BRD4 segment variants, both PB-mCherry-Brd4WTand PB-mCherry-Brd4HAplasmids were used as templates to amplify segments of Brd4WTand Brd4HAsequences. These sequences were then assembled with overhang sequences to generate full-length mutated constructs, including mCherry -Brd4AHHH(AHHH), mCherry-Brd4HAHH(HAHH), mCherry -Brd4HHAH(HHAH) and mCherry-Brd4HHHA(HHHA). These PCR products were subsequently cloned into a lenti-viral expression vector (Addgene #111886) uusing NEBuilder HiFi DNA assembly. FLAG-NLS-mCherry-IDRBRD4WTand FLAG-NLS-mCherry were generated using a similar method. Briefly, the synthesized FLAG-NLS sequence, mCherry, and IDRBRD4WTwere assembled uusing NEBuilder HiFi DNA assembly, with complementary overhang sequences dictating the assembly order. The constructs were then cloned into the same lenti-viral expression vector described above.
[0391] For IDRFUSvariants, the N-terminal IDR region (1-214) of Fus was directly amplified from pDEST_FUS (Addgene #26374). 6xHis or 12xHis was synthesized along with a 3’ overhang matching the 5’ region of Fus and a 5’ overhang matching the 3’region of mCherry. To establish mCherry-IDRFUS, mCherry-6xHis-IDRFUSand mCherry-12xHis-IDRFUSconstructs, fragments of Fus and 6xHis or 12xHis were assembled into a lenti-viral expression vector (Addgene #111886) carrying mCherry uusing NEBuilder HiFi DNA assembly.
[0392] For NLS-mCherry-SEpHluorin construction, the mCherry-SEpHluorin fragment was amplified directly from the mCherry- SEpHluorin plasmid (Addgene #32001). The NLS sequence was incorporated into the forward primer of mCherry during synthesis. The PCR was cloned into a lenti-viral expression vector (Addgene #111886) uusing NEBuilder HiFi DNA assembly.
[0393] To generate transgene cell lines in 293T, piggyBac vectors containing the genes of interest were cotransfected with PBase vector using lipofectamine 3000. Stable lines were enriched by cell sorting based on fluorescent signals. For transgene expression of BRD4 variants, IDRFUSvariants and mCherry-SepHluorin in 293 T or iBMDMs, a 2nd generation lentiviral system was used. Briefly, lentivirus carrying gene of interest were generated by co-transfecting expression vectors and packaging plasmids (psPAX2, pmd2.g) into 293T cells using lipofectamine 3000. Viral supernatants were collected twice at posttransfection 48 hour and 72 hours, filtered, and applied to iBMDMs with spin-fection in the presence of Polybrene (10 pg / mL) at 1250xg forAttorney Docket No. 167705-038401PCT
[0394] 60 min at 30°C. All cell lines were sorted based on mCherry signal to ensure comparable levels of transgene expression.
[0395] To generate Irf2 knockout in iBMDMs, cells Cas9-iBMDMs were infected with lentivirus carrying sgRNAs in pLKO.3G vector (addgene #14748), which included a U6-gRNA scaffold, cPPT, and PGK promoter. Following infection, the iBMDMs were sorted into 96- well, expanded, and analyzed to confirm Irf2 deletions by genotyping and western blot.
[0396] Cell treatments
[0397] Acidic pH: pH medium was prepared using special RPMI-1640 without sodium bicarbonate and supplemented with sodium bicarbonate to the concentration based on chemical equilibrium. The media pH was further adjusted to desired pH value using HC1 (1 M) or NaOH (1 M). The cells were incubated at the indicated pH for at least 4 hours if without specification.
[0398] Inhibitors treatments: 500 nM JQ1, 50 nM MS645 and 2 pM iBET were applied 4 hours prior to LPS stimulation. 200 ng / mL cycloheximide, 100 mM Dibutyryl-cAMP, 5 mM Camptothecin, 50 mM TSA, 0.2 pM or 2 pM aphi dicolin, 5 pg / mL or 50 pg / mL a-amanitin or 10 mM C646 was applied 1 hour prior to LPS stimulation.
[0399] 1,6-hexanediol treatment: for immunofluorescent samples, 10% 1,6-hexanediol was added to cells for 2 min before fixation. For analysis of gene expression, the concentration of 1,6-hexanediol was titrated down to 1% so that cells remained normal morphology. 1% 1,6-hexanediol was applied for 2 hours after 2 hours LPS stimulation, to maximize cell viability.
[0400] Conditioning cells for imaging at different pH: cells were incubated with medium at the indicated pH for 3.5 hours prior to treatment with 100 pM 2,4-Dinitrophenol solution for 30 minutes.
[0401] Manipulating intracellular pH after LPS stimulation: cells were treated with 10 pM nigericin and 120 mM KC1 in pH 6.5 medium for 5 min, followed by pH 7.4 PBS wash for three times, and incubation at normal medium at pH 7.6 for 2 hours.
[0402] H3K27ac, H3k4me3, p65 and IRF3 ChlP-seq sample preparation and analysis
[0403] For ChlP-seq of histone modifications, p65 and IRF3, the experiments were performed as described (Treger, et al., Immunity 50, 334-347. e9.) Briefly, mature BMDMs were plated at 15 million cells in 150 mm TC-treated plates. Cells were conditioned with pH 7.4 or 6.5 growth medium for 4 hours and stimulated with 10 ng / mL LPS for another 4 hours. Cells were crosslinked with 200 mM DSG-PBS for 30 minutes with continuous mixing, followed by 1% formaldehyde for 10 minutes, and quenched with 0.125 M glycine for 5 minutes. The chromatin from approximately 10 million cells (25-30 pg) were used for histone modification ChIP and 30Attorney Docket No. 167705-038401PCT
[0404] million cells (-100 ig) were used for the transcription factor ChlP. Cell pellets were sonicated to an average chromatin fragment of 300-400 bp. The following antibodies were used for each ChlP experiment based on instructions: 10 pg anti-H3K4me3 (ab4729), 10 pg anti-H3K27ac (ab8580), 1:100 anti-IRF3 (D83B9) and 10 pg anti-p65 (sc-372). 100µL of Protein G dynabeads (10003D) were used for each ChlP. Sequencing libraries were constructed using NEB Next Ultra II DNA Library Prep Kit for Illumina (E7645L).
[0405] Reads from Illumina paired end fastq files were mapped to the mouse genome (mm 10) using Bowtie2 with the command “bowtie2 -q —end-to-end -very-sensitive” to generate SAM files. Read duplicates were removed and BAM files were generated with the Picard toolkit. Enriched ATACseq regions were identified using MACS2 using the options “'-f BAMPE — bw 200 -B -g mm”. Bigwig files were generated using deeptools software using the bamCoverage tool with the options “—binSize 10 -normalizeUsing RPGC — effectiveGenomeSize 2864785220 — extendReads”. Bigwig files were visualized with UCSC genome browser as well as used to generate heatmaps (described below).
[0406] BRD4 and BRD9 ChlP-seq sample preparation and analysis
[0407] For BRD4 and BRD9, ChlP-seq samples were prepared as previously described (Ahmed, et al., Proc. National Acad. Sci. 119, e2110812119.) 10-15 million BMDMs were crosslinked in 3 mM disuccinimidyl glutarate for 30 min then in 1% formaldehyde for 10 min at room temperature. After quenching with 125 mM glycine, the cells were washed in 1 * PBS, pelleted, flash frozen in liquid nitrogen, and stored at 80°C. Cell pellets were thawed on ice and incubated in lysis solution (50 mM Hepes KOH pH 8, 140 mM NaCl, 1 mM ethylenediamine tetra- acetic acid (EDTA), 10% glycerol, 0.5% Nonidet P-40, and 0.25% Triton X-100) for 10 min. The isolated nuclei were washed (10 mM TrisHCl pH 8, 1 mM EDTA, 0.5 mM EGTA, and 200 mM NaCl) and sheared in (0.1% sodium dodecyl sulfate (SDS), 1 mM EDTA, and 10 mM Tris-HCl pH 8) with the Covaris E229 sonicator for 10 min. After centrifugation, chromatin was immunoprecipitated overnight at 4°C with 1:100 anti-BRD9 (Bethyl, pAb #A700-153) or 5 pg anti-BRD4 (Bethyl, Rabbit pAb #A301-985A50). The next day, the antibody-bound DNA was incubated with Protein A+G Dynabeads (Invitrogen) in ChlP buffer (50 mM Hepes KOH pH 7.5, 300 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate, and 0.1% sodium dodecyl sulfate), washed, and treated with Proteinase K and RNase A and reverse cross linked. Purified ChlP DNA was used for library generation (NEBNext Ultra II DNA Library Prep Kit for Illumina) according to manufacturer’s instructions.
[0408] Single-end lOObp were aligned to the mouse genome mm 10 using STAR alignment tool (version 2.5). ChlP-seq peaks were called using findPeaks within HOMER using -style factorAttorney Docket No. 167705-038401PCT
[0409] (default settings, fourfold over local tag counts with FDR 0.001 [Benjamin-Hochberg]).
[0410] Differential ChIP peaks were called using getDiffExpression.pl with fold change > 1.5 or < 1.5, Poisson P value < 0.0001. ChlP-seq peaks were annotated by mapping to the nearest transcription start site (TSS) using the annotatePeaks.pl program. Bigwig files were generated using makeUCSCfile on HOMER with flag -style chipseq and were visualized on UCSC genome browser.
[0411] ATAC-seq analysis
[0412] BMDMs were plated on non-TC plates for ATAC-seq analysis. Cells were conditioned with pH 7.4 or 6.5 growth medium for 4 hours and stimulated with 10 ng / mL LPS for another 4 hours before harvesting with 3 mM ice-cold PBS-EDTA. Cell suspensions were counted and ~ 50,000 cells were used for constructing each ATAC-seq library according to the protocol detailed by Buenrostro et al. ( Curr. Protoc. Mol. Biol. 109, 21.29.1-21.29.9.). ATAC-seq libraries were constructed using Illumina Tagment DNA Enzyme and Buffer Small kit.
[0413] Paired-end sequencing was performed with Next-seq 500 with paired end reads of 38 base pairs. Reads were then mapped to the mm 10 mouse genome with Bowtie2 using the option -k 10 -X 1000 — end-to-end -very-sensitive”. Sam files were converted to Bam files, and read duplicates were removed using Picard. Blacklist regions and mitochondrial genomic reads were removed using BEDTools and Picard, respectively. Bam files were converted to Bed files also using BEDTools, and macs2 was used to call peaks using the converted bed file. Macs2 callpeak options used were “-f BED -g mm -q 0.05 - nomodel —shift -75 — extsize 150 — keep-dup all”. Macs2 peaks from each condition were concatenated and then overlapping regions merged using mergeBed from BEDTools. To count the number of reads in each merged peak, featureCounts was used. Read counts from featureCounts were normalized using the TMM method in EdgeR. Bigwig files were generated using using the bamCoverage (Deeptools) tool with the options —binSize 10 -p max — normalizeUsing None — effectiveGenomeSize 2864785220 -extendReads -scaleFactor X”. The scale factor “X” was derived from the TMM normalization. Bigwig files were visualized with UCSC genome browser as well as used to generate heatmaps (described below).
[0414] Heatmap generation
[0415] To identify ATAC-seq peaks associated with each condition, the fold change between normalized read counts was quantified under each peak using R. Additionally, a peak was only considered to be associated with that condition if the merged Macs2 peak overlapped with the condition specific Macs2 peak. For whole gene plots, mm 10 gene positions were downloadedAttorney Docket No. 167705-038401PCT
[0416] from UCSC Genome Browser. Bed files from the condition specific ATAC-seq peaks and gene plots were quantified with the Bigwig files using the computeMatrix tool (deeptools) and visualized with the plotHeatmap tool (deeptools) to generate Heatmaps. ATACseq peaks were also associated with the closest gene using the annotatePeaks.pl tool from Homer. (Heinz, et al., Mol. Cell 38, 576-589.) ATACseq peaks were associated with the closest gene.
[0417] H3K27ac quantification around ATAC-seq peaks
[0418] Feature counts followed by EdgeR TMM normalization was used to quantify H3K27ac chip-seq data Ikbp around the center of each merged ATAC-seq Macs2 peak. The H3K27ac fold change between normalized read counts was quantified around each ATAC-seq peak using R. Additionally, a peak was only considered to be associated with that condition if the merged ATAC-seq Macs2 peak overlapped with the condition specific ATAC-seq Macs2 peak.
[0419] RNA isolation and qRT-PCR
[0420] RNA was purified from cells using Qiagen RNeasy columns (Qiagen, 74106) according to the manufacturer’s instructions. cDNA was reverse-transcribed with MMLV reverse transcriptase using oligodT20 primers. qRT-PCR was performed on a CFX384 Real-Time System (Bio-Rad) using PerfeCTa SYBR Green SuperMix. Relative expression units were calculated as transcript levels of target genes over 1 / 1000 of Actb.
[0421] RNA-seq sample preparation and analysis
[0422] BMDMs were washed twice with ice-cold PBS and collected directly with RLT buffer (Qiagen RNeasy kit). RNA was purified from cells using Qiagen RNeasy columns with on-column DNase digestion according to the manufacturer’s instructions. Sequencing libraries were constructed following Illumina Tru-seq stranded mRNA protocol or NEB Next Ultra II stranded mRNA protocol. Paired-end sequencing was performed with Next-seq 500 with either 76 or 38 bp from each end.
[0423] Illumina fastq files were aligned with Kallisto program with default settings in reference to mouse transcriptome annotation GRCm38 (ftp.ensembl.org / pub / release-90 / fasta / mus_musculus / cdna / ) (Bray, et al., Nat. Biotechnol. 34, 525-527.) The ENSEMBL IDs of each cDNA transcript were matched to the official gene symbols through BioaRt in R. The expression level for each transcript was reported in either TPM (transcripts per million) or as normalized counts, adjusted to a total of 10 million counts. For genes associated with multiple transcripts, the gene's total expression was derived by summing the TPM or count values for all corresponding transcripts.Attorney Docket No. 167705-038401PCT
[0424] Differential expression analysis
[0425] To identify differentially expressed genes, we utilized the Kallisto-Sleuth pipeline with the default settings. This analysis returned 34475 annotated genes in total in the mouse genome. The gene expression is calculated as tpm (transcript per million) or read counts per gene. Read counts per gene were used for downstream analysis, after normalizing the total read counts to 10 million for each sample. For each pairwise comparison, pH 7.4 LPS vs pH 7.4, pH 6.5 LPS vs pH 6.5, pH 7.4 vs pH 6.5, and pH 6.5 LPS vs pH 7.4 LPS, expression fold changes (with a pseudo count 2) and adjusted p-values were calculated with Sleuth. Using a stringent threshold (an adjusted p-value < 0.05, absolute fold change > 3-folds, and an average expression > 5 counts), 1907 genes were identified that were significantly regulated between any pair of tested conditions.
[0426] Expression deconvolution analysis
[0427] To estimate the contribution of LPS stimulation, acidic pH and the interactions between these two conditions to the inflammatory response, the previously developed computational deconvolution algorithm was adopted (Zhou, et al., Mol. Cell 42, 826-836.) Briefly, when the contributions to gene expression are described quantitatively as fold activation, each experimental comparison listed above can be described as the sum of the following expression components in logarithmic scale. The expression components include LPS (the influence of LPS stimulation alone), pH (the influence of acidic pH alone), INT (the influence of the integration between LPS and acidic pH). Each of the comparisons in FIG. 9B can be formulated as:
[0428] pH 7.4 LPS vs pH 7.4 = LPS
[0429] pH 6.5 vs pH 7.4 = pH
[0430] pH 6.5 LPS vs pH 6.5 = LPS + INT
[0431] pH 6.5 LPS vs pH 7.4 LPS = pH + INT
[0432] pH 6.5 LPS vs pH 7.4 = LPS + pH + INT
[0433] The above formula can be transformed into matrix multiplication in the form of Y = X*b + e.
[0434] For each gene, Y represents the fold change matrix calculated from all pair-wise comparisons, X represents the deconvolution matrix, b represents expression components, and e represents noise or error from experimental measurement. Linear regression analysis can be performed to infer the expression components while minimizing e. Two biological replicatesAttorney Docket No. 167705-038401PCT
[0435] (each with a set of 4 RNA-seq data prepared with BMDMs from different source animals) were analyzed together by replicating the deconvolution matrix. The statistical significance is calculated for each b using the formula:
[0436] IP- Po| / o ~ / -distribution with (n-p) degree of freedom, n is the number of measurement (10 with 2 sets of biological replicates) and p is the size of b (in this case 3). s2 is the variance of the linear fit for each gene. To increase the specificity of the detection, Po = 1.5 folds was used for positive expression component and Po = -1.5 folds was used for negative expression component as the null hypothesis.
[0437] Among 1907 significantly regulated genes, 1620 genes were found containing at least 1 significant expression component of LPS, pH or INT (b>= 2-fold, p < 0.05, R2> 0.8). None of these genes included a significant error (a). Majority of the expression variations measured between experimental conditions are well explained using the linear model with 3 expression components (FIG. 2C). All 1620 genes were grouped based on whether a gene contains a significant LPS, pH or INT and the sign of expression components (FIG. 9D). This generated 20 groups with each group containing at least 5 genes.
[0438] 357 genes (Group3,4,6) were induced by LPS independent of pH. 171 genes (Group 4,7,8) were repressed by LPS independent of pH. Among pH-dependent LPS responses, 433 LPS-induced genes (Group 9,10,19) were repressed by acidic pH, while 58 genes were significantly enhanced (Group 15,16,17). Among pH-dependent LPS-dependent repression, the down-regulation of 272 genes (Group 12,13,20) was ameliorated at acidic pH, and 41 genes (Group 11, 18) showed stronger gene repression. Particularly, genes such as Bcl3 (Group 5) and Ccl3 (Group 6), were regulated by acidic pH independent of LPS stimulation. Their LPS-induced activation was independent of pH conditions, and thus were clustered into the pH-insensitive group.
[0439] Gene ontology analysis
[0440] Gene lists were analyzed with Homer for functional enrichment. The resulting gene ontology terms were selected to illustrate representative differences between different gene groups. Genes from specific processes were selected to further illustrate expression differences between groups. The radius of the circle corresponds to the log2(FC), the transparency illustrates statistical significance, and the color indicates whether the changes are due to activation or repression.Attorney Docket No. 167705-038401PCT
[0441] Effective size estimation
[0442] To evaluate the effect size of gene repression, the proportional reduction in expression for each gene was calculated as follows:
[0443] EffpH = 1 - (pH6.5 LPS / pH7.4 LPS)
[0444] EffBRD4 = 1 - (pH7.4 JQ1 LPS / pH7.4 LPS)
[0445] EffBRD9 = 1 - (pH7.4 iBRD9 LPS / pH7.4 LPS) or
[0446] 1 - (pH7.4 dBRD9 LPS / pH7.4 LPS).
[0447] The effective sizes of BRD inhibition and pH-dependent repression was then compared by calculating the effective ratios (RE) for each gene. If pH inhibits the activation of a gene to 10%, while BRD inhibition only prevents the activation to 50%, this gene has an effective ratio of 0.5 / 0.9 = 55%. Among the genes significantly repressed by low pH, the distribution of EffBRD9 for dBRD9 and iBRD9, and EffBRD4 are calculated and presented in the above Examples.
[0448] Nucleus isolation for examining BRD4 condensates
[0449] BMDMs were harvested using 3 mM ice-cold PBS-EDTA and spun down to remove excessive buffer. Cell pellet was washed with hypotonic buffer (20 mM HEPES pH 7.5, 10 mM KC1, 1.5 mM MgCl₂, 1 mM EDTA, 0.1 mM Na₃VO₄, 0.2%NP-40, 10% glycerol, protease inhibitor cocktail (Roche)) and immediately spun down for 10 seconds at 10,000 g. Cell pellets were lysed in two volumes of ice-cold hypotonic buffer by passing through a 26-guage needle 3-4 times using a syringe. A cloudy supernatant indicates lysing of cells. The cell lysate was centrifuged at 10,000 g for 8-10 seconds to remove cytosolic components. The nuclear pellet was resuspended in PBS buffer at pH 7.4 and 6.5 in the presence of containing protease inhibitor cocktail and incubate on ice for 30 min. These nuclei were further seeded into a 24-well plate with matrigel-coated glass coverslips by spinning the plate at 1000 g. The attached nuclei were then fixed in 4% paraformaldehyde for 15 min at RT.
[0450] Coimmunoprecipitation and Immunoblotting
[0451] The immunoprecipitation was performed as described previously (Bi, et al., Mol. Cell 75, 102-116. e9.) Briefly, about 1 x 107cells of FLAGmCherry-IDRBRD4or FLAG-mCherry 293T were harvested and washed with cold PBS. The cells were resuspended with 5 volumes of lysis buffer (50 mM Tris pH 7.4, 150 mM NaCl, 0.5% Triton X-100, 10% glycerol, 1 mM DTT, 1 mM PMSF and 1 / 100 Proteinase inhibitor cocktail), followed by incubation at 4°C with rotation for 30 min. Cell lysates were centrifuged at 12,000 g for 15 min at 4°C to remove debris.Attorney Docket No. 167705-038401PCT
[0452] Next, 20 pL pre-equilibrated FLAG M2 beads (Sigma) were added to the supernatant and incubated overnight with rotating at 4°C. The beads were separated equally and washed with the wash buffer (50 mM Tris, 200 mM NaCl, 0.3% Triton X-100, 10% glycerol) at pH 7.4 or pH 6.5 for 5 times. Proteins were eluted from the M2 beads by boiling in 2 x LDS buffer for 10 min. One-third of the elution was analyzed on Mini-protean TGX stain-free protein gel (BIO-RAD, 4568126). Protein was transferred onto activated PVDF membrane using trans-blot Turbo system (BIO-RAD), and then blocked using EveryBlot Blocking Buffer (BIO-RAD, 12010020) for 5 min at room temperature. Primary antibody was incubated in Solution 1(TOYOBO, NKB-201) at 4°C overnight at recommended dilution (anti-BRD9 1:2000 and anti-FLAG 1:3000, anti-BRD4 1:1000, anti-IRF2 1:500, anti-Endothelin-1 1:2000), and secondary antibody (1:5000) was incubated in 5% milk in TBST at room temperature for 1 hour. Samples were washed 3x with TBST following each round of antibody incubation. Fluorescent images were developed using ChemiDoc™ MP Imaging System (BIO-RAD) and analyzed by Image Lab Touch Software Version 3.0.1.14 (BIO-RAD).
[0453] Live cell imaging and immunofluorescence
[0454] For live cell imaging, full-length mCherry-BRD4WT and mCherry-BRD4HA 293T cell lines were seeded onto matrigel-treated glass-bottom confocal petri dishes (Mattek Corporation P35G-1.5-14-C). The cells were conditioned in pH 7.4 medium for 4 hours, followed by pH 6.5 medium without phenol red, in the presence of 100 pM 2,4-DNP. Imaging was performed using the Airyscan detector on a ZEISS 880 microscope equipped with live-cell imaging module. Each Cell was imaged with Z-stack series to capture the entire nucleus, on a 37°C heated stage with 5% CO2 supplementation. Images were acquired with 63x / 1.4 oil objective. Airyscan images were processed using Fiji (ImageJ) and CellProfiler (Stirling, et al., BMC Bioinform. 22, 433.).
[0455] For immunofluorescence, 293T cells were plated on matrigel-treated glass coverslips, which enhanced the adherence of 293T cells. Macrophages were seeded on 0.1% gelatin-coated glass coverslips. After conditioning with different medium and treatments, cells were fixed in 4% paraformaldehyde for 15 min at RT, permeabilized with 0.5% Triton X-100 (Sigma Aldrich, X100) in PBS for 5 min at RT, and blocked in PBS containing 5% BSA (Sigma) and 0.3% Triton X-100 for at least 45 min at RT. Cells were stained with primary antibodies: anti-BRD4 (confocal 1:100 dilution, STED 1:100), anti-MEDl (confocal 1:100 dilution, STED 1:50), anti-HNRNPU (1:100 dilution), anti-SRSF2 (1:100 dilution), anti-F4 / 80 (1:100 dilution) and anti-CD1 lb (1: 100 dilution) in 1% BSA overnight at 4°C, followed by incubation with secondary antibodies (confocal: Alexa fluor anti-mouse 647 or 488 or 555, Alexa fluor anti-rabbit 647 or 488, 1:1000, STED: abberior Star Orange anti-rabbit 1:500, abberior Star Red anti-mouse 1:500)Attorney Docket No. 167705-038401PCT
[0456] in the dark for 1 hour at RT. The samples were then counterstained with 10 pg / mL Hoechst 33342 for 5 min at RT in the dark, mounted on glass slide using ProLong Glass mounting media. Glass slides were sealed with Fixo gum (Marabu) and store at 4°C. The confocal images were acquired in a Z-stack format using a ZEISS 880 laser scanning confocal microscope with 63x / 1.4 oil objective. The STED images were acquired using Nikon Eclipse Ti2-VSTED microscope with lOOx oil objective. Puncta or median fluorescence intensity was analyzed using Fiji (ImageJ) and CellProfiler. Statistical analysis was performed in GraphPad Prism.
[0457] Condensate and Colocalization analysis
[0458] Confocal images acquired with Airyscan were transformed to gray-scale Tiff images using FIJI. Nucleus staining, BRD4 or MED1 TIFF images were imported into the “Speckle Counting” pipeline from CellProfiler to determine the foci objects of BRD4 and MED1 (available at https: / / cellprofiler.org / examples). The thresholds used for determining foci objects were adjusted with visual inspection and the same threshold was applied across all images within the same experiment. Colocalization Analysis was performed using a customized pipeline based on CellProfiler, using CorrectllluminationCaculate, MaskObjects, CovertObjectsToImage, MeasureObjectlntensity, FilterObjects and RelateObjects in CellProfiler. This analysis generated data the percentage of overlapped foci objects in each cell, which were subsequently analyzed by GraphPad Prism.
[0459] Particle detection and measurement were conducted by a custom written MATLAB Program for STED images. DAPI channel was used to segment the nuclei. This channel was multi-Otsu thresholded to generate masks outlining the nuclei. The BRD4 images were Weiner filtered and background subtracted with a disk structuring element of radius 4 pixel. The generated binary masks from the DAPI channel were used in the BRD4 image to generate two binary images, one for measuring puncta inside the nuclei and the other for measuring puncta outside the nuclei. In both, the binary objects were filtered using a size criterion to remove speckles, and regionprops were used to measure equivalent diameter, centroid and mean intensity of the objects detected. Total number of cells were manually counted. All images were processed identically to generate a contour histogram of the equivalent diameter and mean intensity of the puncta.
[0460] Fluorescence Recovery After Photobleaching (FRAP)
[0461] FRAP was performed on a LSM880 Airyscan microscope equipped with 561nm laser and a 63x / 1.40 oil plan-apochromat objective. Live-cell experiments were performed on 293T cells expressing mouse fulllength mCherry-BRD4WTincubated at 37°C. Images were acquired atAttorney Docket No. 167705-038401PCT
[0462] a resolution of 512 x 512 pixels, with a scan speed of 3.18 frames per second. Before photobleaching, five frames of baseline images were recorded. Bleaching was performed over a defined area rbleach ~ 4 pm using 100% laser power and the fluorescence recovery was monitored with continuous scanning for 30 seconds for post-bleaching. The images of an unbleached region were captured simultaneously from the same field as a reference.
[0463] Fluorescence intensity was measured using FIJI and graphed using GraphPad Prism 10 software.
[0464] siRNA-mediated depletion of Brd4
[0465] To reduce the influence of endogenous human BRD4, 293 T cells were simultaneous transfected with two 7 - / -specific siRNAs or a Scrambled Negative Control. siBrd4 #1 (IDT, hs. Ri. BRD4.13.5, #426567433), siBrd4 #2 (IDT, hs. Ri. BRD4.13.7, #426567436), and Negative control DsiRNA, 5 nmol (IDT, #51-01-19-09 ). In brief, cells were cultured in 24-well TC plates and transfected at 50% confluency with 100 pmol of siRNA using Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer’s protocol. After 24 hours, cells were transferred into matrigel-treated 35 mm Petri dish with the optics of glass bottom for 12-20 hours for live cell imaging.
[0466] pHi measurement using SNARF-4F
[0467] pHi was measured by treating cells with 500 nM pH-sensitive dye SNARF™-4F 5-(and-6)-carboxylic acid (Thermo Fisher Scientific, #S23921) in 1% BSA in PBS at 37°C for 20 mins, followed by flow cytometry analysis. pHi was determined as the ratio of fluorescence intensities measured at two emission wavelengths (580 / 42 nm and 640 / 60 nm). To calibrate SNARF fluorescence, a high potassium buffer (39.6 mM NaCl, 120 mM KC1, 2.3 mM CaC12, 1 mM MgC12, 5 mM HEPES, 10 mM glucose) was employed, spanning pH values from 6.0 to 8.0, in the presence of 10 uM nigericin (Sigma), which facilitated the external potassium ions with internal protons to equilibrate extracellular and intracellular pH level. The data shown were the representative results from 3 independent experiments, with 3 biological replicates in each condition.
[0468] Nuclear pH measurement using SEpHluorin
[0469] mCherry-SEpHluorin iBMDMs were cultured in Matrigel coated glass-bottom confocal petri dishes. The cells were conditioned in pH 7.4 or 6.5 medium (phenol red-free) for 4 h. Prior to imaging, cells were stained with Hoechst for 10 minutes. Imaging was acquired using a ZEISS 880 microscope equipped with an Airyscan detector and a live-cell imaging module, maintained with 5% CO2 at 37°C. Z-stacks series were acquired with 63x / 1.4 oil objective to capture theAttorney Docket No. 167705-038401PCT
[0470] entire nucleus, using 405 nm, 488 nm and 560 nm excitation lasers. To calibrate fluorescence ratios of mCherry-SEpHluorin to calculate nuclear pH, a standard curve was generated using iBMDMs incubated in a high-potassium buffer (39.6 mM NaCl, 120 mM KC1, 2.3 mM CaC12, 1 mM MgC12, 5 mM HEPES, 10 mM glucose), spanning pH values from 6.0 to 8.0, in the presence of 10 uM nigericin.
[0471] For image analysis, backgrounds were subtracted from Z stacks, and nucleus from cells were segmented by Hoechst staining. To calculate mCherry / SEpHluorin intensity ratios, fluorescence intensity was measured using Fiji. The nuclear pH value was determined by applying those intensity ratios to a standard curve.
[0472] ELISA BMDMs were pretreated with medium at pH 7.4 or 6.5 for 4 hours, followed by stimulation with 10 ng / mL LPS for the indicated times. Supernatants were collected, and IL-6 and interferon-β levels were detected with enzyme-linked immunosorbent assay (ELISA) kit according to the manufacturer's protocol (Invitrogen, #887064) or customized protocols. Briefly, 96-well plates were coated with anti-mouse IL-6 antibody (1:250) or anti-mouse IFN-β antibody (1:500) at 4°C overnight. The plates were then blocked with 1% FBS in PBS for 2 hours at 37°C. Standards and Samples were added to the plates and incubated. After washing, the detecting antibody (1:2000) was applied overnight at 4°C and 2 hours at RT. Following additional washing, the secondary antibody (1:2000) was added for 2-3 hours at RT. The reaction was stopped with 2N H2SO4, and absorbance was measured at 450 nm.
[0473] Proliferation assay
[0474] The S-phase cells were detected using Click-iT Plus EdU kit (ThermoFisher, #C 10634) following instructions. Briefly, cells were treated with 10 pM EdU for 1 hour in a CO2 incubator. Following EdU incorporation, the cells were fixed, permeabilized and analyzed according to the kit protocol.
[0475] Seahorse metabolic assay
[0476] Differentiated BMDMs were seeded into 96-well Seahorse tissue culture plates at a density of 50,000 cells / well in complete MGM adjusted to pH 7.4. Cells were allowed to rest at room temperature within TC hood for one hour to allow even distribution within the well, followed by overnight incubation at 37°C. Next day, cells were pre-treated with JQ1 inhibitor (500 nM) or vehicle (DMSO) for 30 mins prior to treatment with LPS (100 ng / mL) or vehicle in MGM at pH 7.4 for 5-6 hours at 37°C. Subsequently, the RPMI medium was removed, and cellsAttorney Docket No. 167705-038401PCT
[0477] were washed twice with warm Seahorse assay medium XF RPMI Medium pH 7.4. Cells were then allowed to equilibrate at 37°C for 45 mins without CO2. Oxygen consumption rates (OCR, in pmol / min) or extracellular acidification rate (ECAR, in mph / min) were recorded on a Seahorse Bioscience XF96 Extracellular Flux Analyzer. The following inhibitors were added sequentially: for Mito-stress test, oligomycin (1.5 pM), FCCP (1.5 pM), and rotenone / antimycin A (0.5 pM); for glycolysis stress test, glucose (10 mM), oligomycin (1.5 pM) and 2-deoxyglucose (50 mM). The Seahorse medium was supplemented according to the assay performed: for the glycolysis stress test, the medium contained 2 mM glutamine; for the mitochondrial stress test, the medium contained 2mM glutamine, 10mM glucose and 1mM sodium pyruvate.
[0478] In silico analysis of pH sensitivity
[0479] The mouse proteome was downloaded from UniProt (50,961) to analyze for putative proteins that were sensitive to a pH shift from 7.4 to 6.5. As most amino acids have minimal difference in protonation state at this pH range, the expected charge shift of peptide sequences was evaluated by focusing on their histidine residues, a gaussian filter spanning 20 residues (Full Width at Half Maximum = 5; σ = 2.12) was applied on the histidine distribution to identify regions locally enriched with pH-sensitive residues. The peaks of the gaussian smoothed charge profile corresponds to the value of DCharge. All peptide regions that contain DCharge > 1 were selected within a window of 20 AA (18596 regions). Each region was extended 50 amino acid residues to the N-terminal side and to the C-terminal side of the DCharge peak. The metapredict function (Emenecker, et al., Biophys. J. 720, 4312-4319.) was used to calculate the consensus disorder score of this extended peptide region (-100 AA) to evaluate overall disordered features. To ease the selection, an extended peptide region was considered as disordered if either N-terminal or C-terminal side had a consensus disordered score > 0.3 (12168 regions) (Emenecker, et al., Biophys. J. 720, 4312-4319.). Within these extended regions, we calculated the enrichment of proline and glutamine by inferring a PQ-score, as the peak value of the overall PQ density by summing of the gaussian smoothed (the same filter as above) densities of proline or glutamine individually. Similarly, the higher score between N- and C-terminal side of the DCharge peak was determined as the PQ score of the region. Applying gaussian filters to the charge distribution, proline or glutamine distributions helped identify regions containing clusters of residues with the desired features.Attorney Docket No. 167705-038401PCT
[0480] Quantification and statistical analysis
[0481] Software for experimental quantifications is named in the respective method details sections. Statistical analyses were performed using the two-tailed, unpaired, Student’s t-test unless otherwise specified in figure legends. The P values were represented as follows: ns, not significant, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
[0482] Other Embodiments
[0483] From the foregoing description, it will be apparent that variations and modifications may be made to the invention described herein to adapt it to various usages and conditions. Such embodiments are also within the scope of the following claims.
[0484] The recitation of a listing of elements in any definition of a variable herein includes definitions of that variable as any single element or combination (or sub-combination) of listed elements. The recitation of an embodiment herein includes that embodiment as any single embodiment or in combination with any other embodiments or portions thereof.
[0485] All patents and publications mentioned in this specification are herein incorporated by reference to the same extent as if each independent patent and publication was specifically and individually indicated to be incorporated by reference.
Claims
Attorney Docket No. 167705-038401PCTWhat is claimed is:
1. A fusion polypeptide comprising a series of histidines fused to a heterologous polypeptide.
2. The fusion polypeptide of claim 1, wherein the heterologous polypeptide comprises an intrinsically disordered region (IDR).
3. The fusion polypeptide of claim 1, wherein the heterologous polypeptide is a condensate forming polypeptide.
4. The fusion polypeptide of claim 2, wherein an ability of the fusion polypeptide to form condensates is disrupted at acidic pH.
5. The fusion polypeptide of claim 3, wherein the ability of the fusion polypeptide to form condensates is disrupted below pH 6.5.
6. The fusion polypeptide of any one of claims 1-5, wherein the series of histidines comprises at least about 6 histidines.
7. The fusion polypeptide of claim 6, wherein the series of histidines comprises between about 6-12.
8. The fusion polypeptide of claim 6, wherein the series of histidines comprises at least 9-12 histidines.
9. The fusion polypeptide of claim 2, wherein the IDR is proximal to the series of histidines.
10. The fusion polypeptide of claim 2, wherein the series of histidines is inserted within the IDR.
11. The fusion polypeptide of claim 1, wherein the fusion polypeptide further comprises a series of proline and / or glutamine residues.Attorney Docket No. 167705-038401PCT12. The fusion polypeptide of claim 11, wherein the series of proline and / or glutamine residues comprises at least 15-20 proline and / or glutamine residues.
13. The fusion polypeptide of claim 11 or 12, wherein the number of proline and / or glutamine residues is about the same.
14. The fusion polypeptide of claim 13, wherein the number of proline residues is within 1-5 residues of the number of glutamine residues.
15. The fusion polypeptide of any one of claims 11-14, wherein the series of histidines comprises at least 4-8 histidines.
16. A polypeptide comprising a mutation in a histidine residue of an intrinsically disordered region (IDR) of the polypeptide.
17. The polypeptide of claim 16, wherein the mutation is a histidine to alanine mutation.
18. The polypeptide of claim 16, wherein the mutation is a histidine to arginine mutation.
19. The polypeptide of any one of claims 16-18, wherein the IDR comprises a series of histidines, and wherein the mutation is in a histidine of the series of histidines.
20. The polypeptide of claim 19, wherein the series of histidines comprises at least 4-12 histidines.
21. The polypeptide of claim 19 or 20, wherein the IDR comprises a plurality of series of histidines.
22. The polypeptide of claim 21, wherein the mutation is in the 1st, 2nd, or 3rdseries of histidines in the plurality of series of histidines.
23. The polypeptide of any one of claims 16-22, wherein the polypeptide is BRD4, or a fragment thereof.
24. The polypeptide of claim 19, wherein the polypeptide is an IDR of BRD4.Attorney Docket No. 167705-038401PCT25. The polypeptide of claim 23 or 24, wherein the polypeptide has at least 85%, 90%, 95%, 99%, or 100% sequence identity to a sequence of Table 6.
26. A polypeptide comprising a deletion of one or more amino acid residues of an IDR of the polypeptide, wherein the deletion is in a domain associated with transcription.
27. The polypeptide of claim 26, wherein the domain associated with transcription is a domain associated with recruitment of a polymerase.
28. The polypeptide of claim 27, wherein the polymerase is an RNA polymerase.
29. The polypeptide of any one of claims 26-28, wherein the domain associated with transcription is a domain associated with recruitment of a transcription factor.
30. The polypeptide of claim 29, wherein the transcription factor is a positive transcription elongation factor (pTEFb).
31. The polypeptide of any one of claims 26-30, wherein the deletion is a deletion of the domain associated with transcription.
32. The polypeptide of any one of claims 26-30, wherein the deletion is a truncation of the domain associated with transcription.
33. The polypeptide of any one of claims 26-32, wherein the domain associated with transcription is a C-terminal domain of the IDR.
34. The polypeptide of any one of claims 26-33, wherein the polypeptide is BRD4, or a fragment thereof.
35. The polypeptide of claim 34, wherein the polypeptide is an IDR of BRD4.
36. The polypeptide of claim 34 or 35, wherein the polypeptide has at least 85%, 90%, 95%, 99%, or 100% sequence identity to a sequence of Table 6.Attorney Docket No. 167705-038401PCT37. An expression vector comprising a polynucleotide encoding a BRD4 IDR sequence.
38. A polynucleotide encoding the fusion polypeptide of any one of claims 1-15, or the polypeptide of any one of claims 16-36.
39. An expression vector comprising the polynucleotide of claim 38.
40. The expression vector of claim 37 or 39, further comprising an inducible promoter driving expression of the polynucleotide41. The expression vector of claim 40, wherein the promoter is a TetOn promoter.
42. A cell comprising the fusion polypeptide of any one of claims 1-15, the polypeptide of any one of claims 16-36, the polynucleotide of claim 38, or the expression vector of any one of claims 37 or 39-41.
43. The cell of claim 42, wherein the cell is a human cell.
44. The cell of claim 42 or 43, wherein the cell is an immune cell.
45. The cell of claim 44, wherein the immune cell is a macrophage, T cell, or B cell.
46. A method of conferring pH-sensitivity on a heterologous protein, the method comprising fusing the heterologous protein to a polypeptide sequence comprising at least about 6-12 histidine amino acid residues, thereby conferring pH-sensitivity on the heterologous protein, wherein the heterologous protein comprises an intrinsically disordered region (IDR).
47. The method of claim 46, wherein the polypeptide sequence comprises at least about 9-12 histidine amino acid residues.
48. A method of conferring pH-sensitivity on a heterologous protein, the method comprising fusing the heterologous protein to a polypeptide sequence comprising at least about 4-8 histidine amino acid residues, thereby conferring pH-sensitivity on the heterologous protein, wherein the heterologous protein comprises an intrinsically disordered region (IDR), wherein the IDRAttorney Docket No. 167705-038401PCTcomprises a polypeptide sequence comprising at least about 15-20 proline and / or glutamine amino acid residues.
49. The method of any one of claims 46-48, wherein the IDR is fused to the polypeptide sequence.
50. A method of conferring pH-sensitivity on a heterologous protein, the method comprising fusing the heterologous protein to a polypeptide sequence comprising at least about 4-8 histidine amino acid residues and 15-20 proline and / or glutamine amino acid residues, thereby conferring pH-sensitivity on the heterologous protein, wherein the heterologous protein comprises an intrinsically disordered region (IDR).
51. A method of conferring pH-sensitivity on a cell, the method comprising transducing the cell with a polynucleotide encoding a heterologous protein fused to a polypeptide sequence comprising at least about 6 histidine to about 12 histidine amino acid residues, thereby conferring pH-sensitivity on the cell.
52. The method of claim 51, wherein the cell is in vitro or in vivo.
53. The method of claim 51 or 52, wherein the cell is a human cell.
54. A method of modulating transcription and / or expression of a polynucleotide of Tables 1-4, the method comprising contacting a cell with a polypeptide of any one of claims 16-36, a polynucleotide of claim 38, or the expression vector of any one of claims 37 or 39-41, thereby modulating transcription and / or expression of a polynucleotide of Tables 1-4 as compared to a reference.
55. A method of increasing transcription and / or expression of a polynucleotide of Tables 1-4 under low pH conditions, the method comprising contacting a cell with a polypeptide comprising a BRD4 IDR polypeptide sequence, a polynucleotide encoding a polypeptide comprising a BRD4 IDR polypeptide sequence, or an expression vector comprising a polynucleotide encoding a polypeptide comprising a BRD4 IDR polypeptide sequence.
56. The method of claim 55, wherein the BRD4 IDR sequence is a wild-type IDR sequence.Attorney Docket No. 167705-038401PCT57. A method of increasing transcription and / or expression of a polynucleotide of Tables 1-4 under low pH conditions, the method comprising contacting a cell with a polypeptide of any one of claims 16-25, a polynucleotide of claim 38, or the expression vector of any one of claims 37 or 39-41, thereby increasing transcription and / or expression of a polynucleotide of Tables 1-4 under low pH conditions as compared to a reference.
58. The method of claim 57, wherein the intracellular or extracellular pH is less than about 7.4, less than about 7.0, about 6.5, of less than about 6.5.
59. The method of claim 57 or 58, wherein the low pH conditions comprise hypoxic conditions.
60. A method of decreasing transcription and / or expression of a polynucleotide of Tables 1-4, the method comprising contacting a cell with a polypeptide of any one of claims 18 or 26-36, a polynucleotide of claim 38, or the expression vector of any one of claims 39-41, thereby decreasing transcription and / or expression of a polynucleotide of Tables 1-4 as compared to a reference.
61. The method of claim 60, wherein the intracellular or extracellular pH is at least 7.5, between about 7.0 and 7.5, or greater than about 6.5.
62. A method of modulating immune response, the method comprising contacting an immune cell with a polypeptide comprising a BRD4 IDR polypeptide sequence, a polynucleotide encoding a polypeptide comprising a BRD4 IDR polypeptide sequence, or an expression vector comprising a polynucleotide encoding a polypeptide comprising a BRD4 IDR polypeptide sequence.
63. A method of modulating immune response, the method comprising contacting an immune cell with a polypeptide of any one of claims 16-36, a polynucleotide of claim 38, or the expression vector of any one of claims 37 or 39-41.
64. The method of claim 63, wherein the immune cell is a macrophage, a T cell, or a B cell.
65. A method of modulating an immune response in a subject in need thereof, the method comprising administering to the subject a polypeptide comprising a BRD4 IDR polypeptideAttorney Docket No. 167705-038401PCTsequence, a polynucleotide encoding a polypeptide comprising a BRD4 IDR polypeptide sequence, or an expression vector comprising a polynucleotide encoding a polypeptide comprising a BRD4 IDR polypeptide sequence.
66. A method of modulating an immune response in a subject in need thereof, the method comprising administering to the subject a polypeptide of any one of claims 16-36, a polynucleotide of claim 38, or the expression vector of any one of claims 37 or 39-41.
67. A method of treating a disease associated with an excessive or inadequate immune response in a subject in need thereof, the method comprising administering to the subject a polypeptide comprising a BRD4 IDR polypeptide sequence, a polynucleotide encoding a polypeptide comprising a BRD4 IDR polypeptide sequence, or an expression vector comprising a polynucleotide encoding a polypeptide comprising a BRD4 IDR polypeptide sequence.
68. A method of treating a disease associated with an excessive or inadequate immune response in a subject in need thereof, the method comprising administering to the subject a polypeptide of any one of claims 16-36, a polynucleotide of claim 38, or the expression vector of any one of claims 37 or 39-41.
69. The method of claim 67 or 68, wherein the disease is sepsis or inflammatory bowel disease (IBD).
70. The method of any one of claims 65-69, wherein the subject has hypoxia.
71. A method of reducing the proliferation or survival of a neoplastic cell, the method comprising contacting the neoplastic cell with a cell of any one of claims 42-45.
72. A method of reducing the proliferation or survival of a neoplastic cell, the method comprising contacting the neoplastic cell with an immune cell comprising: a polypeptide of any one of claims 16-25, a polynucleotide encoding a polypeptide of any one of claims 16-25, or an expression vector comprising a polynucleotide encoding a polypeptide of any one of claims 16-25.
73. A method of reducing the growth or survival of a tumor in a subject, the method comprising administering to the subject a cell of any one of claims 42-45.Attorney Docket No. 167705-038401PCT74. A method of reducing the growth or survival of a tumor in a subject, the method comprising to the subject an immune cell comprising: a polypeptide of any one of claims 16-25, a polynucleotide encoding a polypeptide of any one of claims 16-25, or an expression vector comprising a polynucleotide encoding a polypeptide of any one of claims 16-25.
75. A method of treating a subject having a neoplasia, the method comprising administering to the subject a cell of any one of claims 42-45.
76. A method of treating a subject having a neoplasia, the method comprising administering to the subject an immune cell comprising: a polypeptide of any one of claims 16-25, a polynucleotide encoding a polypeptide of any one of claims 16-25, or an expression vector comprising a polynucleotide encoding a polypeptide of any one of claims 16-25.
77. The method of any one of claims 62-70, wherein the immune response is inflammation.
